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Background: Over 5000 paediatric cardiac surgeries are performed in the UK each year and early survival
has improved to > 98%.
Objectives: We aimed to identify the surgical morbidities that present the greatest burden for patients
and health services and to develop and pilot routine monitoring and feedback.
Design and setting: Our multidisciplinary mixed-methods study took place over 52 months across five UK
paediatric cardiac surgery centres.
Participants: The participants were children aged < 17 years.
Methods: We reviewed existing literature, ran three focus groups and undertook a family online discussion
forum moderated by the Children’s Heart Federation. A multidisciplinary group, with patient and carer
involvement, then ranked and selected nine key morbidities informed by clinical views on definitions and
feasibility of routine monitoring. We validated a new, nurse-administered early warning tool for assessing
preoperative and postoperative child development, called the brief developmental assessment, by testing
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this among 1200 children. We measured morbidity incidence in 3090 consecutive surgical admissions over
21 months and explored risk factors for morbidity. We measured the impact of morbidities on quality of life,
clinical burden and costs to the NHS and families over 6 months in 666 children, 340 (51%) of whom had
at least one morbidity. We developed and piloted methods suitable for routine monitoring of morbidity
by centres and co-developed new patient information about morbidities with parents and user groups.
Results: Families and clinicians prioritised overlapping but also different morbidities, leading to a final list
of acute neurological event, unplanned reoperation, feeding problems, renal replacement therapy, major
adverse events, extracorporeal life support, necrotising enterocolitis, surgical infection and prolonged
pleural effusion. The brief developmental assessment was valid in children aged between 4 months and
5 years, but not in the youngest babies or 5- to 17-year-olds. A total of 2415 (78.2%) procedures had no
measured morbidity. There was a higher risk of morbidity in neonates, complex congenital heart disease,
increased preoperative severity of illness and with prolonged bypass. Patients with any morbidity had
a 6-month survival of 81.5% compared with 99.1% with no morbidity. Patients with any morbidity
scored 5.2 points lower on their total quality of life score at 6 weeks, but this difference had narrowed by
6 months. Morbidity led to fewer days at home by 6 months and higher costs. Extracorporeal life support
patients had the lowest days at home (median: 43 days out of 183 days) and highest costs (£71,051 higher
than no morbidity).
Limitations: Monitoring of morbidity is more complex than mortality, and hence this requires resources
and clinician buy-in.
Conclusions: Evaluation of postoperative morbidity provides important information over and above 30-day
survival and should become the focus of audit and quality improvement.
Future work: National audit of morbidities has been initiated. Further research is needed to understand
the implications of feeding problems and renal failure and to evaluate the brief developmental assessment.
Funding: This project was funded by the NIHR Health Services and Delivery Research programme and will
be published in full in Health Services and Delivery Research; Vol. 8, No. 30. See the NIHR Journals Library
website for further project information.
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Plain English summary
Over 5000 heart surgery procedures are performed in children in the UK each year and early survival hasimproved to > 98%. Although early survival is important, most people now think that this does not
provide enough information. Therefore, we aimed to study health-related issues following surgery that are
generally considered as ‘bad for the patient’. The medical term for these issues is ‘morbidities’, but often
they are called ‘complications’.
We reviewed existing literature, ran three family focus groups and undertook a family online discussion forum.
A group of health professionals and family representatives then considered the possible ‘morbidities’ and
decided on a list of the nine most important ones, which were defined by a group of specialists. This included
medical complications, such as needing support with a mechanical pump after the operation, but also
‘morbidities’ that were particularly serious to families, such as feeding difficulties.
Working in five of the UK centres, we involved children aged < 17 years with congenital heart disease and
their parents to:
l successfully test a new method for nurses to check child development in 1200 children (we found that
this worked in children aged between 4 months and 5 years old)
l measure how often ‘morbidities’ happened after 3090 operations (we found that 21.8% experienced
at least one)
l measure the impact of ‘morbidities’ in 666 children over 6 months (one important finding was that
although patient quality of life was reduced when these happened, over 6 months it improved
in survivors).
We developed new ways to inform parents and the organisation that monitors the results of children’s heart
surgery (national audit) about complications, with a view to empowering parents. Monitoring ‘morbidity’ is
more difficult than monitoring mortality, so it requires resources and clinician commitment. Further research is
needed to work out how best to help children with feeding problems and delays in development.
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Scientific summary
Parts of this section are reproduced from Brown KL, Pagel C, Ridout D, Wray J, Anderson D, Barron DJ, et al.What are the important morbidities associated with paediatric cardiac surgery? A mixed methods study.
BMJ Open 2019;9:e028533. This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The text below includes minor additions and formatting changes to the original text.
Background
Over 5000 paediatric cardiac surgery procedures are performed in the UK each year and early survival has
improved to > 98%. Most stakeholders now believe that although 30-day survival remains an important
safety measure, it is not discriminatory enough as an outcome measure for teams seeking to improve care
and for families who wish to know what to expect after surgery.
Aims
The research aims as stated in the original study protocol were to identify which surgical morbidities
present the greatest burden on patients and health services following paediatric cardiac surgery and to
establish how they should be routinely monitored.
Objectives
The objectives that were stated in the original study protocol as required to achieve these aims were to:
l identify the key surgical morbidities following paediatric heart surgery, taking into account views from
patients, carers, psychologists, nurses and clinicians, that together capture important aspects of the
clinical and health economic burden
l develop objective definitions and measurement protocols for the identified morbidities
l determine which morbidities are suitable for routine monitoring and are amenable to service improvement
l validate a tool suitable for routine screening of neurological disability perioperatively
l measure the incidence of defined morbidities in the UK patient population and in subgroups defined by
case complexity
l evaluate the impact of defined morbidities on quality of life and estimate their clinical and health
economic burden
l develop and pilot sustainable methods for collection and feedback of surgical morbidity data for use in
future quality assurance and for patient and carer information.
Design and setting
Our multidisciplinary mixed-methods study took place over 52 months, across five UK paediatric cardiac
surgery centres that care for half of all patients nationally.
Participants
The participants were all children aged < 17 years with congenital heart disease.
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Methods
We reviewed existing literature, ran three family focus groups and undertook a family online discussion forum
moderated by the Children’s Heart Federation (a user group). These data were subjected to thematic analysis.
A multidisciplinary group with patient and carer involvement then ranked and selected a list of nine key
morbidities, using the nominal group technique and secret voting. This ‘selection panel’ was informed by
clinical views on definitions and feasibility of routine monitoring provided by an independent ‘definition panel’.
We validated a new, nurse-administered early warning tool for assessing preoperative and postoperative
child development, called the brief developmental assessment, by testing this among 1200 children.
We measured morbidity incidence in 3090 consecutive surgical admissions over 21 months and explored
the relationship between risk factors and morbidities. We measured impact of morbidities for 6 months in
666 children, of whom 340 (51%) had at least one morbidity. Impact was evaluated based on the:
l quality of life and psychological burden on children and parents using age-specific measures
l days at home by 6 months (as an additional measure of disruption to family life)
l NHS costs, including further interventions and hospitalisations, and costs borne by families.
We developed and piloted methods suitable for routine monitoring of morbidity by centres, and
co-developed new patient information about morbidities with parents and user groups.
Results
Selection and definition of morbidity
Families and clinicians prioritised overlapping but also different morbidities, leading to a final selected and
defined list of acute neurological event, unplanned reoperation, feeding problems, renal replacement
therapy, major adverse events, extracorporeal life support, necrotising enterocolitis, post-surgical infection
and prolonged pleural effusion or chylothorax.
We considered children with more than one of these events separately as ‘multiple morbidity’. Children
who needed extracorporeal life support were considered as having the morbidity of extracorporeal life
support as standalone morbidity, while recognising that this is a very severe event which nearly always
occurs with other morbidities.
Based on the selection and definition meetings and our qualitative analysis of focus groups and online
forum data, we found some divergence between the views of clinicians and families about the fundamental
issue of what the important morbidities linked to paediatric cardiac surgery are. Health professionals tended
to prioritise clearly clinical issues related to the heart (use of extracorporeal life support and reoperation),
whereas parents placed greater emphasis on holistic outcomes for their child (feeding, child development
and communication).
Incidence morbidity
From prospective assessment of 3090 consecutive paediatric cardiac surgery procedure-related admissions
in the five participating centres, we found that 2415 (78.2%) of procedures had no morbidities, 478 (15.4%)
procedures had one single morbidity, including extracorporeal life support, and 197 (6.4%) procedures had
multiple morbidity excluding extracorporeal life support.
Patients with any of the morbidities had a 6-month survival of 86.5% compared with 99.1% for patients
with no morbidity. The 6-month survival was lowest in extracorporeal life support patients (50%), whereas
it was 82.9% in those with multiple morbidity and 95.2% in patients with single morbidities other than
extracorporeal life support.
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Procedures with any morbidity led to a median postoperative hospital stay of 24 (interquartile range
15–42) days compared with 8 (interquartile range 5–13) days with no morbidity. The postoperative
hospital stay was longest with extracorporeal life support, at 43 (interquartile range 20–84) days; it was
35 (interquartile range 22–56) days with multiple morbidity and 20 (interquartile range 13–31) days for
patients with single morbidities other than extracorporeal life support.
Significant risk factors for morbidity
Multivariable analysis indicated that young age was an important risk factor for the occurrence of any
morbidity, with an adjusted odds ratio for neonates of 5.26 (95% confidence interval 3.90 to 7.09), as was
the more complex cardiac diagnosis group, with an adjusted odds ratio for the most complex conditions
of 2.14 (95% confidence interval 1.41 to 3.24) and prolonged bypass time in excess of 90 minutes, which
had an adjusted odds ratio of 2.8 (95% confidence interval 1.67 to 3.12). A palliative or staged procedure
increased the chance of a morbidity, as did the related condition of a functionally univentricular heart.
There was some contribution from severity of illness factors, such as pre-procedure mechanical ventilation
or shock. Factors that were less influential, although significant, were a child being underweight or having
acquired comorbidity, congenital comorbidity and additional cardiac risk factors.
Impact of morbidity
Data on 666 children contributed to the impact study; of these children, 19 had died by 6 weeks and
39 had died by 6 months post operation.
Quality-of-life impact
Quality-of-life impact was assessed based on the responses from 478 and 403 children at the two time
points of 6 weeks and 6 months, respectively. The greatest impact was seen on physical quality-of-life
scores for all patient groups, and total scores were significantly lower at the 6-week time point (e.g. patients
with any morbidity scored, on average, 5.2 points lower). At the 6-month mark, patients with most types of
morbidity had comparable quality-of-life scores with those of patients without morbidity, except patients
with multiple morbidity, who still had significantly lower scores. Extracorporeal life support patients also had
a clinically important score reduction at 6 months, which did not reach statistical significance.
Days at home by 6 months
The outcome of days at home by 6 months was based on data from 662 children. All morbidities except
renal support had a statistically significant reduction in days at home by 6 months. Again, the most severely
affected were extracorporeal life support patients, who had an adjusted median reduction in days at home
of 114.7 (interquartile range 76.4–153.1) days and multiple morbidities with minus 21.8 (interquartile range
15.5–28.1) days.
Health economic impact
Health economic data were derived from multiple sources, with differing levels of missing data by source:
these are stated in the report. Patients with single and multiple morbidities were significantly associated
with higher hospital resource use and costs than patients with no morbidities. Extracorporeal life support
and multiple morbidities had a substantial impact: unplanned reintervention, feeding morbidities, renal
support, necrotising enterocolitis and prolonged pleural effusion were also associated with significantly
higher costs. Extracorporeal life support and multiple morbidities were associated with significantly lower
quality-adjusted life-years.
Neurological and developmental surveillance and follow-up
The brief developmental assessment
The brief developmental assessment was valid in children aged between 4 months and 5 years, but not
in the youngest babies or 5- to 17-year-olds.
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Neurodevelopmental outcomes
We note that, in the selection work, neurodevelopmental morbidities came up as the most important
morbidity, affecting children with congenital heart disease across all stakeholders. Nonetheless,
postoperative acute neurological event had a rate of 0.5% as a single event and 2.1% in combination
with other morbidities. This low acute neurological event rate may be reviewed in the context of the brief
developmental assessment validation study, in which we assessed a representative sample of children with
congenital heart disease using validated neurodevelopmental tests against which the brief developmental
assessment was compared. In the sample of 400 children between the ages of 15 months and 5 years,
which is an age band where developmental tests are more reliable than at a very young age band where
they are less reliable, we found that the Mullen Scales of Early Learning result was more than 2 standard
deviations below the normative mean in between 17% and 21%.
Feeding back to stakeholders about morbidity
Co-developed parent information
We used study data collected during the course of the morbidity project to co-develop parent and carer
information resources. To date, this has been focused predominantly on showing what the morbidities are
and how their incidence and the length of stay may vary based on the complexity of the child’s condition.
Parents told us that it helps to know, first, that they are not alone in facing a complication; second, that
clinical teams have seen complications before and know how to deal with them; and, third, that it is better
as a parent to ‘be prepared’. Furthermore, they indicated that information about impact, such as nearly all
children who experience a complication and recover, will have a similar quality of life to children who did
not experience a complication by the 6-month mark, was very useful to know.
Quality assurance
In centres
Within the scope of this project a new Excel® tool (Microsoft Corporation, Redmond, WA, USA) has been
developed and piloted that enables clinical teams to benchmark and report the local rates of morbidities
with a quality assurance goal, such as in a mortality and morbidity conference.
National audit
Over the course of the project, we have kept in close contact with the National Congenital Heart Diseases
Audit and the Clinical Reference Group for congenital heart disease services. The National Congenital Heart
Diseases Audit has already started to collect postoperative morbidities within the nationally mandated data
set, using the definitions that we developed. The first centre-specific results were reported by the national
audit in 2019.
Limitations
As with any study, the results and conclusions are reliant on the quality of the data. We used a range of
strategies to check and clean our data and the information from hospital-based data sources was of high
quality. The greatest amount of missing data were within the family cost questionnaire responses.
Measures that are defined by a treatment rather than a condition, such as ‘renal support’ or feeding
problems based on ‘presence of a feeding tube’, although pragmatic, are also problematic and may not
capture the morbidity perfectly.
Monitoring morbidity is more complex than monitoring mortality, and hence this activity requires resources and
clinician buy-in.
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Conclusions
At the end of our project we are even more certain than when we started that morbidity is a better
measure of paediatric cardiac surgery outcome than early mortality. We are very proud of the prospective
data we have collected during this study, which, to our knowledge, is unique worldwide.
We note that the length of stay and mortality outcomes within the population of patients who did not
experience any morbidities were excellent: their survival at 6 months post operation was 99.1% and their
median length of stay was 8 days, and this leads us to believe that the morbidities we selected do capture
most of the complication-related adverse outcomes for this context.
Based on the measures of impact that we studied, extracorporeal life support and multiple morbidities are
particularly important adverse outcomes: this should be considered by centres and the national audit
going forwards.
Patient families have consistently told us that outcomes affecting the child as a whole over the medium
or longer term are very important to them. However, these morbidities, such as feeding problems and
developmental difficulties, are the most complicated and problematic outcomes to capture.
Future practice and research
The measurement and monitoring of morbidity is inherently complex and there are logistic difficulties in
taking forward some of the morbidity measures. It was noted that, in particular, feeding problems are
difficult to capture, although these were considered important by families and hence there is strong
motivation to explore these further. Additional research may help determine the best way to alleviate the
impact of feeding problems in congenital heart disease.
Our measure of renal failure was the need for renal support, and this may not be the optimal method
to capture this morbidity. Further research may help us to understand the best approach to manage
postoperative renal injury in congenital heart disease.
Since undertaking the brief developmental assessment validation study, we have completed a Delphi survey
in three rounds to establish consensus as to the process for evaluation of suspected neurodevelopmental
abnormalities in children with congenital heart disease and a secondary analysis of our study data to explore
how many children with low scores on gold-standard testing were under appropriate child development
services. We suggest that there is a pressing need to take this topic forwards with changes to the follow-up
pathway for neurodevelopment in children who have congenital heart disease. We suggest that further
research is needed to explore at what time points in the patient pathway should the brief developmental
assessment be used, what actions should be taken when the brief developmental assessment is amber or
red and whether or not use of the brief developmental assessment is effective.
It is hoped that the Excel tool we have developed for local morbidity monitoring by centres has the future
potential to supplement the previously developed software for monitoring of 30-day mortality rates.
Although straightforward to use, resources are required for morbidity monitoring to be implemented.
We believe that the developed parent information resources represent a major step forwards; however,
they would be optimally backed up by an evaluation study and a plan for their dissemination.
Funding
This project was funded by the NIHR Health Services and Delivery Research programme and will be
published in full in Health Services and Delivery Research; Vol. 8, No. 30. See the NIHR Journals Library
website for further project information.
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Chapter 1 Background and rationale
What is paediatric cardiac surgical morbidity?
Morbidity is defined as a state of being unhealthy or of experiencing an aspect of health that is ‘generally
bad for you’. Morbidity associated with paediatric cardiac surgery is illness or lack of health that has a
temporal connection to such an operation and, as such, may be regarded as an adverse outcome.
Although there has been considerable research on measuring, understanding and reducing perioperative
mortality for paediatric cardiac surgery,1–4 there has been less attention on surgical morbidities. The Society
of Thoracic Surgeons (STS) taskforce subcommittee on patient safety in the USA has defined a range of
unwanted events that may contribute to postoperative morbidity, including complications, adverse events,
harm, medical error, or injury and near misses.5 This patient safety taskforce further noted that in the
current era of falling mortality rates after paediatric cardiac surgery, improvement in health care as
measured by reduction in adverse outcomes is more likely when unwanted events are acknowledged,
measured and responded to in terms of health-care delivery.5
The main focus of our study, which is set in five of the 10 paediatric cardiac tertiary centres in the UK,
incorporating around half of the national cases, is on early paediatric cardiac surgical morbidities that are
considered potentially avoidable or reducible or can be mitigated.
Why does morbidity after paediatric cardiac surgery matter?
Much of the previous research on surgical morbidities after paediatric cardiac surgery has focused on
establishing their links with longer stays in hospital and establishing that children who experience prolonged
hospitalisation and complications are also at greater risk of further adverse events and even death.6,7 In
addition, over the long term, children with specific heart conditions who experienced prolonged stays in
hospital following surgery, which are often related to complications or morbidities, have been shown to
develop higher levels of neurological disability.8,9 Children who experienced the most difficult postoperative
courses involving a period of mechanical circulatory support developed neurological disability in around
50% of cases.10 Prolonged hospitalisation due to morbidities can be very expensive to manage, with
mechanical circulatory support costing > £10,000 per day.11,12
Morbidity, disability and quality of life are increasingly viewed as key outcomes by patients, families and
clinical teams who are looking to deliver further improvements in service quality, partly owing to decreasing
mortality rates. Although previous studies did not include patient perspectives to select morbidities for
monitoring and were based on clinical opinion of what is important rather than the measured impact of
morbidities, recent initiatives in the USA13 and Canada14 are illustrative of growing attention worldwide
on the issue of surgical morbidity in this population. In the UK, a recent major review of the specialty
highlighted the need to monitor outcomes in a timely and meaningful fashion,15 and commissioners of
services are appropriately seeking evidence on outcomes and quality assurance from providers.
Previous relevant morbidity definitions and measurements
A series of detailed articles by professionals from the MultiSocietal Database Committee for Pediatric and
Congenital Heart Disease, based in the USA, profiled an extensive range of complications incorporating all
organ systems, including examples such as kidney failure, deep-seated infections and failure of the original
operation leading to reintervention.16–23 The US STS database selected a narrower range of defined major
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complications that were retrospectively available within the registry, and demonstrated that rates varied
from 1% to 38%, with greater prevalence at increased procedural complexity.13 A Canadian study
indicated that prospective monitoring of complications may lead to greater case ascertainment and, hence,
a perception of higher complication rates.14
Routine audit of postoperative mortality in paediatric cardiac surgery is well established in the UK via
the National Congenital Heart Disease Audit (NCHDA),24 which has published centre-specific results of
individual operations online since 2005 and programme-based 30-day mortality rates with case mix
adjustment since 2012. Stakeholders, including children’s heart surgery programmes, congenital heart
patient support groups and the NCHDA, share a goal of adding to these mortality outcomes by reporting
morbidity. In 2015, at the start of our study, the NCHDA initiated the capture of preliminary morbidity
measurements, which they based on our study protocols; however, those UK national audit data have yet
to be analysed.
It is important to note that views may differ between professionals and non-professionals over what
exactly the term morbidity refers to, and which morbidity events are most important. A recent study
showed differing perceptions and priorities between clinicians and patients regarding chronic obstructive
pulmonary disease services and outcomes.25 Focus groups and formal consensus methods have been used
to elicit patient and carer perspectives, and determine group priorities in many contexts.26 The nominal
group technique was successfully used among general practitioners (GPs) to identify prioritised lists of
quality markers for the management of children in general practice26 and by kidney transplant patients in
ranking outcomes by importance.27 A recent National Institute for Health Research-funded study showed
differing perceptions and priorities between clinicians and patients regarding chronic obstructive pulmonary
disease services and outcomes.25 Therefore, within our research we set out to combine patient and carers’
perspectives with those of professional groups in defining a prioritised list of outcomes for audit may be
valuable to other specialties. We aimed to address these major gaps in current knowledge by setting out
to establish robust definitions for, and the current incidence of, major morbidities and their impact in the
UK paediatric population following heart surgery.
The particular case of neurological damage and child development
Neurological damage following cardiac surgery is considered crucial by patients, families and clinical staff.
Systematic evaluation of infants undergoing common congenital heart repairs in the USA with a ‘gold-
standard’ assessment indicated that neurological difficulties occurred in up to 25% of patients, making
this the most frequent morbidity among children with heart disease.28 However, at the time our project
commenced, the UK national audit reported deterioration in cerebral performance category29 in 1.2%
of children following surgery (Dr David Cunningham, National Institute for Cardiovascular Outcomes
Research, London, UK, 2012, personal communication). This was almost certainly an underestimate,
with data quality undermined by lack of expertise among cardiac specialists in assessing neurological
development, exacerbated by the medical complexity and age mix of the patients. The importance
of improving these assessments goes beyond audit and quality assurance: early detection of
neurodevelopmental deficits can prompt timely intervention and improve outcomes.
The different types of neurodevelopmental abnormalities in survivors of cardiac surgery30 include motor
deficits,31–34 seizures,35–38 poor executive functioning,39 communication problems,8,33,40 impairments in visual
construction and perception,8,40–43 poor attention44,45 and learning difficulties.33,34,45 Deficits can range in
severity and may be subtle and therefore more easily overlooked, particularly in children with less complex
congenital heart disease (CHD), and throughout the course of childhood and adolescence the presentation
of neurodevelopmental abnormalities can change. Some deficits may resolve spontaneously; others may
not be apparent until later childhood. Recent longitudinal evaluation of a cohort of preschool-aged
children at high risk of developmental delay indicated an improving developmental trajectory in some,
but approximately 20% had scores in one or more developmental domains which decreased over time.46
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Presentation of deficits can be obscured or confounded by a range of factors, including those related to
cardiac surgery, the effects of hospitalisation and other comorbidities.
In 2012, the American Heart Association47 published guidelines for systematic surveillance, screening,
evaluation and intervention to identify neurodevelopmental problems early and optimise outcomes in the
short and longer term, building on earlier guidelines from the American Academy of Pediatrics.48 They also
highlighted the importance of continued monitoring because the level of risk for neurodevelopmental
impairment can change over time, as different impairments become apparent during different periods
of development. Furthermore, children at risk for poor late outcomes are frequently not identified from
results of early testing.49 It is therefore not surprising that increasing numbers of follow-up programmes
for children with CHD and neurodevelopmental concerns are now being implemented, particularly in the
USA50 and some countries in Europe.
Finding a solution for neurodevelopmental surveillance in an
NHS context
Every child in the UK, irrespective of any known health problems, has an allocated health visitor
(a community-based nurse or midwife) who should make a minimum of five key visits in which the child’s
development is reviewed from birth up until the age of 2–2.5 years. However, the health visiting service
is recognised to be overstretched, with not all children getting full access to this. Children with CHD are
under follow-up with a paediatric cardiologist; however, such professionals are, in general, not trained
to undertake developmental assessments, as their specialisation is focused on the heart. Children with
CHD and other comorbidities, including known neurological events or developmental delay, may also
be under the care of a paediatrician at their local hospital and may be referred by the cardiac centre or
their paediatrician to local services based on suspicion of developmental delay, but there is seldom the
opportunity or resources for any developmental testing to provide evidence to support those concerns.
After an acute neurological event (ANE) post surgery, a child with heart disease in an NHS specialist centre
will be assessed by a neurologist.
As stated in The particular case of neurological damage and child development, children with CHD are a
particularly high-risk group for neurodevelopmental problems that may arise from multiple aetiologies and
at all stages in their early lives and care pathways,30,31,35,38 hence these may be an issue prior to the age
of 2–2.5 years. A formal standardised assessment of development using comprehensive tests, such as the
Bayley Scales of Infant Development,51 the Griffiths Mental Development Scales52 or the Mullen Scales of
Early Learning (Mullen),53 is considered to be the gold standard, but these are not tests that are used for
early recognition of developmental delay. If a problem is identified and a child is referred for follow-up,
such tests are usually undertaken by someone who has had specialist developmental training and has
time dedicated to perform the testing. However, if a child is not referred, such tests are unlikely to be
performed as they are not integrated into the routine follow-up of children. Moreover, this would not be
feasible because the tests are time-consuming and not practicable with sick children or within the context
of a busy ward or outpatients. Of note, children may require multiple cardiac interventions and the level of
risk may change over time, thereby necessitating some mechanism for repeated routine monitoring and
early recognition of developmental problems in all children with CHD.
Given this whole picture, and as we know anecdotally from our own clinical practice, developmental delay
is often detected late – frequently not until a child starts school and education services become involved –
thereby precluding the opportunity for early intervention and causing stress to families who may be aware
that ‘something is wrong’.
With the above in mind, we determined that an early recognition tool would help to address some of
the current shortcomings and facilitate appropriate and timely referral for further, more comprehensive
neuropsychological evaluation for those in whom this is indicated. After reviewing existing tools and
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establishing that none would be fit for this purpose, we undertook the development of a new tool that
had the potential to be routinely used within tertiary programmes for managing children with CHD.54
One of the objectives of this study was to validate this new tool, which is called the brief developmental
assessment (BDA).
Methods for the reporting of morbidity outcomes
To enable routine monitoring of morbidities, approaches to data analysis and display are required. Analytical
and graphical methods for the timely reporting of risk-adjusted mortality outcomes for the purposes of
quality improvement are well established in adult cardiac surgery practice.55 Our research group developed
the method of variable life-adjusted display (VLAD), which is now used nationally in the UK to monitor
contemporaneous risk-adjusted postoperative survival rates for paediatric cardiac surgery.56 These approaches
have received positive feedback and are judged useful by a range of stakeholders; hence, within the scope
of this project we set out to develop something similar for the reporting of morbidity events.
Considering previously reported attempts at reporting of morbidity outcomes, two single-centre studies
have attempted to generate an aggregate ‘Morbidity Index’ by assigning subjective weights to postoperative
complications.7,57 The STS in the USA has attempted a similar ‘Morbidity Score’.13 Condensing diverse
morbidities into a single score loses information, and recent work on using graphical methods to routinely
monitor a range of morbidities14 highlighted the complexity of graphically summarising multiple morbidities
(see also commentary by Utley et al.58). The Pediatric Cardiac Critical Care Consortium (PC4) was set up
in 2009, with the aim to improve the quality of care given to patients with critical paediatric and congenital
cardiovascular disease in North America and abroad. The PC4 database provides partner sites with access to
real-time, reliable and actionable data to be used for local quality improvements and has been the basis for
a range of excellent publications related to postoperative complications after paediatric cardiac surgery.59–62
However, membership of PC4 is voluntary for institutions on a subscription basis, the reported measures,
although of great importance, have all been selected by clinicians and the reporting of outcomes is
accessible only to subscribing member institutions.
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Chapter 2 Aims and objectives
Aims
The research aims, as stated in the original study protocol, were to identify which surgical morbidities
present the greatest burden on patients and health services following paediatric cardiac surgery and to
establish how they should be routinely monitored.
Objectives
The objectives that were stated in the original study protocol as required to achieve these aims were to:
l identify the key surgical morbidities following paediatric heart surgery, taking into account views from
patients, carers, psychologists, nurses and clinicians, that together capture important aspects of the
clinical and health economic burden
l develop objective definitions and measurement protocols for the identified morbidities
l determine which morbidities are suitable for routine monitoring and are amenable to service improvement
l validate a tool suitable for routine screening of neurological disability perioperatively
l measure the incidence of defined morbidities in the UK patient population and in subgroups defined
by case complexity
l evaluate the impact of defined morbidities on quality of life and estimate their clinical and health
economic burden
l develop and pilot sustainable methods for collection and feedback of surgical morbidity data for use in
future quality assurance and for patient and carer information.
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Chapter 3 Exploring patient and family perspectives
on morbidity after paediatric cardiac surgery
Parts of this chapter are reproduced with permission from Rajagopal et al.63 This is an Open Accessarticle distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
Introduction
Morbidity associated with cardiac surgery can be very challenging for patients and families, and for those
with the most severe morbidities the impact may be life-changing or, in some cases, life-limiting. As more
children with increasingly complex CHD successfully undergo surgery, there are a growing number of
children living with the impact of a range of morbidities. It is therefore imperative that information about
morbidities is prospectively communicated in an empathic and clear way to ensure that there is an
accurate understanding by those who will potentially live with the consequences.
In this chapter, we describe qualitative research undertaken in the first year of our study to explore family
perceptions on the meaning of morbidity, family understanding of what different types of morbidity exist
and family viewpoints about which morbidities are important. As parents are in general lay people who
do not possess specialist knowledge about paediatric cardiac surgery, inevitably much of their information
is gathered from health professionals. Therefore, in this section of our research we focused not only on
what parents understood, but also on the manner and quality of health professional communication about
morbidities. As set out in our original study protocol, we used two separate and complementary approaches
to solicit parent and family viewpoints on the topic of interest: an online discussion forum and more
traditional focus groups.
The rationale for an online discussion forum
Traditional methods of accessing parental views can limit access for some people, thereby impairing
inclusivity.64,65 Logistics, time and discomfort in face-to-face and group interaction may deter some
individuals. As the use of the internet continues to increase, it represents a vital tool for the delivery of
health-care information. Online forums are an important way in which internet users seek this information
and communicate with others who have had similar health-care experiences, and there is an increasing
focus on understanding the potential value of this method of data collection in qualitative research.66,67
Forums have successfully been used in previous health-care research68–73 because they provide a flexible
and safe space, where open and honest discussions can be held over a period of months, in a conveniently
non-synchronous way for potentially large numbers of users in different geographical areas.64,65,74 There is
no burden on travel and participation results in minimal disruption to daily life. We therefore hoped that
the inclusion of an online forum as a method of engaging with families, alongside more traditional
approaches, might enable us to access the views of those who find it hard to attend in person or take
part in interviews and focus groups, adopting a similar approach to that used by our group previously.75
Online forum methodology
The Children’s Heart Federation (CHF), a national parent charity and co-applicant for the wider study,
facilitated and moderated a closed, anonymous, online discussion group via their Facebook page
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(Facebook, Inc., Menlo Park, CA, USA), following a similar approach to that reported in a previous study.75
The discussion group was advertised on the charity’s home webpage and potential participants were
directed to the charity’s Facebook page, where they could access more information about the study and
the governance surrounding it. Any person who wished to participate was asked to provide some basic
demographic details (age, sex, ethnicity and geographical region) and on completion of this information
they were directed to the closed Facebook group, where they were able to respond to questions posted
there. The research team provided questions to be posted on the forum at the start of the process and the
charity were responsible for deciding when new questions should be posted or any prompts introduced,
based on participant responses and the rate of responding. Questions posted on the forum are shown in
Box 1. The forum ran continuously over a 3-month period in the spring of 2014.
BOX 1 Questions posted in the online forum
1. When thinking about children’s heart surgery, what does the word ‘complication’ mean to you?
2. When thinking about children’s heart surgery, what does the word ‘morbidity’ mean to you? Can you give
an example of how this affected you or your child?
3. As the experience of heart surgery becomes more distant and in the past, and your child is older, are there
any difficulties that your child has now which you think may relate to the operation?
4. Thinking about yourself and your family, can you help us understand the impact that any complications had
on you, your child or any other family members:
l While your child was still in hospital?
l After you got home?
5. We are thinking about measuring and recording how often complications happen, but we want to
concentrate on the things that matter most to the child and family. Here is a list of problems that we know
can happen:
l Children who have heart problems may sometimes experience different types of brain damage and this may
lead to disability ranging from loss of hearing to problems with learning or movement or all types
of disability.
l A child may sometimes need an extra operation during the same stay in hospital that was not planned at
the start.
l Infection may sometimes happen after heart surgery.
l A child’s kidneys may stop working and need to be supported with a machine for a period of time.
l The muscle that helps a child to breathe may be weakened because the nerve supplying it is bruised or
damaged – sometimes an operation is needed to strengthen the breathing muscle (diaphragm muscle).
l A child may need to stay in intensive care for a long time because he/she needed assistance with breathing
or he/she needed tubes to remain in place.
l A child’s gut may not digest milk or food and she/he may need to have nutrition via a drip.
l A child’s heart may become very weak such that a machine to support the body called ‘ECMO’
was needed.
l Damage can happen to the nerve supply of the heart so that the child needs to have a pacemaker put in to
regulate the heartbeat.
Which of these complications seems the worst or most worrying to you?
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6. We are thinking about measuring and recording how often complications happen, but we want to
concentrate on the things that matter most to the child and family. Here is a list of problems that we know can
happen:
l Children who have heart problems may sometimes experience different types of brain damage and this may
lead to disability ranging from loss of hearing to problems with learning or movement or all types
of disability.
l A child may sometimes need an extra operation during the same stay in hospital that was not planned at
the start.
l Infection may sometimes happen after heart surgery.
l A child’s kidneys may stop working and need to be supported with a machine for a period of time.
l The muscle that helps a child to breathe may be weakened because the nerve supplying it is bruised or
damaged – sometimes an operation is needed to strengthen the breathing muscle (diaphragm muscle).
l A child may need to stay in intensive care for a long time because he/she needed assistance with breathing
or he/she needed tubes to remain in place.
l A child’s gut may not digest milk or food and she/he may need to have nutrition via a drip.
l A child’s heart may become very weak such that a machine to support the body called ‘ECMO’
was needed.
l Damage can happen to the nerve supply of the heart so that the child needs to have a pacemaker put in to
regulate the heartbeat.
Could you please tell us why you think one or more of these complications is ‘worse’ than other complications?
Are there things that happened to your child after their operation that you think ‘went wrong’ which should be
on this list but is not?
7. Could you please let us know what information you were provided with regarding the complications of your
child’s heart surgery?
8 (a). Do you feel you were provided with the right amount of information regarding complications before
surgery?
8 (b). How much information would you like (more or less)? How much detail is helpful?
9. What visual (books, etc.) methods could be developed for letting families know the risk of complications to
better inform them about what might happen after surgery?
10. What do you think about everyone being able to see (on the internet) the numbers of complications
occurring after children’s heart surgery at different hospitals?
11 (a). Do you have any further comments regarding complications following heart surgery? Is there anything
we should know to improve services? Is there anything else you can think of?
11 (b). Is there anything we could have done to improve the online study? Do you think we should have asked
questions more frequently, for example? Any other suggestions?
ECMO, extracorporeal membrane oxygenation.
BOX 1 Questions posted in the online forum (continued )
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Focus group methodology
We held three focus groups for patient families in the first 6 months of 2014, which took place in Glasgow,
Birmingham and London. The focus groups were advertised via the CHF website and potential participants
contacted the CHF if they wanted to take part. The CHF organised the groups, which were held on a
Saturday and were moderated by an independent, experienced researcher who used the same questions
that were used for the online forum as a topic guide (see Box 1). Focus group participants provided written
consent for their participation, recording and the use of anonymised quotations in dissemination of the
findings. Each focus group was audio-recorded and transcribed verbatim.
Data management and analysis
Responses from the online forum were collated into a single transcript and each focus group formed a
single transcript. The four transcripts from the online forum and the three focus groups were thematically
analysed.76 Transcripts were read and codes attached to segments of data independently by three
members of the research team (JW, CP and VR). Similar codes were then brought together to create
themes. The researchers met to discuss the themes and to agree the descriptive names assigned to them.
Discussion continued until consensus was reached.
Participant demographics
The online discussion forum ran over 3 months and involved 72 participants (68 mothers, one father,
one patient and two grandmothers, with an age range of 15–59 years). The vast majority of participants
were white British (n = 70, 97%), and there was a spread of participants across England, Wales and Scotland.
The three focus groups each lasted for approximately 2 hours and comprised 13 participants in total
(10 mothers, two fathers and one adult CHD patient). The ages of the parents’ children ranged from
14 months to 24 years (however, only one ‘child’ was an adult, the others all being aged ≤ 14 years,
with a median age of 5 years at the time of the focus group). The sex ratio of the participants’ children was
seven boys to five girls. Two children had recognised clinical syndromes and one of the mothers was bereaved.
Themes from analyses
A number of codes were identified from the online forum and focus group data, and collated to form
three themes, with seven subthemes, relating to communication between health-care professionals and
families about complications arising from cardiac surgery. The themes are shown in the first column of
Table 1, with subthemes in the second column and illustrative quotations in the third column. These are
discussed further as follows.
Clinicians’ use of language
Immediate barriers to comprehension
Technical language used by clinicians about complications of surgery was often poorly understood by
families. In particular, jargon (e.g. words such as ‘morbidity’, ‘stenotic’, ‘hypoplastic’) was used instead of
lay language and percentages were used to communicate risk. These were often confusing to participants
and led to misunderstandings with lack of information transfer. Some parents expressed the view that it
would have been useful to hear from another parent who had been through a similar experience and
could tell them ‘mum to mum’, with ‘no jargon’, what to expect.
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TABLE 1 Themes from the analysis of online forum data
Theme Subtheme Quotation
1. Clinicians’ use
of language
Comprehension/consistency It’s just jargon . . . Please . . . English . . . so we can
understand it!
. . . some doctors are better than others . . . at explaining
. . . they go into the usual doctor terminology
. . . they use hypoplastic instead of small, stenotic instead
of stiff
It’s really easy to get yourself tied up in knots with risks and
percentages, when they’re really not explained properly
Percentages are rarely accurate anyway, so why do we – as
parents – hang on to them so dearly (me included!!!!). We
were given 13% but it wasn’t properly explained that this
was risks (i.e. morbidity) not death alone
I think it’s assumed that parents have a basic
understanding of statistics when it’s such a complicated
measurement and it’s not properly explained to us
Morbidity to me means death
Just to talk mum to mum . . . then you’re not getting the
medical jargon
I found a huge discrepancy between the way the
cardiologists describe surgery, i.e. very optimistic,
complications are rare, and the surgeons who spell it out in
order to cover themselves. Personally I prefer the latter as it
means when it does happen you are aware of it and know
it has happened before, whereas the former makes you
feel so unlucky and wondering why things have happened
We were given very detailed information by the surgeons
on the eve of our son’s op but . . . up until that time we
had only seen cardiologists who were really quite blasé
. . . We were told ‘he’ll be fine’ they do switches all the
time. Turns out it was far from that . . .
2. Being unprepared
for complications
Differing priorities of health-care
professionals and families/timing
of consent
NG [nasogastric tube] feeding was never something
I thought about when we considered the prospect of
having a congenital heart disease child
We weren’t mentally prepared for the longer stay as we
were told ‘in and out in 5 days’
I really wish someone had prepared me for the
psychological side effects . . . anything explaining how
trauma and complications can have a negative impact on
your child’s self-esteem and mental well-being
. . . tell parents beforehand . . . This is very likely going to
affect development in growth, height, learning and
development and things like that
They do tell you some of the physical things that might
happen but not how it might affect . . . a person’s
behaviour or emotions
You know when they do the consent forms it’s usually
the night before surgery which . . . is a bad idea, because
you’re not taking that in . . . if you did it a week before
. . . you take in a lot more . . . It’s easy for you to digest
and understand
continued
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Inconsistency of content
Participants described individual clinicians as giving different messages about what complications to expect
following surgery. Although some individuals played down complications, others were seen as being more
upfront and frank about complications during consent conversations. These inconsistencies between
individuals led to mistrust and a perception that some clinicians were being more honest than others.
Being unprepared for certain complications
Differing priorities of health-care professionals and families
Clinical teams and families appear to have had some differences in the perception as to what was
considered as key content for information sharing about morbidities. This appears to have led to the
clinicians focusing on more immediate technical issues related to the heart and circulation, whereas the
families wanted to know more about later events affecting the child at home, such as child development.
For example, feeding difficulties and the need for a nasogastric tube to support milk intake after discharge
were of huge significance to families; however, parents were frequently not made aware of this as a
potential complication prior to surgery and were surprised when this transpired. Another important
example identified by many of the parents was the unanticipated psychological side effects on their child,
the siblings and themselves, which were reportedly not mentioned by professionals during the hospitalisation.
TABLE 1 Themes from the analysis of online forum data (continued )
Theme Subtheme Quotation
3. Information needs
of families
No right amount of
information/types of
information/access to
staff/lay support
Some parents will want to know everything and others
want to know as little as possible
If we knew all the potential outcomes I think signing the
consent would have been so much harder
You can’t have a blanket rule of ‘We must tell them
every possible thing that could go wrong’ or, ‘We only
tell them the most common’. You need to look at it
case-by-case
It’s such a delicate balance . . . you’ve got to try and test
the waters with the patient’s parents and the patient’s
themselves to find out how much information . . . you
need to give this person. It has to be an individual
case-by-case scenario
Something to take away and look at and digest in your
own time
Even a simple information sheet . . . you might not have
internet access . . . you might need to go into your room
or sit by the bed and have another look at it a bit later
Little Hearts Matter . . . DVD pack for antenatal
diagnosis. It was brilliant
Community liaison nurses are very useful and parents
should be given contact numbers as a matter of course
. . . knowing who to ask . . . that there’s somebody you
can ask about things you might spot . . . signposting
Reproduced with permission from Rajagopal et al.63 This is an Open Access article distributed in accordance with the terms of
the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/.
EXPLORING PATIENT AND FAMILY PERSPECTIVES ON MORBIDITY AFTER PAEDIATRIC CARDIAC SURGERY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
Timing of consent
The timing of the consent conversations was also highlighted as being suboptimal in order for morbidities
to be explained and understood, thus leaving families unprepared for certain morbidities. Examples were
given of consent being taken the night before surgery, when parents were feeling not only anxious but
also left with little time to reflect on or think through what had been said.
Families information needs
There is no right amount of information
It was clear that there was no ‘right amount of information’ that suited every individual. Although some
parents wanted to know about all possible morbidities or complications, others felt that too much
information would have been overwhelming, potentially paralysing them in the consent process, when, in
reality, faced by a child requiring paediatric cardiac surgery in order to survive long term, they often have
little true decision-making power. Participants felt that the detail of information being conveyed should be
tailored according to the needs of the individual receiving it, rather than using a ‘one size fits all’ approach.
Types of information
Written and audio-visual materials were reported as helpful supplements. Being able to take something
back to their accommodation, that could be read and digested in their own time, was valued. As well as
more high-tech information, simple leaflets were appreciated as something that could be read without the
need for internet access and a telephone or computer.
Access to staff/lay support
Parents valued having access to a member of staff whom they could contact with further questions and
who could signpost them to other information as needed. In addition, parents expressed that being able
to speak to another parent who had gone through something similar, and who actually knew how it felt
to be a parent going through this, would have been a source of comfort and help.
Discussion of findings
Overview
This section of our study provided a clear steer that parents consider longer-term events that on the surface
may not appear to be directly related to the heart itself, such as difficulties establishing oral feeding after
discharge home and parental psychological stresses, to be ‘legitimate morbidities’ linked to paediatric cardiac
surgery. As such, these are suitable topics to cover during preparation for paediatric cardiac surgery, ideally
backed up by appropriate data concerning incidence and impact. Furthermore, the analysis of parental
comments highlighted clinician, parental and situational factors that may influence parental understanding
of potential morbidities following paediatric cardiac surgery and, consequently, aspects of communication
about morbidities that can be targeted for improvement. These are discussed further as follows.
Communication content
Clinicians’ use of jargon, the lack of consistency between clinicians and an individual clinician’s skill in
communication have been previously identified as important factors in patient comprehension and
adherence,77,78 and in the current study all of these aspects had an impact on the qualitative assessment of
parental satisfaction and understanding. Individual communication skills vary, with one participant noting
that some clinicians are ‘just better’ at it than others. Although this may be an innate strength or weakness
for a given individual, clinicians may benefit from communication training and assessments as they
undertake for other elements of practice.
Amount of information
The amount of information given by clinicians can have both positive and negative effects on parental
anxiety.79,80 Parents want their clinicians to be accessible, honest and caring and to use lay language at a
pace that can be understood.81 This was also reflected in our study data, which suggested that the
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information given needs to be tailored to the information needs of the individual receiving it. Taking
the time to ascertain the best fit for an individual parent is an important investment not only in their
understanding, but also in their ability to make decisions and cope with the situation that lies ahead. In
addition, what the parents want to know is what is likely to happen to their child, such that the risk of
complications would ideally be tailored to the individual characteristics of the child for whom surgery is
being discussed. This is easier said than done, in as much as the population of cardiac children becomes
increasingly complex, and as surgical and medical techniques evolve, we are constantly pushing boundaries
meaning that uncertainty is inevitable. The approach taken to support parents and families in coping with
uncertainty is an important part of the care we provide.
Time pressure
Stress and time pressure are barriers to informed consent.82,83 Previous studies84,85 have indicated that levels
of distress, time pressure and the quality of ‘clinician–parent communication’ can adversely affect parental
understanding of information given, with the potential to limit parents’ ability to make informed decisions.79
Children with CHD may at times be severely ill, which leads to discussions with clinicians occurring under
pressure of time; however, this is not always the case. Our participants commented on the difficulties that
they faced with consent the night before surgery. When possible, a staged consent approach86 should be
used, such that an initial consultation will be used to just relay information, followed by a period of time
allowing consideration by the parents, before a second conversation when consent is actually sought.
Limitations
The data we obtained relied on participants’ retrospective recall of conversations. An evaluation of
clinician–parent communication in real time would provide a valuable insight into what is actually said and
the interpretation at the time – not only of parents, but also of clinicians. What did the parents understand
from the conversation and what did the clinicians believe the parents understood from the conversation?
Despite specifically choosing a data collection method to increase the accessibility of the research to potential
participants, our participants did not reflect a broad range of ethnic groups or sex, therefore limiting the
generalisability of our data to the wider population of parents of children with CHD in the UK. The challenges
of including ethnically, culturally and linguistically diverse populations, as well as fathers, in paediatric research
studies are well documented.87,88 However, an innovative approach that successfully includes minority groups
needs to be adopted to ensure the broadest capture of parental and family views. Finally, we did not collect
the same demographic information from participants in the online forum and the focus groups, which limited
our ability to describe certain aspects of our participants across both data collection approaches.
Conclusion and next steps
The importance of ‘good communication’ goes beyond just promoting understanding between parties.
Meert et al.81 ask whether or not the way in which clinicians communicate may impact on the psychological
adjustment and functioning of parents and families. The feedback we obtained suggests that there is wide
variability and lack of consistency in the way clinicians describe complications, much of which may not be
absorbed or retained by parents, particularly during times of extreme stress and distress.80,89 Hence, the
participants commented on the feeling of being ‘unprepared’, in particular for morbidity events taking
place further along in time after their child had gone home and events that were not ‘on the face of it’
immediately obviously linked to the heart (e.g. impaired child development, psychological stress and feeding
difficulties). We suggest that future work should seek to understand whether or not clinicians are able
to mitigate some of the short- and long-term distress experienced by families in this situation, through
adjustments to communication to make this more consistent and less jargon heavy. These findings also
provide motivation for a later section of our project in which we set out to develop parent information
resources related to perioperative morbidities.
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Chapter 4 Selection by a panel of clinicians and
family representatives of important early morbidities
with paediatric cardiac surgery
Parts of this chapter are reproduced from Pagel et al.90 This is an Open Access article distributed inaccordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions
and formatting changes to the original text.
Introduction
Our account of the selection of important early morbidities associated with paediatric cardiac surgery by a panel
of clinicians and family representatives is based on the open access publication on this topic in BMJ Open.90
Reporting of early morbidities associated with paediatric cardiac surgery has been driven largely by the
data available within the databases of professional societies,91 clinical consortia61 or those available within
data sets curated by individual clinical teams.14 Quality assurance initiatives rooted in such data sets benefit
greatly from considerable effort, often over many years, to agree definitions of the outcomes collected and
design data collection processes. However, it is inevitable that the data sets agreed on, constructed and
curated by clinicians (as individuals or via professional societies) focus largely on outcomes considered
important from the perspective of that clinician or professional group. Research in other specialties has
shown that patients and carers can have quite different perceptions to clinicians on what outcomes are
important to monitor as part of service evaluation.92
Selection panel process overview
We convened three meetings of a panel of family representatives, surgeons, liaison nurses and other
health-care professionals to shortlist and then select surgical morbidities for routine monitoring.
The shortlist of surgical morbidities was selected by the panel using a modified nominal group technique,
informed by a comprehensive list of possible morbidities that can occur in relation to paediatric cardiac
surgery that was generated by a systematic review [see the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) diagram in Appendix 1, search terms and the list of references in
Report Supplementary Material 1], and the parent focus groups and online forum information presented
in Chapter 3. The question addressed by the panel was ‘What are the important surgical morbidities to
monitor routinely following paediatric cardiac surgery?’ We assessed group preferences between options
using the robust secret voting process developed by Utley et al.93
We held three selection panel meetings over the course of the project: two during year 1 (April and
September 2014) and a final meeting in year 4 (May 2018). At the first meeting of the panel, the emphasis
was on shortlisting the morbidities considered important and potentially reducible, with participants
encouraged not to self-censor owing to issues of definition and measurement. The output of this meeting
was a prioritised list of 24 candidate morbidities with other, less-favoured options discarded at this stage. At
the second meeting, informed by the definition group (see Chapter 5), the panel discussed issues raised by
the definition group on the shortlisted morbidities before, again, individually ranking the remaining options in
a secret vote, shortlisting nine morbidities for the incidence and matched cohort studies (objectives 4 and 5).
A third and final round of discussion took place following completion of the incidence and matched cohort
studies (in May 2018).
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Composition of the selection panel
In forming the panel, we aimed to include clinicians from surgical centres, referring hospitals and primary care,
as well as family representatives. We wanted a panel of enough people to provide a range of perspectives
while also being manageable. The panel comprised 15 people: three family representatives, three paediatric
cardiac surgeons, two paediatric intensive care doctors, two paediatric cardiologists, two paediatricians, one
paediatric intensive care nurse, one clinical nurse specialist and one clinical psychologist who had experience
of working with children with CHD and their families. The panel was chaired by a cardiothoracic surgeon
with extensive experience of chairing multidisciplinary panels. We tried, but did not manage, to recruit a GP
to the panel.
With the permission of panel members, year 1 selection panel meetings were recorded and professionally
transcribed. Each selection panel meeting also had a predetermined seating plan to ensure that people
from similar specialties were not grouped together.
Selection panel meeting 1: shortlisting
Preparation
The aim of the first meeting was to identify a shortlist of 15–20 candidate morbidities that would then be
considered by the definitions group. Prior to the meeting, the panel was supplied with an extensive list of
candidate morbidities identified through:
l a systematic review of the literature – the search terms, a PRISMA diagram and an exhaustive list of
morbidities (see Appendices 1 and 2) and the reference list are provided (see Report Supplementary
Material 1)
l three facilitated focus groups held in different UK cities, with parents recruited by the CHF
l an online forum for patients and families hosted on the website of the CHF.
The panel was also sent an abridged version of the study protocol, a description of the role of the selection
panel and an agenda. Each panellist was asked to identify among or beyond this list of candidate
morbidities those they judged most important to monitor routinely according to a deliberately broad
working definition of a surgical morbidity as:
Any health or emotional problem that arose as a result of the fact of surgery (whether directly caused
by surgery/post-operative care or not).
For the first meeting, panellists were requested not to censor their suggestions on the grounds of the
perceived difficulty of definition or measurement and it was stressed that another group would be making
these judgements.
We used the nominal group technique,94,95 augmented by a robust voting process to determine group
rankings of morbidities (see Appendix 3). The nominal group technique is designed to reduce the influence
of perceived power differentials and of dominant personalities on group decision-making, while retaining
the benefit of discussion absent from other systematic approaches to group decision-making, such as
Delphi.96 We inferred group preferences from individual rankings, using a method developed by Utley et al.,93
which is briefly described in Appendix 3.
Structure of the first panel meeting
Each panellist was given the opportunity to speak uninterrupted for 2 minutes on the morbidities they
considered important. Each suggestion was entered onto a spreadsheet, which was projected in the
meeting room to ensure that there was accurate transcription. The panel was then given the opportunity
to add to this initial list if they thought that something important had been missed.
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The chairperson (TT) led a process of identifying suggestions that fell outside the working definition above
(see Preparation): duplication among suggestions and merging of closely related suggestions. There was
then a secret ballot in which panellists were asked individually to rank the resulting list of candidate
suggestions in order of descending importance. The voting process and the method for generating group
preferences from individual ranking data are described further in Appendix 3.
During a scheduled break, the group preferences were calculated from the individual rankings by CP and
MU, who did not have a vote on which morbidities to measure. After the break, the group preferences
were fed back to the panel. The chairperson then led a second round of discussion, focusing on the group
preferences and giving panellists the opportunity to argue for specific morbidities being given greater
importance, and for the group to further consolidate the list of morbidities.
There was a second round of secret ranking followed by feedback of group preferences, prior to
a consensus being sought as to the prioritised shortlist of morbidities to be passed to the separate
definition panel for an assessment on the feasibility of defining, measuring and monitoring each in
routine practice.
Results of the first panel meeting
Of the 15 panellists, three could not attend. At this meeting, 66 morbidity terms were suggested during
the round of 2-minute contributions from each panellist (see Appendix 3). In the discussion that followed,
seven terms were removed as being irrelevant to our study, related to impacts of post-surgical morbidity
that would be measured as part of our empirical study, were too long term in nature to be captured
within our study or redundant given other terms suggested.
Of the remaining 59 terms, seven were accepted as candidate morbidities as they were and a further
five terms were simply relabelled before being accepted. The remaining 47 terms were mapped onto
16 groups of two to eight terms, with each group considered to relate to a sufficiently similar phenomenon
for them to be single candidate morbidities. Members of the panel confirmed that they wanted the term
‘extracorporeal membrane oxygenation (ECMO)/mechanical support’ to feature on its own, as well as being
an indicator of a ‘major adverse event’ (MAE). A new term (‘liver injury’) was added as a candidate at this
stage, with the agreement of the panel. This gave 29 candidate morbidities.
These candidate morbidities and the group ranking of importance among them in the first round of voting
are shown in Table 2. It is worth noting that, in this first round of voting, the group ranked ‘new global
permanent neurological impairment’ as the most important morbidity. After that, there was a group of
22 candidate morbidities that could only be separated by applying tie-breaks, with the other six candidate
morbidities [including ‘necrotising enterocolitis’ (NEC)] ranked as less important.
In the discussion that followed the first round of voting, the panel merged the two items describing
neurological impairment and individual panellists expressed surprise at the low ranking of ‘NEC’ and
‘vascular thrombosis’, leading to a discussion of these particular morbidities and their impact.
The results of the second round of voting are shown in Table 3. Although the panel’s view of the top
three morbidities [including the merged item of ‘new permanent neurological impairment (global or focal)]
was clear, there was a large group of 21 candidates that could only be separated by applying tie-breaks.
This group included ‘NEC’ and ‘vascular thrombosis’. Given the lack of unambiguous group preference
among these 21 candidates, the panel decided to request that the separate definition panel considered the
24 candidate morbidities given in bold in Table 3, with the remainder discarded.
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Between panel meetings 1 and 2
Causal mapping
Following the first selection group meeting, it was decided that it might be useful for non-clinical members
of the panel to have an accessible summary of any causal relationships among candidate morbidities so
that, when choosing the best set of morbidities to monitor, any overlap or redundancy among candidates
could be accounted for. To this end, a set of causal mapping exercises was conducted by one of the
facilitative team (MU) separately with two of the panellists (IM and HJ). In each exercise, cards representing
shortlisted morbidities were placed on a large sheet of paper and arranged left to right, with lines drawn
to indicate potential causal relationships. Photographs were taken of these causal maps, which were then
converted to diagrams (see Appendix 4).
TABLE 2 Candidate morbidities at the end of the first round of voting
Morbidity
Rank
Before tie-breaks After tie-breaks
New global permanent neurological impairment 1 1
New impaired cognitive function more than a month after surgery 2 2
Unplanned reoperation/reintervention 2 3
Developmental delay 2 4
MAE 2 5
Problems feeding (graded) 2 6
Mental health consequences 2 7
Length of ICU stay 2 8
New focal permanent neurological impairment 2 9
Low cardiac output (categorised) 2 10
Poor communication between clinical team and family 2 11
ECMO/mechanical support 2 12
Acute kidney injury (graded) 2 13
Prolonged pleural effusion 2 14
Complications during surgery 2 15
Hospital acquired infection (graded/categorised) 2 15
Prolonged hospital length of stay 2 17
Complete heart block (categorised) 2 18
Surgical bleeding (graded) 2 19
Questionable clinical team decision and diagnosis 2 20
Level of support from hospital available at home 2 21
Recurrent laryngeal nerve palsy 2 21
Phrenic nerve injury 2 23
Necrotising enterocolitis 24 24
Vascular thrombosis (graded) 25 25
Junctional ectopic tachycardia 26 26
Elevated pulmonary vascular resistance 27 27
Liver injury (graded) 27 27
Sensory neural deafness 27 27
ICU, intensive care unit.
Reproduced from Pagel et al.90 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
This table includes minor additions and formatting changes to the original text.
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Selection panel meeting 2: incorporating feasibility and overlap
Preparation
Prior to the second panel meeting, panellists were provided with a pack of materials containing:
l a summary of any estimates of incidence and impact of candidate morbidities from the
systematic review
l the judgement of the definition panel on the feasibility of defining, measuring and monitoring routinely
each candidate morbidity
TABLE 3 Morbidity rankings after the second round of voting
Morbidity
Rank
Before tie-breaks After tie-breaks
New permanent neurological impairment (global or focal) 1 1
New impaired cognitive function more than a month after
surgery
2 2
Unplanned reoperation/reintervention (categorisation) 3 3
Length of ICU stay 4 4
MAE 4 5
Problems feeding (graded) 4 6
Developmental delay 4 7
ECMO/mechanical support 4 8
Low cardiac output (categorised) 4 8
Mental health consequences 4 10
NEC 4 11
Hospital acquired infection (graded/categorised) 4 12
Prolonged hospital length of stay 4 13
Acute kidney injury (graded) 4 14
Prolonged pleural effusion 4 15
Poor communication between clinical team and family 4 16
Recurrent laryngeal nerve palsy 4 17
Vascular thrombosis (graded) 4 18
Surgical bleeding (graded) 4 19
Complications during surgery 4 20
Complete heart block (categorised) 4 21
Questionable clinical team decision & diagnosis 4 22
Phrenic nerve injury 4 23
Level of support at home 4 24
Junctional ectopic tachycardia 25 25
Sensory neural deafness 26 26
Elevated pulmonary vascular resistance 27 27
Liver injury (graded) 27 27
ICU, intensive care unit.
Note
Twenty-four candidate morbidities are given in bold.
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l a summary of potential long-term impacts of each candidate morbidity from the definition panel
l a summary of the parent and family focus groups and the online forum
l diagrams generated through the causal mapping exercise provided in Appendix 4
l minutes from the first meeting
l a statement of the purpose of the second meeting and its agenda.
Structure of the second panel meeting
At the beginning of the second meeting the panel were given a brief reminder of the scope of the overall
project, the remit of the selection panel and the time scales we were working to.
The panel were tasked with narrowing the list of shortlisted candidates to a selection of 6–10, the
incidence and impact of which would be measured in five centres over 18 months. It was explained that
the upper limit of 10 morbidities was a result of the sample size required for measuring the impact of
distinct morbidities. It was explained that we could measure just the incidence of other morbidities, if
possible, from routine data. Panellists were also alerted to the (then) recently launched ‘NHS England
consultation on the future of Children’s Heart Services in England’, which highlighted the possibility of
future national audit of surgical morbidities.
Panellists were asked to consider the following.
Feasibility of measurement including time scales
Given our plans to measure the impact of morbidities, the project team stressed that selected morbidities
needed to be identifiable in a timely manner. This aspect was the special consideration of the definition
panel (see Chapter 5).
Overlap and redundancy among selected morbidities
The project team made the point that selecting morbidities that almost always occur with other selected
morbidities would pose problems in terms of measuring their individual impact. It highlighted that length
of stay measures are particularly problematic in this respect.
Incidence
Selected morbidities needed to have an incidence of at least 1.5–2% to measure their impact over
18 months, owing to sample size considerations.
A summary of the judgements of the definition panel was presented to the panel, consisting of an array
showing the shortlisted candidates placed vertically based on the group ranking of importance from meeting
1 and horizontally in terms of the feasibility of monitoring that morbidity (this is shown in Chapter 11).
The panel were then asked in a secret ballot to nominate morbidities for exclusion and others for inclusion,
without further discussion. The panel discussed the remaining morbidities as a group.
After the panel meeting, a written summary of the discussion was circulated and an online poll conducted
to obtain the group ranking of importance among the shortlisted candidate morbidities. The poll was
conducted to elicit the views of panellists who were not able to attend and to identify replacement
morbidities if any of those selected were judged to be infeasible to monitor in routine practice. We used
the online voting tool (URL: www.crankit.io; accessed 22 September 2014), which uses the same algorithm
for robustly inferring group preferences from individual preference data that was used in the selection
meetings and which is outlined in Appendix 3.
Results of the second panel meeting
Of the 15 panellists, six could not attend. An overview of the results of the first year’s selection process
is given in Figure 1. The initial assessment of the definition panel as to the feasibility of defining and
monitoring each of the candidate morbidities still in contention after the first selection panel meeting is
shown to the right-hand side of Figure 1.
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Brain damage
New permanent neurological impairment (global or focal)
New impaired cognitive function more than a month after surgery
Unplanned reoperation/reintervention
Length of ICU stay
Near miss (categories, e.g. cardiac arrest, ECMO, SUI)
Problems feeding (graded)
Developmental delay
Low cardiac output (categorised)
Mental health consequences
Hospital-acquired infection (graded/categorised)
Acute kidney injury (graded)
Prolonged pleural effusion
Recurrent laryngeal nerve palsy
Vascular thrombosis (graded)
Surgical bleeding (graded)
Complete heart block (categorised)
Questionable clinical team decision and diagnosis
Phrenic nerve injury
Level of support at home
Elevated pulmonary vascular resistance
Liver injury (graded)
Introduced at consolidation stage
Brain injury
Focal permanent neurological impairment
Easier to define
and monitor
Candidates not passed
to definition panel
Suggestions from
individual panellists
Candidate morbidities
following consolidation/discussion
Candidates in descending order of importance as judged
by selection panel on second round of voting and arranged
horizontally based on definition panel feedback on ease
of definition and monitoring in routine practice
Suggestions removed
at consolidation stage
Harder to define
and monitor
Global permanent neurological impairment
Irreversible neurological damage
Seizures
Impaired cognitive function more than a month after surgery
Unplanned reoperation within 30 days
Chest exploration
Length of ICU stay
Prolonged ventilation
Cardiac arrest
ECMO/mechanical support
Any serious incident during patient stay
Delay in establishing feeding
Gastrosomy
Problems feeding
Reflux/vomiting
Tracheostomy
Growth retardation
Developmental delay
Low cardiac syndrome
Myocardial ischaemia
Adjustment to difference (by child)
Anxiety/fear/aggression in child
Hospital procedural anxiety
Post-traumatic stress disorder
Psychological/behavioural issues
Necrotising enterocolitis
Mediastinitis
Respiratory infection
Sepsis
Stemal wound infection
Prolonged hospital length of stay
Acute kidney injury
Long-term renal support (dialysis)
Renal failure/insufficiency
Renal replacement therapy
Pleural effusion
Chylothorax
Poor communication between clinical team and family
Laryngopharyngeal disfunction
Vocal cord disfunction
Swallowing and choking
Thrombosis
Thrombosis of venous pathways
Massive haemorrhage
Complications during surgery
Permanent pacemaker
Wrong clinical decision
Wrong clinical diagnosis
Diaphragmatic palsy
Lack of support at home by health service
JET
Sensory neural deafness
Pulmonary hypertension
Swelling of head and neck
Delayed chest closure
Superior vena cava obstruction
Attachment problems between parents and child
Financial difficulties
Quality of life
Cost per quality measure
Death before surgery/delayed surgery
Neurological insult
Stroke
New permanent neurological impairment (global or focal)
Unplanned reoperation/reintervention
Acute kidney injury (graded)
Length of ICU stay
Complete heart block (categorised)
JET
Sensory neural deafness
Elevated pulmonary vascular resistance
Liver injury (graded)
Near miss (categories, e.g. cardiac arrest, ECMO, SUI)
ECMO/mechanical support
Necrotising enterocolitis
Prolonged hospital length of stay
Prolonged pleural effusion
New impaired cognitive function more than a month after surgery
Developmental delay
Recurrent laryneal nerve palsy
Low cardiac output (categorised)
Complications during surgery
Phrenic nerve injury
Hospital-acquired infection (graded/categorised)
Poor communication between clinical team and family
Selected immediately at
second selection panel meeting
Selected after discussion at
second selection panel meeting
Excluded immediately at
second selection panel meeting
Excluded after discussion at
second selection panel meeting
Not selected as a morbidity for
study but to be tracked
Problems feeding (graded)
Mental health consequences
Questionable clinical team decision and diagnosis
Level of support at home
Vascular thrombosis (graded)
Surgical bleeding (graded)
FIGURE 1 Overview of results as presented to the selection panel. ICU, intensive care unit; JET, junctional ectopic tachycardia; SUI, sudden unforeseen incident. Reproduced
from Pagel et al.90 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. This figure
includes minor additions and formatting changes to the original text.
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Eleven candidate morbidities were considered straightforward to define and monitor in routine practice:
(1) ‘unplanned reoperation (URO)/reintervention’; (2) ‘length of intensive care unit (ICU) stay’; (3) ‘MAE
(e.g. cardiac arrest, ECMO, serious untoward incident)’; (4) ‘ECMO/mechanical support’; (5) ‘NEC’;
(6) ‘prolonged hospital length of stay’; (7) ‘acute kidney injury’; (8) ‘prolonged pleural effusion (PPE)’;
(9) ‘vascular thrombosis’; (10) ‘surgical bleeding’; and (11) complete heart block’.
Six candidate morbidities were considered less straightforward: (1) ‘new permanent neurological impairment
(global or focal)’; (2) ‘problems feeding’; (3) hospital-acquired infection’; (4) ‘poor communication between
clinical team and family’; (5) ‘complications during surgery’; and (6) ‘phrenic nerve injury’.
The remaining seven candidate morbidities were deemed difficult to define and monitor in routine practice:
(1) ‘new impaired cognitive function more than a month after surgery’; (2) ‘developmental delay’; (3) ‘low
cardiac output’; (4) ‘mental health consequences’; (5) ‘recurrent laryngeal nerve palsy’; (6) ‘questionable
clinical team decision and diagnosis’; and (7) ‘level of support at home’.
The output from the causal mapping exercises given (see Appendix 4) highlighted how ‘mental health
consequences’ could be a result of several other candidate morbidities, how the majority of candidate
morbidities could result in prolonged stay in the ICU or hospital and how ‘low cardiac output’ could
become manifested in several of the other candidate morbidities.
Based on these assessments and the selection panel’s own previous assessment of the importance of these
morbidities, it was agreed that the following candidate morbidities would be selected without further
discussion: ‘new permanent neurological impairment (global or focal)’; ‘URO/reintervention’; ‘problems
feeding’; ‘acute kidney injury’; and ‘poor communication between clinical team and family’.
The following candidate morbidities were discarded at this point without further discussion: ‘mental health
consequences’; ‘prolonged hospital stay’, ‘questionable clinical team decision and diagnosis’; and ‘level of
support at home’.
The remaining 15 candidate morbidities were then discussed, with the panel reminded of the need to
select at most five from these 15. Group decisions were made to select ‘ECMO’, ‘MAE’, ‘NEC’, ‘hospital-
acquired infection’ and ‘recurrent laryngeal nerve palsy’. Note that the group accepted that ‘MAE’ should
not include ECMO, as this had been selected as a distinct morbidity.
Group decisions were made to discard at this stage ‘new impaired cognitive function more than one
month after surgery’, ‘developmental delay’, ‘low cardiac output’, ‘PPE’, ‘vascular thrombosis’, ‘surgical
bleeding’, ‘complications during surgery’, ‘phrenic nerve injury’ and ‘length of ICU stay’.
The online poll conducted after the second panel meeting identified ‘recurrent laryngeal nerve palsy’,
‘phrenic nerve injury’, ‘complete heart block’ and ‘PPE’ as potential substitute morbidities in the event of
the definition panel vetoing any of the selected morbidities in routine practice.
Review of selected morbidities by definition panel and
chief investigators
The selected morbidities were then reviewed by the definition panel, which could veto inclusion of a
selected morbidity if, after careful consideration and discussion with the chief investigators (VT and KB),
it was deemed infeasible to define and monitor in routine practice.
Of the morbidities selected by the panel, two (‘poor communication between clinical team and family’
and ‘recurrent laryngeal nerve palsy’) were removed from the final list. In each case this was carried out
on the grounds that the morbidity concerned would be too problematic to measure in routine practice.
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The morbidity ‘PPE’ was added to the final list of morbidities as a substitute, as this was the next ranked
morbidity, at number 10. Feeding problems due to symptomatic recurrent laryngeal nerve palsy were then
included under ‘problems feeding’. The definition panel and the project team decided to monitor the
incidence of phrenic nerve injury and complete heart block by using routinely collected cardiac audit data.
These changes were shared with the selection panel.
The final nine morbidities chosen for inclusion in the study, using the revised labels provided in the final
selection, are listed in Box 2.
Alongside these nine morbidities, the study team committed to measuring poor communication between
the clinical team and the family among the patients entering the matched cohort phase of our study, and
to conducting secondary analyses to identify the impact of longer stays in the ICU above and beyond the
impact of the selected morbidities.
Selection panel meeting 3: review of the selected morbidities
The final definition panel took place (January 2018) before the final selection panel, so that the final definition
panel views on feasibility could feed into the final selection panel meeting. The final selection panel
meeting was held in May 2018, with seven panellists being unable to attend. Panel members were given
the preliminary results of the incidence and impact study data which are covered, in full, in Chapters 7–9.
Members who could not attend were given the opportunity to provide comments to the chairperson
beforehand for inclusion in the discussion, which three absent members did do before the meeting. During
the meeting, CP presented the overall results to the group and the group discussed each of the morbidities
in turn in terms of its suitability for routine monitoring within hospitals. Members were told that at this stage
no morbidities needed to be dropped and that morbidities should be considered in terms of:
l the incidence of each candidate morbidity as measured in the study
l the experience and any difficulties that teams had in capturing the relevant data
l partial/preliminary analysis of the impact that each morbidity has in terms of quality of life, length of
stay in hospital and other outcomes at 6 months
l the extent to which monitoring each of the morbidities studied could support improvement initiatives.
BOX 2 The nine candidate morbidities
Morbidity
1. Acute neurological event (ANE).
2. Unplanned reintervention (URO).
3. Feeding problems (Feed).
4. Need for renal replacement therapy (Renal).
5. Major adverse event (MAE).
6. Extracorporeal life support (ECLS ECMO).
7. Necrotising enterocolitis (NEC).
8. Post-surgical infection (SSI).
9. Prolonged pleural effusion or chylothorax (PPE).
DOI: 10.3310/hsdr08300 HEALTH SERVICES AND DELIVERY RESEARCH 2020 VOL. 8 NO. 30
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
The panel also noted the low mortality rates and lower lengths of stay among children who had none
of the nine measured morbidities, giving confidence that the main morbidities were indeed captured
within the study.
Finally, the panel discussed the initial results from the communication questions from the impact substudy
(see Chapter 8). The panel thought that the results were very interesting and although they considered
measuring communication routinely within hospitals infeasible, they suggested that NHS England could be
asked to consider including the six communication questions within their parent congenital survey that is run
every few years and to report results back to each unit. The panel recommended that future funding should
be sought to better understand the communication and interaction between families and clinical teams.
Summary, limitations and future steps
Neurodevelopmental outcomes
At each stage of selection, the morbidity that was ranked of greatest importance by the panel was
neurological impairment. This came as little surprise to the study investigators and vindicates the inclusion
in our overarching programme of research of a parallel evaluation of the BDA, which it is hoped will
provide a tool that can be deployed by nursing staff to identify patients who would benefit from referral
to specialist neurological or other developmental services.
Differing priorities between health-care professionals and lay people
We found that opening up the process of choosing the metrics by which services should monitor their
performance to include the perspectives of patients and family representatives, which is in line with policy
initiatives in England,97 brought challenges. Throughout our work, there was a tension between choosing
a ‘clean’ set of ‘clinical’ measures that most closely matched the understanding of ‘surgical morbidity’
among the tertiary clinicians on the panel, and the inclusion of arguably murkier phenomena considered
hugely important by families and those working in secondary care. It is fair to say that inclusion on the
panel of family representatives and clinicians from outside the tertiary surgical centres brought other issues,
such as problems feeding and poor communication between clinical teams and families, to greater
prominence than if the panel had consisted solely of tertiary clinicians, or if the study investigators had
chosen the morbidities themselves.
Attribution of cause
In particular, those working in surgical centres were more concerned than family representatives and others
with the attribution of morbidity to the surgical act, keen to include morbidities that may be related in part
to surgical technique (laryngeal nerve palsy and phrenic nerve injury) and degree of success (low cardiac
output), and were anxious to avoid the attribution to surgical teams of morbidities that are currently
considered to ‘come with the territory’ of CHD and its surgical treatment. Family representatives and others
highlighted the value of gathering information on the incidence and impact of key morbidities, even if they
were not caused by surgery, not least as some of them may be reducible through interventions at other
points in the care pathway.
Benefits and limitations of the methodology we used
We consider that the features of our study design were vital in terms of drawing out and balancing the differing
perspectives. The nominal group technique, starting as it does with an opportunity for each panellist to speak
without interruption and within an embedded democratic process, is specifically designed to minimise the
influence of perceived power differentials and dominant personalities within a group. This was reinforced
by the use of a secret ballot process to determine group preferences, allowing panellists to record their
disagreement with the positions stated by others without that being openly declared. The voting tool used
distinguishes between unambiguous group preferences and those that rely on tie-breaking. This acceptance
and presentation of lack of consensus helped to focus discussion on where it would be most valuable to the
task of selecting a group of morbidities and divert unnecessary debate focused on achieving a false consensus
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through attrition. Nonetheless, we recognise that the final selection of morbidities inevitably reflects the
composition of the panel. In choosing panel members we wanted to keep the numbers down to a
manageable number for an in-person group; we took the view that a group of > 14–18 participants would be
too many for a constructive discussion to be feasible. Moreover, we also wanted a balance between project
partners and independent panel members from non-study sites. We were disappointed that despite our best
efforts we were unable to recruit a GP to the panel.
In addition, our choice to separate the process of identifying which morbidities are most important from
the process of assessing the feasibility of defining and monitoring morbidities prevented all parties from
self-censoring and clinical panellists from unconsciously using or claiming privileged knowledge of
measurement processes to strengthen the case for morbidities that they wanted to include.
Firm and expert chairing was essential to maintaining this discipline. Having a chairperson conversant with
the clinical area but also experienced in working with multistakeholder groups, including patient and
family representatives, was also key. Although it meant that the chairperson brought their own clinical
perspective to the table, the panel benefited from the chairperson’s ability to distinguish between the
wheat and chaff of clinical discussions and summarise for non-clinical participants. It is also questionable
whether or not a chairperson that was not an accomplished surgeon and clinical researcher would have
held the respect of all parties through the process.
Separating the processes of judging the importance and the feasibility of routinely monitoring morbidities
did, however, risk some of the subtlety of discussions slipping through the gaps between two panels
of people. Although the preparation of detailed summaries of panel meetings and the presence of the
same facilitating team (CP and MU) at all meetings reduced this risk, we acknowledge that the defined
morbidities that will be monitored do not correspond exactly in all cases to the phenomena deemed
important by the selection panel.
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Chapter 5 Definition of important early morbidities
after paediatric cardiac surgery
Parts of this chapter are reproduced from Brown et al.98 This is an Open Access article distributed inaccordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions
and formatting changes to the original text.
Introduction
This chapter details the definitions of morbidity that the panel recommended and is based on our open
access publication on this topic in the Cardiology in the Young journal.98
As has been noted in Chapter 1, in order for morbidities that may arise after paediatric cardiac surgery to
become more visible, they must first be selected and defined. The definitions need to be feasible to apply
during the conduct of usual care within the NHS. Hence, working in parallel alongside the selection panel,
a second group consisting entirely of health professionals, referred to as the definition panel, worked with
the prioritised list of potential morbidities to both define and assess the practicality of measuring them in
routine clinical practice.
Definition panel process overview
We convened three meetings with the surgical morbidity definition panel over the course of the study:
two meetings were held in years 1–2 of the study, each taking place after the selection panel had met
(June 2014 and February 2015), and a third meeting was held in the final year (January 2018).
The panel members consisted of three paediatric cardiac surgeons (one was the chairperson), three paediatric
cardiologists (one specialising in adult CHD), three paediatric intensive care specialists and two children’s
heart disease nurses.
The definition panel aimed to:
l establish the diagnostic criteria that constitute the definition of each of the morbidities, as prioritised by
the selection panel (see Chapter 4)
l define the measurement protocol for each of the morbidities, including any aspects that require
additional specialist input or alternatively surveillance outside the tertiary centre
l outline the minimum standards of the clinical pathway and necessary referrals and treatment for
children who experience morbidities over the first 6 months post operation.
This third part of the work drew on information selected from literature review and any relevant
established guidelines.
Meetings 1 and 2
In its first phase of work, conducted through an initial face-to-face meeting followed by e-mail
correspondence, the definition panel provided the selection panel with views on whether or not each
candidate morbidity nominated by the first meeting of the selection panel was definable, measurable
and feasible to measure in routine practice, highlighting any additional issues identified in relation
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to each morbidity. One or two clinical leads were identified to take forward each of the individual
shortlisted morbidities, utilising both e-mail and web-based interactions to develop each morbidity
definition, reporting back at the second meeting of the definition group with an agreed package to
sign off. Clinical leads consulted with other experts in the relevant field in order to optimise definitions
and protocols, when necessary.
At the first meeting, the definition panel considered 22 morbidities listed for them at the first selection
panel meeting (see Table 3). After consideration by the definition panel, both within the meeting and after
individual deliberation and consultation outside the meeting, these were fed back to the selection panel
with a directive as to the feasibility of measurement (Figure 2).
At the second definition panel, the group went through a short list of 11 morbidities that were ranked and
presented to them by the selection panel. These morbidities were each individually discussed in more
detail. The protocols for identification, measurement and management of the nine shortlisted morbidities
are presented in Table 4. These are listed in order, as ranked by the selection panel, and details presented
include time and measurement criteria, when applicable. All nine morbidity definitions were designed for
use in a multicentre evaluation of morbidity incidence and impact, with suitability for routine use a key
requirement. Two further morbidities that were ranked by the selection panel, communication problems
and prolonged length of stay, were not included in the final list of nine and are discussed further in
Chapters 8–10.
MOST IMPORTANT
STRAIGHTFORWARD OK DIFFICULT
Unplanned reoperation/reintervention
New permanent
neurological impairment
(global or focal)
Problems feeding (graded)
New impaired cognitive
function > 1 month
after surgery
Developmental delay
Low cardiac output (categorised)
Mental health consequences
Recurrent laryngeal
nerve palsy
Questionable clinical team
decision and diagnosis
Level of support at home
Hospital-acquired infection
Poor communication
between clinical team
and family
Complications during surgery
Phrenic nerve injury
Length of ICU stay
Major adverse event (e.g. cardiac
arrest, ECMO, SUI)
ECMO/mechanical support
Necrotising enterocolitis
Prolonged hospital stay
Acute kidney injury (graded)
Prolonged pleural effusion
Vascular thrombosis
Surgical bleeding
Complete heart block
FIGURE 2 Summary of the feasibility of defining and measuring vs. importance. SUI, sudden unforeseen incident.
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TABLE 4 Final definitions for the nine paediatric cardiac surgical morbidities
Morbidity Time scale for identification Definition
Measurement protocol
(if additional to definition) Minimum treatment protocol
ANE Includes neurological morbidities
that, based on best clinical
judgement, arose as new findings
around the time of surgery that
were detected within the same
hospitalisation as the surgery.
It is recognised that in certain
circumstances, such as when a
child is very sick on life support,
pre-procedure assessment is
challenging. In these circumstances,
as full an evaluation as possible is
to be completed, incorporating
serial assessments over time
Neurological events, including
seizure, abnormal movement
(includes choreiform or athetoid),
focal neurological deficit (includes
hemiplegia and monoplegia),
intracranial haemorrhage, stroke,
brain death, reversible ischaemic
neurological dysfunction,
hypoxic–ischaemic encephalopathy,
spinal cord ischaemia, basal ganglia
damage or brain stem injury
(includes abnormal cough or gag
reflex)99
Includes new abnormality in any of
the following:
l electroencephalogram
l brain scan (either computerised
tomography or magnetic
resonance)
l clinical evaluation
(Seizures or movement disorder,
focal neurological signs, generalised
neurological signs, altered
conscious level, including even
brain death)
The treatment protocol is variable
depending on the type of
neuromorbidity
Specialist consultation with a
neurologist, a full evaluation of any
brain injury and neurodevelopmental
follow-up would be a minimum
URO or reintervention UROs are procedures outside the
expected patient pathway, which
may be undertaken at any time
from the start of the postoperative
admission up until 30 days
following the primary operation.
Additional procedures or revisions
undertaken within the primary
trip to the operating theatre
(incorporating return onto
cardiopulmonary bypass) are not
included in the definition of
reoperation
UROs include procedures that were
not intended during the planning
phase, follow an initial primary
cardiac surgery and result in
‘substantive alteration to heart’,
incorporating cardiac bypass,
cardiac non-bypass, pacemaker
placement, interventional
catheterisations and also diaphragm
plications (which are not related
to the heart itself). The definition
does not include support or other
non-cardiac surgery procedures
Unplanned return to the operating
room or cardiac catheter laboratory
within 30 days
(Excludes interventional catheters
that were planned preoperatively,
excluding delayed chest closure and
procedures for bleeding)
(Includes diaphragm plication
and insertion of pacemaker for
surgically acquired arrhythmia)
Not applicable. The minimal
assessment is cardiovascular
evaluation of the repair with
echocardiography and tolerance
of weaning from life supports
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TABLE 4 Final definitions for the nine paediatric cardiac surgical morbidities (continued )
Morbidity Time scale for identification Definition
Measurement protocol
(if additional to definition) Minimum treatment protocol
Feeding problems A diagnosis of postoperative
feeding problems should be
considered during recovery after
surgery and prior to discharge from
the specialist centre either to home
or to secondary care if the child is
unable to feed normally. The goal
is detection of feeding problems
which are new post surgery, and
it is recognised that this may be
challenging when a child was not
fed preoperatively for cardiac
reasons, as feeding ability will not
have been assessed objectively
A child may fail to feed normally
following paediatric cardiac surgery
for a range of reasons, including
gastro-oesophageal reflux, vocal
cord paralysis, oral–motor
dysfunction, oral aversion and
neurological impairment.100 If for
any of these reasons a child is not
able to orally feed or completely
orally feed and is tube dependent
at discharge from the tertiary
centre or at 30 days (if he or she is
otherwise clinically stable enough
to feed at that time point), then a
postoperative feeding problem will
be diagnosed
The requirement for any feeding
support
Includes via the intravenous route
or via an enteral tube
Excludes feeding support that was
present to treat a primary problem
diagnosed before the surgery,
feeding support related to an
episode of NEC and feeding
support because the child dislikes
a special diet
Treatment includes assessment by
the dietitian and the speech and
language therapist, and assessment
of the patient’s weight. Progress
with feeding should be monitored
by the clinical care team responsible
at each stage of the journey
Need for renal replacement
therapy
Includes renal replacement therapy
when initiated as a new support
at any time from the start of the
postoperative admission to ICU up
until 30 days following the primary
operation
The child requires renal
replacement therapy (peritoneal
dialysis or haemofiltration) for renal
failure (oliguria of < 0.5 ml/kg/hour
and elevated creatinine level for
age) and or fluid overload. In
patients for whom renal support
is required alongside ECLS, the
primary morbidity is viewed as ECLS
The measurement protocol is
simply the presence of (new) renal
support. (Excludes renal support on
ECLS.) Data on renal biochemistry
and urine output will be collected
Instigation of effective renal
replacement therapy
If recovery of kidney function does
not occur within 3–5 weeks, then
consultation with paediatric renal
physician is required
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Morbidity Time scale for identification Definition
Measurement protocol
(if additional to definition) Minimum treatment protocol
Major adverse cardiac events or
never events
Events within this morbidity may
be identified during the tertiary
hospital stay (either ward or ICU)
following the primary surgery
These morbidities include:
l cardiac arrest, when the child
receives any chest compressions
or defibrillation
l chest reopening on the ICU or
ward for any reason
l major haemorrhage in the ICU
following surgery
l a ‘never event’ applicable to
paediatric cardiac surgery, as
selected from the ‘never events’
list published by the NHS for
2015101 (including wrong site or
wrong patient surgery, wrong
prosthesis surgery, retained
foreign object post procedure,
wrong route administration of
medication, transfusion or
transplantation of main red cell
group incompatible blood
components or organs,
misplaced nasogastric or
orogastric tubes)
l tissue injury to limb or vital
organ, such as perforated viscus
or ischaemic limb injury
Major haemorrhage is defined as
bleeding > 10ml/kg/hour on ICU
for 2 consecutive hours
A ‘never event’ includes the events
listed plus harm to the patient, for
example if a nasogastric tube is
misplaced, detected and removed
in a timely manner before any harm
is done then this is not a ‘never
event’. Conversely, if the misplaced
nasogastric tube is not noted, and
feed is given into the bronchus,
then this is a ‘never event’
All events will result in immediate
treatment as part of current
practice
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TABLE 4 Final definitions for the nine paediatric cardiac surgical morbidities (continued )
Morbidity Time scale for identification Definition
Measurement protocol
(if additional to definition) Minimum treatment protocol
ECLS ECLS following surgery and before
discharge from the tertiary hospital,
including the rare cases when a
child was on ECLS before surgery
This morbidity is defined by the
presence of an ECLS system
connected to the patient following
the operation, whether it was
placed in the operating theatre
or in the ICU, and whether the
indication was cardiac arrest, low
cardiac output state, poor cardiac
function, arrhythmia, residual
or recurrent cardiac lesion, or
pulmonary, including pulmonary
hypertension or sepsis
It is recognised that children on
ECLS following paediatric cardiac
surgery have high rates of other
complications, including renal
support, bleeding, sepsis, sternal
reopening, and cardiac arrest.102
When such complications arise
as part of ECLS, the morbidity is
defined as ECLS
The morbidity is in fact a treatment
modality offered so this is not
applicable. Centres offering ECLS
follow protocols based on those
provided by the ECLS organisation13
NEC NEC as a new diagnosis from after
surgery until discharge from the
tertiary hospital
NEC class 1a or 1b,103 which
incorporates babies with systemic
signs of inflammation and
abdominal clinical signs, such as
distension or larger than normal
gastric aspirates or mild rectal
bleeding, but no radiological
changes are included, if a general
surgery specialist has seen the child
and commenced a course of
intravenous antibiotics and
parenteral nutrition for 5–7 days.
Cases of severe NEC with
radiological signs, systemic
instability and bowel perforation
are also included
Data in respect of systemic clinical
signs, intestinal signs and radiology
will be collected, as well as the
treatments deployed, thus enabling
the NEC diagnosis to be graded
between 1a and 3b14
Consultation with general surgery
and further management in respect
of antibiotics, nutrition, radiological
investigation and surgical
intervention
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Morbidity Time scale for identification Definition
Measurement protocol
(if additional to definition) Minimum treatment protocol
Surgical site infection and
bloodstream infection
Surgical site and bloodstream
infections diagnosed within the
hospital admission following
surgery or following readmission to
the same unit during postoperative
recovery, where the treating clinical
team assesses the infection to be
linked to the recent operation. It is
noted that mediastinitis may be
detected > 30 days after cardiac
surgery;104 hence this time cut-off is
not applicable
Deep surgical site Infection and/or
mediastinitis includes any infection
of an incised wound that
undergoes any reintervention
by a surgeon (such as opening
of the wound, vacuum dressing),
mediastinitis and false aneurysm,
independent of culture positivity23
Bloodstream infection includes both
catheter related and non-catheter
related. Cases have systemic signs
of infection, a positive culture not
judged to be a contaminant, and in
the case of line related a catheter
in place with positive cultures
from the line or from the line tip
when removed
Endocarditis based on clinical,
imaging or culture evidence judged
to be diagnostic of endothelial/
endocardial infection and its
sequelae cardiac or
extra-cardiac
Deep surgical site infection excludes
superficial site infection managed
without a surgeon’s reoperation by
conventional nurse dressing only,
even if the wound heals by
secondary intention
The minimum treatment protocol
consists of antibiotics based on
organism and sensitivities and,
when relevant, the removal of the
line. Surgical intervention may be
required for deep surgical site and
in some cases of endocarditis. Both
conditions require prolonged
antibiotic therapy
PPE or chylothorax PPE is a post-procedural effusion
with a duration of > 10 days.
Chylothorax is diagnosed from after
surgery until discharge from the
tertiary hospital
Either a chylous pleural effusion,
significant chylous pericardial
effusion, significant chylous ascites
or a prolonged non-chylous
effusion that necessitates thoracic
drainage at least 10 days following
index cardiac surgery
Chylous effusions are characterised
by a milky appearance and a
pleural fluid white blood cell count
of > 1000 cells/µl, with lymphocytes
> 80%.105 If the child is on normal
feeds the triglyceride level in the
pleural fluid will be > 1.1 mmol/l
or the ratio between the pleural
triglyceride level and the serum
triglyceride level will exceed 1
Diet consisting of medium-chain
triglycerides or low fat for
chylothorax. On a patient-by-
patient basis other treatments
include parenteral nutrition,
octreotide infusion, intervention for
venous obstruction thoracic duct
ligation and pleurodesis
Reproduced from Brown et al.98 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. This table includes minor
additions and formatting changes to the original text.
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Implementation of definitions
The morbidity definitions were implemented by a small group of nurses, intensive care doctors and
cardiothoracic surgeons, within five children’s heart centres based in the UK, over a period of 2 months at
the commencement of the incidence study. During the prospective identification of cases of morbidity as
part of the wider research study,106 the definitions underwent further refinement and clarification in order
to ensure that they were workable in the context of routine audit within the NHS.
Multiple morbidities
Within the context of the current study, which aimed to prospectively measure the incidence and impact
of defined morbidity events, the approach to the categorisation of morbidities within a given patient was
determined to be as follows:
l single morbidity events, as defined in Table 4
l extracorporeal life support (ECLS) morbidity, which may incorporate further identified morbidities
alongside ECLS
l multiple morbidities in instances when a patient has one or more morbidity, excluding ECLS.
Prolonged hospital stay
The selection panel further highlighted the importance of prolonged hospitalisation and poor communication
between the treating team and the family, which they considered to be morbidities. It was noted by the
definition panel that prolonged hospitalisation is linked to all post-procedural complications and, hence,
including the length of stay as a morbidity would make measurement of the incidence of individual
morbidities very challenging. It was noted that length of stay data will be reviewed and presented as part
of the data analysis.
Poor communication between treating team and family
The definition panel considered that there was the potential to define poor communication between the
treating team and family in the future, but that it would necessarily involve asking parents about their
experience in a way that would involve new data collection. The quality of communication between the
treating team and the family has previously been assessed within the context of a patient satisfaction
survey for all paediatric inpatients in England, commissioned by the Care Quality Commission and
undertaken by the organisation Picker Institute Europe.107
The survey questions were formally developed using focus groups and formally validated. The Picker Institute
agreed to assist the definition panel in identification of a shortlist of six questions to ask parents about
communication, and issued the research team with a licence to allow our study to use these questions
for patients recruited to a 6-month follow-up substudy, to delineate this issue further. From a long list of
25 candidate questions from the Picker Institute Questionnaire identified by the definition panel, the Picker
Institute ran the following analyses:
l Frequency analysis to ascertain the percentage of missing data and the percentage of patients
answering each of the possible responses.
l Interitem correlation analysis and principal component analysis to identify questions that provided
different dimensions of communication experience.
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The Picker Institute then advised the definition panel on five to seven questions that could be asked of
parents within 6 weeks of the patient’s primary operation. The final questions chosen by the definition
panel after discussion with the Picker Institute were:
l Question 1: did new members of staff treating your child introduce themselves?
l Question 2: were you encouraged to be involved in decisions about your child’s care and treatment?
l Question 3: were you told different things by different people, which left you feeling confused?
l Question 4: were the different members of staff caring for and treating your child aware of their
medical history?
l Question 5: before the operation or procedure, did a member of staff explain to you what would be
done during the operation or procedure?
l Question 6: did a member of staff tell you what to do or who to talk to if you were worried about your
child when you got home?
We did not set a threshold for what defines ‘poor communication’; instead, we will explore the range of
responses among control and case patients in our 6-month follow-up substudy and possible associations
with other clinical factors as part of secondary data analysis.
Summary
We present a list of consensus-based definitions of morbidities arising with paediatric cardiac surgery
that have been designed for prospective audit. The prioritised and defined morbidities reflect a range of
viewpoints and priorities, including those of professionals, patients and parents, as detailed in Chapter 4.
We note that the list contains morbidities that were previously prioritised as ‘complications’ by specialist
professionals and included in a recent consensus-based statement from the US MultiSocietal Database
Committee for Pediatric and Congenital Heart Disease,108 which are ECLS, renal support, pacemaker
placement, diaphragm palsy, new permanent neurological deficit and reoperation. However, our list also
contains further items not previously identified and prioritised, which are feeding problems, PPE and sepsis.
Challenges and limitations
In reaching these definitions certain challenges arose.
Consideration of pre-procedural factors
A major difficulty when contemplating the monitoring of morbidity following paediatric cardiac surgery
is achieving a distinction between the morbidity that was present in the patient before the operation,
compared with new morbidities that arose after surgery. It must be acknowledged that preoperative events,
such as existing congenital diagnoses and patient condition, are inextricably linked to the postoperative
journey6,9 and, indeed, both pre and postoperative events matter for the patient. Preoperative events may
also potentially be subject to quality control, for example the collapse of a neonate from late diagnosis of
heart disease leads to higher rates of multiple organ failure,109 and may be averted by antenatal diagnosis
and prospective management of the circulation.110 Nonetheless, our focus is on early outcomes after
paediatric cardiac surgery, not the entire care pathway. Hence, the definitions are designed to delineate
postoperative events as clearly as possible. The delineation of new neurological morbidity in a postoperative
patient may be challenging because of the inherent difficulties of assessing (in particular) small infants
that may be critically ill. Prospective serial evaluation including pre and postoperative scans and detailed
neurodevelopmental follow-up is the ideal. However, this is not feasible within a UK NHS context, where
cranial scans may only be undertaken based on clinical indicators of suspected neurological injury, hence
our definition is pragmatic by necessity, although we hope that in the future it will be supplemented by
enhanced methods of assessment.
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Post-procedural timing
Conventionally, the time horizon linked to surgical complications has been taken as 30 days following
the operation.108 For mortality outcomes, registries, such as STS in the USA, view the relevant time horizon
as within the same operative hospitalisation or 30 days, whichever is longer.111 For the majority of the
morbidity definitions the time limit of within 30 days and/or within the same hospitalisation was applied
(see Box 1) based on what was considered most appropriate for the individual morbidity event. Certain
morbidities, particularly those defined by the use of a technology (e.g. renal support, ECLS), are likely to
occur only within a hospitalisation, whereas others may occur at any time point over an operated child’s
lifespan (reoperation, endocarditis, feeding problems); hence, a time limit was placed accordingly in order
to enhance the feasibility of postoperative audit, despite this time limit in some cases appearing arbitrary.
It was noted that deep surgical site infection or mediastinitis, although always linked to cardiac surgery,
may arise after discharge home and later than 30 days post surgery, so the timeline was extended for
this morbidity.
Consistency and complexity of definitions
There are inherent practical difficulties with prospective audit of complex outcome measures; this is one
reason for the historic focus on mortality as an outcome, as this is much easier to measure than morbidity.
For some of the morbidities, a treatment indicating the presence of morbidity was considered the better
option, rather than basing the diagnosis on clinical findings. This applies to the postoperative morbidities
of renal failure, diaphragm paralysis and feeding problems, for which postoperative renal support, the
need for diaphragm plication and technology-assisted feeding at discharge were selected as the most
objective definitions available. A concern with using a treatment, rather than a diagnosis, as a measure
of morbidity is that treating centres may initiate therapy at differing thresholds. During the course of our
study, additional data items will be collected to explore the potential for such variation. To illustrate this
further with examples: practice patterns in respect of technology-assisted feeding in cardiac babies vary
widely between geographic regions and diagnostic groups, and it is acknowledged that the audit of
feeding problems at discharge rather than over time in outpatients may not capture the full picture.112
For the case of ECLS, there is an inextricable link between the severe condition of patients requiring this
therapy and the burden of the treatment itself,10,11,102 and, therefore, this is reasonably widely accepted as
a major morbidity after paediatric cardiac surgery by all stakeholder groups.1 Moreover, considering the
example of renal failure, given the complex inter-relationship between the patient’s preoperative condition
(which may incorporate renal dysfunction28), their age (especially very young neonates, as is common32),
their body mass index (which may be low in CHD), their postoperative condition and their measures of renal
function, a definition involving a specified measure of renal function was considered to be impractical to
define for routine use. Of note, it proved infeasible for the panel to agree a clear and usable definition of
low cardiac output syndrome for use in routine audit.
Reflections from the final definition panel meeting and future steps
During a final meeting of the definition panel in January 2018 (see Appendix 5), feedback on specific
morbidity definitions was discussed. It was noted that at the commencement of the current study,
the NCHDA has commenced mandatory audit of a subset of these morbidities: ECLS, URO, the need for
renal support and PPE.
It was noted that the definition of feeding problems was one of the most challenging to implement because
of the variable time horizon over which this can occur. The panel recommended that more thought should
be given to timelines for identification (e.g. at first outpatient appointment) and who would make the
assessment (e.g. nurse, dietitian, doctor).
The definition panel noted that the definition as stated of ANE is not fit for the purpose of capturing
neurodevelopmental outcomes and/or longer-term cognitive impairment, but that it does capture at least
some ANEs that remain important to measure.
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The definition panel noted that the NCHDA used a 7-day window to identify PPE for mandatory national
audit, rather than 10 days. The panel recommended that secondary analysis be undertaken to understand
the difference in incidence between 7 and 10 days but, in general, the 10-day definition was preferred.
The definitions presented in Table 4 incorporate feedback from five UK paediatric cardiac surgical centres
that implemented them prospectively with paediatric cardiac surgery patients as part of this funded
research study; however, we acknowledge that, as yet, the long-term practicalities involved in monitoring
these morbidities are unclear. The next stage is to report on the morbidities for the purposes of quality
assurance and to assess their impact on patients and families with formal prospective analysis.
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Chapter 6 Validation of the brief developmental
assessment
Parts of this chapter are reproduced from Brown et al.113 This is an Open Access article distributed inaccordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions
and formatting changes to the original text.
Introduction to neurodevelopmental issues in paediatric cardiac patients
Developmental and behavioural difficulties are common in children with CHD and may affect intelligence,8,36
academic achievement,40,114 language (development, expressive and receptive),33,40 visual construction and
perception,41,115 attention,44,45 executive functioning,116 fine motor skills,116 gross motor skills32,117 and
psychosocial maladjustment (internalising and externalising problems).118,119
The American Association of Pediatrics 2012 statement on neurodevelopmental outcomes in children
with CHD47 concludes that over and above what is offered to healthy children, those with CHD require
‘periodic developmental surveillance, screening, evaluation, and re-evaluation throughout childhood may
enhance identification of significant deficits, allowing for appropriate therapies and education to enhance
later academic, behavioural, psychosocial, and adaptive functioning’.
Stakeholders, especially parents, view the evaluation of developmental and behavioural difficulties in children
with CHD as one of their highest priorities.90 Although the benefits of early intervention for developmental
difficulties have not been specifically studied in children with CHD, early intervention has been recommended
across a range of paediatric contexts120 and is supported by studies of premature infants121 and autism;122
early recognition and intervention is also more satisfactory to families.123
Potential benefit of an early warning tool for children requiring
specialist cardiac care
As part of wider health screening in the UK, all children undergo periodic clinical checks with a
community-based nurse, referred to as a health visitor. These checks do not rely on formal developmental
tests, apart from the Ages & Stages Questionnaire® (Ages and Stages),124 which is used with children at
the age of 2 years. Despite the recognised higher risk of children with CHD (and indeed other young
children who suffer critical illnesses) for developmental delay, they do not routinely undergo any additional
developmental scrutiny over and above what is offered to the wider population of children, and nor do
they undergo any standardised assessment of neurodevelopment either before or after cardiac operations.
Health-care professionals trained in cardiac-related specialties (e.g. paediatric cardiologists, paediatric
cardiac surgeons and paediatric cardiac nurses) are not also trained in paediatrics or in child development
in the UK and, therefore, do not consider themselves equipped to undertake such assessments.
Paediatric cardiac services in the UK are centralised to 11 high-volume centres, which are responsible for the
majority of the follow-up of babies and young children with heart disease within linked networks of care. This
presents a potential opportunity for children to undergo periodic additional assessment of neurodevelopment.
NHS resources are not available for every child with CHD to undergo full neurodevelopmental assessment
by a child development specialist and, therefore, an alternative approach to this clinical problem is necessary.
The BDA was developed with a view to bridge this gap in care within the NHS,54 and an objective of this
section of work was to prospectively validate the BDA.
This section is adapted from our open access paper in Cardiology in the Young by Brown et al.113
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Overview of the brief developmental assessment
The BDA tool is a new questionnaire covering different age bands (0–16.9 weeks, 17–34.9 weeks,
35–60 weeks, 15 months–2.9 years, 3.0–4.9 years and 5–16.9 years) to account for the different stages
of development. Copies are provided in Report Supplementary Material 1. The BDA was developed at
Great Ormond Street Hospital and a full account of this process is available in the paper by Wray et al.54
Key excerpts of pre-validation information are provided in the next section.
Designed for neurodevelopmental surveillance by nurse practitioners rather than specialists, the BDA has
the following promising features: it assesses the key domains of neurodevelopment at risk in paediatric
critical illness; includes direct observations and history (both are required, as parents of surgical patients may
be stressed or their assessment impaired by their child’s general condition); is designed for non-specialists,
facilitating routine collection and audit; and provides prompts for further developmental evaluation
and treatment.
Pre-validation information on validity and reliability of the brief
developmental assessment
Face validity
The BDA tool was designed by a multidisciplinary group, including paediatric neurologists, developmental
experts, paediatricians, psychologists, nurses and a statistical expert. The BDA development group consulted
the published literature on long-term outcomes of children with cardiac disease and critical illness in order
to identify the optimal domains to incorporate within the measure, these being gross motor skills,14,36,38,125,126
fine motor skills,14,36,127,128 daily living skills,8,127,129 receptive and expressive communication,14,36,38,128,129
socialisation,130,131 and behaviour and coping skills.8,119,132,133
Within each age band of the BDA, individual items were selected by the expert panel based on review of
the following measures: Mullen,53 Battelle Developmental Inventory,134 Battelle Developmental Inventory
Screen,135 Denver Developmental Screening Test II,136 Bayley-III Screener Test,137 Bayley-III Scales of Infant
and Toddler Development, Bayley Infant Neurodevelopmental Screen,51 Ages and Stages,124 Developmental
Neuropsychological Assessment,138 Wechsler Individual Achievement Test,139 Wechsler Abbreviated Scale of
Intelligence (WASI-II),140 Wechsler Intelligence Scale for Children,141 Children’s Memory Scale,142 Behaviour
Rating Inventory of Executive Function,143 Behavioural Assessment of the Dysexecutive Syndrome144 and
Parents’ Evaluations of Developmental Status.145
Preliminary testing of the BDA during the development phase is reported separately,54 with key excerpts
presented as follows.
Internal reliability
The pre-validation data on internal reliability of the BDA were collected for 138 children. Of note, certain
poorly performing items (α < 0.6) were revised in the next iteration of the BDA (version January 2014),
which was used in the validation study.
Construct validity
The pre-validation data on construct validity of the BDA related to 17 children in a known group
(Down’s syndrome, n = 12; other genetic syndromes, n = 5) who had significantly lower BDA scores
[median 10; interquartile range (IQR) 8–15] than their age-matched counterparts (median 16, IQR 5–50,
z = 3.08; p = 0.002), with an effect size of 0.53 (equating to a medium effect size). There were at least
two matched pairs in each of the five age bands; hence, individual numbers in each age band were too
low for valid statistical comparison.
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Inter-rater reliability
The pre-validation inter-rater reliability data for the BDA based on 74 children were excellent. In terms of
inter-rater concordance for children scoring as a ‘red’ in each age band, there was perfect agreement on
both the BDA gross motor and the BDA cognitive score scales for children in each of the age bands 1–4
(κ = 1; p < 0.0.001).
Acceptability and feasibility
l The BDA took up to 10 minutes to complete and score, unless there was a requirement to use
an interpreter.
l It was feasible to undertake the BDA in a ward or clinic setting, in terms of timing, space and
integration with other ward or clinic work.
l A range of clinicians, in particular those based in community paediatric settings, were in favour of the
traffic lights scoring system.
l Parents responded favourably to the BDA, reporting that the content was relevant to their child and
that they found it acceptable and useful for their child to be assessed with it, and nurses commented
that completing the BDA was a good ‘ice-breaker’ for children at pre-admission clinics and that it
helped to build rapport with the child and family.
l The importance of training with explicit instructions for each item was emphasised by clinicians using
the BDA.
Proposed use of the brief developmental assessment
The BDA is an early recognition tool for childhood neurodevelopment that contains both direct observation
and parental report. The BDA can be used without additional special equipment that is commonly necessary
for child developmental assessment. Nurses or doctors who do not have specific training in child development
but who have been trained in its use, may undertake the BDA. The BDA takes 5–10 minutes to complete
and is designed for pre-school children up to the age of 5 years and consists of five individual age bands of
0–16.9 weeks, 17–34.9 weeks, 35–60 weeks, 15 months–2.9 years and 3.0–4.9 years. The BDA covers all of
the measurable areas of child development relevant to CHD in children aged < 5 years, within the domains
of gross motor skills, fine motor skills, daily living skills, communication and socialisation, as well as general
understanding for the oldest age band.
Scoring of the brief developmental assessment
Brief developmental assessment scores have been defined in order that results generate a useful guide to
action. These are:
l no suspicion of any abnormality of child development (green)
l possible abnormality based on age-appropriate milestones (amber)
l likely abnormality based on age-appropriate milestones (red).
The scores are allocated to the BDA on completion, based on the following. Within each developmental
domain, individual items are scored as ‘yes’ or ‘no’, based on the child’s undertaken activity. Within each
age band there are four subsections for scoring based on gradations of age, hence based on the child’s
exact age. The score for each domain is graded as red, amber or green. The overall BDA result is graded
red if there are any red domains. The BDA result is graded amber if there are any amber domains, but no
red domains. If all domains are green the BDA result is green.
An example of the BDA version applicable to age group 17–34.9 weeks is shown in Report Supplementary
Material 1.
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Brief developmental assessment validation methods
Study population
The study setting was at the three tertiary children’s cardiac centres based in London and the time period
of the study was January 2014 to July 2015. By approaching all children between birth and 17 years of
age with heart disease attending outpatient or inpatient settings, excluding those who were clinically
unwell within the ICU, a representative convenience sample of 200 patients with heart disease within each
age band was recruited. Once the target of 200 participants was reached in any age band, recruitment to
that age band ceased.
Study procedures
Written informed consent was obtained from parents.
Children were assessed in a quiet room by a small team of trained psychology assistants under the
supervision of a single senior psychological researcher (JW) and a medical lead (AH).
Elements of the validation
The internal consistency of the BDA was assessed for items within each domain, between totals for
domains and across the entire measure based on Cronbach’s alpha.
The internal reliability of the BDA was evaluated in terms of inter-rater agreement when two raters
simultaneously and independently performed and scored the BDA. The study team consisted of at least
three raters throughout the study duration, and the inter-rater performance assessment was undertaken
whenever two raters could be scheduled to be free at the same time. Again, recruitment ceased as soon
as the required number of patients was recruited.
External measures used for validation of the BDA in children aged < 5 years were Mullen53 and the Ages
and Stages,124 details of which are presented in Table 5.
In children aged < 5 years the concurrent validity of BDA scores was assessed against Mullen scores.
In children aged between 5 and 17 years the concurrent validity of BDA scores was assessed against
WASI-II scores.
TABLE 5 Overview of external measures used to assess ‘Brief Developmental Assessment’ performance including
definition of outcomes
Pertinent features of the measure
Protocol for scoring of the measure as
stated in the published instructions
Outcome definitions used in the
validation study
Primary assessment: The Mullen Scales of Early Learning
l A validated measure for early
developmental assessment between
birth and 5 years.146 This has
been used in infant CHD for
developmental surveillance147
l Five individual scales: four cognitive
scales of visual reception, fine motor,
receptive language and expressive
language and a fifth individual scale
of gross motor function applicable
from birth to 33 months
l Age range is equivalent to the study
population of preschool age children
l Takes only 30–40 minutes to
complete, thus increasing its
acceptability to research participant
families attending clinic
l The ‘raw’ scores for four cognitive
scales and separately for the gross
motor scale are computed to form
age-standardised ‘T scores’ in
each area
l Mean ‘T scores’ for each scale within
the general population are 50 (SD 10)
l The cognitive ‘T scores’ applicable to
the four cognitive scales combined
may be further computed to generate
a composite score which within the
general population has a mean of
100 (SD 15)
Mullen standardised scores53
categorised as follows:
l Patients with age-standardised
cognitive or gross motor scores
that fell between 1 and 2 SDs
below the mean were scored as
amber (cognitive scores 70–84,
gross motor scores 30–39)
l Patients with age-standardised
cognitive or gross motor scores
of > 2 SDs below the mean were
scored as red (cognitive scores
< 70, gross motor scores < 30)
l All other patients were classified
as green
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Evaluation of construct validity was based on detection of known abnormalities and, to that end, study
participants were defined as falling within a ‘known group’ when the child had been diagnosed to have
a condition linked to neurodevelopmental problems (a congenital syndrome,150 an acquired condition,
such as stroke,151 or a previously diagnosed developmental delay based on a specialist clinical assessment,
even if the cause was not stated), and when the Mullen result was amber or red.
Construct validity was further assessed by calculating sensitivity and specificity of the BDA for detection of
neurodevelopmental abnormalities against both of the external measures.
Data analysis
Analysis criteria for measures
For the evaluation of agreement of BDA scores between two independent raters and with external measures:
l Each of the age bands was analysed individually.
l Raw scores were used in order to remove within-measure age standardisation, as this standardisation is
undertaken differently within the BDA and the Mullen/WASI-II.
l Gross motor comparisons were available for only children aged < 33 months, reflecting the protocol for
the Mullen, for which this domain is only assessed in younger children aged less than this cut-off.
l For children aged < 33 months, cognitive and gross motor scores were analysed separately, as this
reflects the validated scoring protocol for the Mullen, which contains a cognitive summary score
covering the domains of visual reception, fine motor, receptive language and expressive language,
combined and a fifth individual domain of gross motor function separated.
Thresholds for validity
Interim analysis
An interim analysis was conducted in November 2014, when the first 100 scores for the BDA and the external
measure (Mullen or WASI-II) were compared based on intraclass correlation coefficients. The stopping rule:
if intraclass correlation coefficient for agreement between BDA and relevant gold standard < 0.6 to abandon
study for that age band.
TABLE 5 Overview of external measures used to assess ‘Brief Developmental Assessment’ performance including
definition of outcomes (continued )
Pertinent features of the measure
Protocol for scoring of the measure as
stated in the published instructions
Outcome definitions used in the
validation study
Secondary assessment: Ages and Stages Questionnaire – 3
l A validated screening questionnaire
consisting of 21 age-versions that
are applicable between birth and
66 months.148 Has been used in
infant CHD for surveillance149
l Five developmental domains
with responses based on parental
report: communication, gross motor,
fine motor, problem solving and
personal social
l Used with the aim of capturing
the Adaptive, and Social and
Emotional domains not
covered by the Mullen scale
l Of note, does not entail
direct observation
l Each item is scored depending
on whether the child performs
consistently (10 points), sometimes
(5 points) or not (0 points)
l The total achievable score for each
domain ranges from 0 to 60. Based
on the published means and SDs for
each age-version questionnaire, two
thresholds have been established for
each tested area to define a child’s
score as ‘close to cut off’ (between
1 and 2 SDs from normative mean)
and ‘below the normal range’
(> 2 SDs from the normative mean)
Parental responses within the
questionnaires were categorised as
follows (which is based on the
manual for usage):124
l Patients with any domain falling
between 1 and 2 SDs below the
normative mean were scored
as amber
l Patients with any domain scores
> 2 SDs below the normative
mean were scored as red
l All other patients were classified
as green
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Inter-rater agreement
Inter-rater agreement was judged based on intraclass correlation coefficients for raw BDA general total
scores that reflect the cognitive domains combined and weighted kappa statistics for the ordinal measure
raw BDA gross motor scores. Successful validation was defined as the lower 95% confidence limit for the
intraclass correlation coefficient (or weighted kappa) exceeding 0.75.
Validity based on external measures
For comparison with the Mullen, the raw BDA scores for the first 100 recruited patients were used to generate
regression models for predicting the raw Mullen scores. These predictions were then tested in the subsequent
100 recruited patients in each age band for both BDA general scores and BDA gross motor raw scores.
Successful validation was defined as the lower 95% confidence limit for the intraclass correlation coefficient
(or weighted kappa) between observed and predicted Mullen scores exceeding 0.75 in the test sample.
Sensitivity and specificity
Although the BDA represents an early recognition tool, rather than a developmental screener, the
threshold for acceptability with respect of detection of known abnormalities and sensitivity or specificity
was based on the American Academy of Pediatrics Committee on Children with Disabilities 2001
guidelines for desirable sensitivity and specificity for a developmental screening tool of 70–80%.152
Review of sample size
For the evaluation of the inter-rater reliability of the BDA, we required 56 patients per age band to estimate
an expected inter-rater intraclass correlation of 0.9 with a precision of 5% [i.e. lower bound of the 95%
confidence interval (CI) is 0.85].
For the agreement of the BDA with the Mullen, we required 200 patients per age band to allow us to estimate
an intraclass correlation coefficient of 0.8 with 5% precision (i.e. lower bound of the 95% CI is 0.75).
Within each of the age bands (excluding the youngest babies), a sample size of 200 (approximately
50 children with known developmental abnormality and 150 children presumed to have normal development,
anticipated prevalence of 25%153) provided sufficient numbers to detect a 0.5 standard deviation (SD) difference
in mean BDA scores between known groups, with 80% power and 5% significance. When assessing the ability
of the BDA to discriminate between children with and without developmental abnormalities, the study was
powered to detect a developmental abnormality with 12% precision, for an assumed sensitivity of 80%. We
anticipated that the use of the BDA would result in a lower specificity, possibly 65%, and for this our sample
provided 8% precision for this estimate. We were less concerned about the level of specificity, as false positives
of when a child is subjected to medical review are unlikely to be harmful. Furthermore, we expected the BDA
to have a higher sensitivity, of 90%, for detecting severe developmental abnormalities, so, for a conservative
estimate of prevalence for severe cases of 10%, our sample size of 200 would provide a precision of 14%.
Results
Interim analysis
The interim analysis involving the first 100 patients in each of the six age bands is shown in Table 6. As
can be seen, the threshold for go was not met in the oldest age band; hence the BDA was not considered
valid in this age group and further validation work stopped at this point. The younger five age bands
involving children aged from 1 month to 5 years passed the interim analysis and the validation work
continued as planned.
VALIDATION OF THE BRIEF DEVELOPMENTAL ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
Final analysis
The case mix of 982 consented participants in the final validity study is shown in Table 7. The age
distribution of the sample is skewed towards younger babies because the width of the five age bands
narrows as age falls [median age across all age bands is 11.5 months (IQR 5 months–2.6 years)].
Internal reliability
The internal reliability of the BDA, expressed as Cronbach’s alpha, is shown in Table 8. This was high
between BDA total scores and between all items, but low in selected domains of the BDA, particularly
within the youngest two age bands representing children under 8 months old.
TABLE 6 Interim analysis for the BDA
Age band Intraclass correlation (95% CI)
0–16.9 weeks 0.89 (0.81 to 0.94)
17–34.9 weeks 0.89 (0.80 to 0.94)
35–60 weeks 0.87 (0.79 to 0.93)
15 months–2.9 years 0.84 (0.76 to 0.89)
3–4.9 years 0.91 (0.86 to 0.95)
> 5 years 0.57 (0.43 to 0.68)
TABLE 7 Demographics and clinical features of the study cohort by age band for the BDA study
Variable
Age band
1: 0–16.9
weeks
2: 17–34.9
weeks
3: 35–60
weeks
4: 15 months–
2.9 years
5: 3–4.9
years
Number of patients included 199 188 192 198 205
Number (%) male 110 (55) 82 (44) 106 (55) 103 (52) 103 (50)
Median (IQR) age (months) 2.2
(1.4–3.1)
6.2
(5.1–7.1)
11.4
(10.0–13.2)
25.2
(20.8–30.9)
48.0
(41.9–53.8)
Number (%) single ventricle circulation 25 (13) 12 (6) 9 (5) 23 (12) 25 (12)
Number (%) with more than one
operation
16 (8) 15 (8) 15 (8) 33 (17) 51 (25)
Number (%) with more than one
catheter
4 (2) 6 (3) 7 (4) 7 (4) 11 (5)
Number (%) with no known
developmental delay or linked condition
163 (81.9) 138 (74.2) 147 (76.6) 154 (77.8) 149 (72.3)
Number (%) with a congenital condition
linked to developmental delay
23 (11.6) 35 (18.8) 39 (20.3) 30 (15.2) 34 (16.5)
Number (%) with a developmental delay
of unknown cause
4 (2) 4 (2.1) 4 (2.1) 7 (3.5) 15 (7.3)
Number (%) with an acquired brain injury 9 (4.5) 8 (4.3) 1 (0.5) 7 (3.5) 6 (2.9)
Number (%) with a combination of
developmental delay related diagnoses
0 1 (0.5) 1 (0.5) 0 2 (1)
Reproduced from Brown et al.113 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. This table
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Inter-rater reliability
A total of 160 children participated in the evaluation of inter-rater reliability of the BDA (Table 9).
Correlations were very high for all age bands, thus passing the pre-set threshold for inter-rater validity.
Agreement between the brief developmental assessment and the Mullen
Of the 981 participants, 21 did not complete one or more domains of the Mullen and thus a total of
960 children participated in the evaluation of concurrent validity of BDA against the Mullen (see Table 9).
For age bands 2–5, the pre-set thresholds were met with the exception of gross motor in age band 2;
however, in age band 1 the BDA displayed a much weaker correlation with the Mullen and therefore did
not pass the pre-set threshold for validity.
Developmental outcomes
The developmental outcomes of participants based on the BDA, the Mullen and the Ages and Stages are
presented in Table 10 and summarised as follows.
Of 960 children completing both the BDA and the Mullen, for BDA a total of 364 (38%) children had
a green result, 361 (38%) children had an amber result and 235 (24%) children had a red result.
For Mullen, and considering both Mullen cognitive composite scores and (when applicable based on age)
gross motor scores, 639 (67%) children had a green result, 178 (18%) children had an amber result and
143 (15%) children had a red result.
Data were missing for at least one Ages and Stages domain in 149 children (15%), and all of these
children were excluded from validity analyses involving the Ages and Stages. Of 832 children completing
the Ages and Stages, only 238 (29%) had a green result, whereas 213 (26%) had an amber result and
381 (46%) had a red result.
TABLE 8 Internal reliability of the BDA by age band
Internal reliability of based on
Cronbach’s alpha
Age band
1: 0–16.9
weeks
2: 17–34.9
weeks
3: 35–60
weeks
4: 15 months–
2.9 years
5: 3–4.9
years
Number of patients included 199 188 192 198 205
Between domain totals 0.84 0.86 0.88 0.89 0.90
Between all items 0.84 0.86 0.90 0.91 0.92
Between items within gross motor
domain
0.59 0.51 0.82 0.68 0.69
Within fine motor domain 0.46 0.71 0.49 0.61 0.70
Within daily living skills domain 0.40 0.60 0.58 0.55 0.67
Within communication domain 0.51 0.36 0.61 0.82 0.81
Within socialisation skills domain 0.52 0.33 0.61 0.57 0.51
Within cognition domain N/A 0.45 0.46 0.58 0.80
N/A, not applicable.
Reproduced from Brown et al.113 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. This table
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TABLE 9 Inter-rater agreement of the BDA and concurrent validity of the BDA against the Mullen, expressed as correlation by age band
Validation goal for the BDA Definition of success
Age band
1: 0–16.9 weeks 2: 17–34.9 weeks 3: 35–60 weeks 4: 15 months–2.9 years 5: 3–4.9 years
Number of patients included 36 25 29 35 35
Inter-rater agreement cognitive
scores (95% CI)
Intraclass correlation: lower
95% CI > 0.75
0.99 (0.98 to 0.99) 0.99 (0.98 to 1.00) 0.99 (0.99 to 1.00) 1.00 (0.99 to 1.00) 1.00 (1.00 to 1.00)
Inter-rater agreement gross
motor scores (95% CI)
Weighted Kappa: lower
95% CI > 0.75
0.93 (0.76 to 1.00) 0.98 (0.92 to 1.00) 0.99 (0.96 to 1.00) 1.00 (0.99 to 1.00) 0.99 (0.98 to 1.00)
Comparison between the BDA and the Mullen
Number of patients in test set 99 88 92 98 105
Agreement of raw cognitive
scores (test data) (95% CI)
Intraclass correlation: lower
95% CI > 0.75
0.75 (0.67 to 0.83) 0.86 (0.80 to 0.91) 0.90 (0.85 to 0.94) 0.91 (0.87 to 0.94) 0.91 (0.88 to 0.94)
Agreement of raw gross motor
scores (test data) (95% CI)
Intraclass correlation: lower
95% CI > 0.75
0.71 (0.62 to 0.79) 0.68 (0.58 to 0.78) 0.84 (0.78 to 0.89) 0.83 (0.78 to 0.89) 0.83 (0.78 to 0.89)
Reproduced from Brown et al.113 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. This table includes minor
additions and formatting changes to the original.
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Construct validity
Of the 960 participants who undertook the Mullen, 227 (24%) had a condition linked to developmental
delay, of whom 153 (67%) also had a red or amber Mullen result, thus meeting the criteria for a ‘known
group’ with which to evaluate construct validity. Of these, 141 (92%) were also detected based on a red
or amber BDA result, thus passing the pre-set threshold of 80%.
Surprisingly, 74 (33%) children with a condition linked to developmental delay had a Mullen result of
green. Of these 74 children, 40 (54%) were under the age of 8 months and therefore based on young
age, developmental delay may not yet be evident. Furthermore, although 17 (23%) children had a defined
genetic condition such as Down’s syndrome, 13 (18%) had perioperative neurological events of unknown
significance and the remaining 44 (59%) had a range of congenital abnormalities in which development
incorporates a range of outcomes, including normality.
TABLE 10 Descriptive table of developmental scores and known groups by age band for the BDA
Group
Age band
1: 0–16.9
weeks
2: 17–34.9
weeks
3: 35–60
weeks
4: 15 months–
2.9 years
5: 3–4.9
years
Cognitive, n (%)
Mullen: red 2 (1) 6 (3) 12 (6) 32 (17) 37 (19)
Mullen: amber 24 (12) 19 (10) 21 (11) 32 (17) 18 (9)
Mullen: green 171 (87) 161 (87) 157 (83) 128 (66) 140 (72)
Gross motor, n (%)
Mullen: red 0 22 (12) 40 (21) 24 (14) N/A
Mullen: amber 25 (13) 28 (15) 47 (25) 22 (13) N/A
Mullen: green 172 (87) 136 (73) 103 (54) 123 (73) N/A
Cognitive and gross motor combined result, n (%)
Mullen: red 2 (1) 24 (13) 40 (21) 40 (21) 37 (19)
Mullen: amber or red 38 (19) 57 (31) 90 (47) 81(42) 55 (28),
cognitive only
Ages and Stages: red 99 (62) 82 (52) 84 (49) 63 (37) 53 (31)
Ages and Stages: amber 36 (22) 40 (26) 43 (25) 56 (33) 38 (22)
Ages and Stages: green 26 (16) 34 (22) 45 (26) 52 (30) 81 (47)
BDA: red 38 (19) 49 (26) 54 (28) 61 (31) 39 (19)
BDA: amber 84 (42) 77 (42) 62 (32) 75 (38) 74 (36)
BDA: green 77 (39) 60 (32) 76 (40) 62 (31) 93 (45)
Known group and all types 36 (18) 48 (26) 45 (23) 44 (22) 57 (28)
Known group and Mullen red 1 (0.5) 14 (8) 24 (13) 24 (13) 32 (16)
Known group and Mullen red
or amber
13 (7) 30 (16) 35 (18) 34 (18) 41 (21)
N/A, not applicable.
Reproduced from Brown et al.113 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. This table
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Moreover, there were 168 children with a Mullen result of red or amber, representing 18% of the study
cohort that were not in a known group (i.e. they had no known genetic or acquired condition linked to
developmental problems and no known diagnosis of developmental delay either stated by the parents or
written anywhere in their medical records that were based at the tertiary hospital). The charts of these
patients were reviewed (see Discussion and next steps) and this finding may relate to the underdetection
of true abnormalities in the study population.
As might be expected, given that child development assessments in general are more reliable in older
children, the sensitivity and specificity of the BDA against the external measures improved with increasing
age, with the best performance in age band 5 and the poorest performance in age band 1, which did not
meet the criteria for validity. As expected (given that the Ages and Stages is based on parental report only,
whereas the Mullen is an objective-validated developmental test) the BDA performed better against the
Mullen than the Ages and Stages. Considering all of the age bands 2–5 combined:
l The test measure of BDA red or amber has excellent sensitivity against the Mullen and good sensitivity
against the Ages and Stages, but moderate to low specificity for both external measures.
l The test measure of BDA red has variable sensitivity but high specificity for both external measures. When
considered, based on American Association of Pediatrics standards for the performance of a developmental
screening tool (which state the sensitivity and specificity of a developmental screening tool should fall
between 70% and 80%),152 the BDA outcome of red against an outcome of Mullen red is compliant.
Positive and negative predictive values, as well as comparisons between the Ages and Stages and the
Mullen, are presented for information purposes in Table 11.
Discussion and next steps
Summary of validation
The primary aim to validate the BDA as an early recognition tool for childhood developmental delay was
achieved within a population with heart disease between the ages of 4 months and 5 years. Previous
researchers have presented sensitivity and specificity across a range of thresholds, as a method to judge
the performance of a new test against validated measures, and have used this approach to select the
optimal threshold to trigger an abnormal result,154,155 as has been undertaken in this study. These analyses
support the use of BDA results of both amber and red as thresholds to trigger further evaluation of a child,
although after reassessment a proportion of such children may turn out not to have developmental delay.
The protocol for such reassessment is currently being delineated within a Delphi survey and goes beyond
the scope of the current study. The Delphi survey entails a series of questions to a large group of health
professionals from a range of settings and backgrounds, which seeks to achieve a consensus as to the
referral and reassessment pathway for children who have either an amber or a red BDA test result picked
up by the cardiac team at the tertiary centre.
Limitations of the validation
Our positive evaluation of BDA validity and reliability relates only to tests at a single time point and the
constructs of test–retest validity and responsiveness over time could not be assessed within the scope of
this study. Both concepts are challenging to test within a rapidly developing population of very young
children with a significant health problem, such as CHD, and a further dedicated study will be required
to explore these, in particular repeated testing over time.
We note that the BDA has been developed as an early recognition tool for child development and it is
not intended to replace full, formal neurodevelopment evaluation. It is our hope and intent that children
flagged up by the BDA, when it is used with them by the cardiac team, will be speedily referred to and
assessed by a neurodevelopmental clinic with a more detailed formal evaluation, using gold-standard
neurodevelopmental tests.
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TABLE 11 Sensitivity and specificity of test measures in age bands 2–5, combined
Test measure
Comparison measure
(measure utilised as
gold standard for
each specific
comparison)
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
Positive
predictive
value, %
Negative
predictive
value, %
Abnormality based
on test measure,
n (%)
Abnormality based on
comparison measure,
n (%)
BDA vs. Ages and Stages
Red or amber Red or amber 70.2 (65.7 to 74.3) 59.4 (52.5 to 66.1) 78.9 47.9 408 (60.8) 459 (68.4)
Red or amber Red 78.7 (73.5 to 83.4) 52.2 (47.1 to 57.2) 54.4 77.2 408 (60.8) 282 (42.0)
Red Red or amber 32.7 (28.4 to 37.2) 92.5 (88.0 to 95.6) 90.4 38.8 166 (24.7) 459 (68.4)
Red Red 42.6 (36.7 to 48.6) 88.2 (84.5 to 91.2) 72.3 67.9 166 (24.7) 282 (42.0)
BDA vs. Mullen (cognitive)
Red or amber Red or amber 92.1 (87.1 to 95.6) 46.6 (42.5 to 50.7) 34.2 95.1 476 (62.4) 177 (23.2)
Red or amber Red 100.0 (95.8 to 100) 42.5 (38.7 to 46.3) 18.3 100.0 476 (62.4) 87 (11.4)
Red Red or amber 55.9 (48.3 to 63.4) 83.3 (80.0 to 86.2) 50.3 86.2 197 (25.8) 177 (23.2)
Red Red 70.1 (59.4 to 79.5) 79.9 (76.7 to 82.8) 31.0 95.4 197 (25.8) 87 (11.4)
BDA vs. Mullen (cognitive and or gross motor)
Red or amber Red or amber 85.9 (81.3 to 89.7) 51.5 (46.9 to 56.0) 51.1 86.1 476 (62.4) 283 (37.1)
Red or amber Red 99.3 (96.1 to 100) 46.0 (42.0 to 50.0) 29.4 99.7 476 (62.4) 141 (18.5)
Red Red or amber 48.1 (42.1 to 54.0) 87.3 (84.0 to 90.1) 69.0 74.0 197 (25.8) 283 (37.1)
Red Red 70.2 (61.9 to 77.6) 84.2 (81.1 to 87.0) 50.3 92.6 197 (25.8) 141 (18.5)
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Test measure
Comparison measure
(measure utilised as
gold standard for
each specific
comparison)
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
Positive
predictive
value, %
Negative
predictive
value, %
Abnormality based
on test measure,
n (%)
Abnormality based on
comparison measure,
n (%)
Ages and Stages vs. Mullen (cognitive)
Red or amber Red or amber 96.6 (92.2 to 98.9) 39.6 (35.3 to 44.0) 31.4 97.6 449 (68.4) 146 (22.3)
Red or amber Red 98.5 (92.0 to 100) 35.0 (31.1 to 39.0) 14.7 99.5 449 (68.4) 67 (10.2)
Red Red or amber 81.5 (74.2 to 87.4) 68.8 (64.6 to 72.8) 42.8 92.9 278 (42.4) 146 (22.3)
Red Red 95.5 (87.5 to 99.1) 63.7 (59.6 to 67.6) 23.0 99.2 278 (42.4) 67 (10.2)
Ages and Stages vs. Mullen (cognitive and or gross motor)
Red or amber Red or amber 95.8 (92.5 to 98.0) 47.4 (42.5 to 52.3) 51.2 95.2 449 (68.4) 240 (36.6)
Red or amber Red 99.1 (95.3 to 100) 38.1 (34.0 to 42.3) 25.4 99.5 449 (68.4) 115 (17.5)
Red Red or amber 77.9 (72.1 to 83.0) 78.1 (73.8 to 82.0) 67.3 86.0 278 (42.4) 240 (36.6)
Red Red 97.4 (92.6 to 99.5) 69.3 (65.2 to 73.2) 40.3 99.2 278 (42.4) 115 (17.5)
Reproduced from Brown et al.113 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. This table includes minor
additions and formatting changes to the original.
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A motivation underpinning our study was a hypothesis that the processes in place to assess the
neurodevelopment of children with CHD require improvement within the UK, and children with CHD and
developmental delay may be under-recognised. Indeed, 168 children with red or amber Mullen results
were not in a known group, and a chart review, undertaken by one of three clinicians, revealed concerns
from the parents about the child’s development and/or other risk factors for abnormal development, such
as a history of cardiac arrest or mechanical circulatory support,10,156 in the majority. A review of the services
that children were under and what actions might need to be taken to meet their needs is under way,
and goes beyond the scope of the validation study. Health-care professionals and parents have commented,
anecdotally, that children with CHD, such as those under the age of 5 years recruited to this study, are in
general undergoing treatments for their heart, including surgery, and this represents the main focus of
contacts with health professionals, including both those at the cardiac centres and also in the community
such as health visitors. This may be represent a reason for these 168 children with red or amber Mullen
results not already being identified as in a known group.
The BDA was developed for use with children who have heart disease, and has not been used or validated
with healthy children. There is the potential that the BDA might be useful within other groups of children
who, for medical reasons, are at greater risk of neurodevelopmental problems, such as survivors of other
types of critical illness. However, in order to take this forward, further testing and research would be required.
Comment on external measures
Parents who were concerned about their child’s development preferred to watch the entirety of the testing,
and were less likely than parents who had no concerns about their child to complete the Ages and Stages
while their child was being assessed. This is supported by a comparison of the Mullen cognitive results
between children with missing Ages and Stages (29% Mullen cognitive results red or amber) and those
who completed Ages and Stages (19% Mullen cognitive results red or amber). The overall proportion of
red results for the Ages and Stages (46%) was very high, and perhaps proportion of Ages and Stages
results that were red would have been even higher, had the missing 15.2% been included.
This is not a cohort study with longitudinal follow-up, thus limiting interpretation. However, as displayed
in Table 11, developmental delay based on Mullen results was detected least frequently in the youngest
babies, in contrast with developmental delays based on Ages and Stages results, which were detected
most frequently in the youngest babies. Medical ill health in children with CHD is more prevalent in infancy,
as this is a period when interventions are commonly undertaken. These observations support a hypothesis
that, in children with CHD, the Ages and Stages may be picking up a range of issues (including developmental
delay), but also general ill health. This further emphasises the importance of an initial evaluation for signs of
developmental delay that incorporates direct observation of children with CHD, such as the BDA provides.
Furthermore, this emphasises the recognised importance of periodic assessment of neurodevelopment over
time in children with heart disease.
Summary and next steps
The development and validation of the BDA represent an opportunity to improve the future quality of
peri-intervention assessment for children with heart disease between the ages of 4 months and 5 years in
UK children’s cardiac centres. This initiative of using the BDA within the cardiac centres would complement
the health visitor assessments that all children receive and will be undertaken by cardiac staff aware of
details of the child’s history, such as cardiac arrests and mechanical circulatory support that predispose to
neurodevelopmental problems.
One problem with the current system of surveillance for young children in the UK, as it pertains to children
with heart disease, is that in addition to them being inherently higher risk than other children, and therefore
potentially benefiting from additional scrutiny, the standard health visitor reviews correspond with a period
in these children’s lives when cardiac conditions are often having a significant impact. This may be a barrier
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to the systems effectiveness for them and may account, in part, for the occurrence of undetected
neurodevelopmental problems in the population that we observed.
Roll-out of the BDA will require a training package for users and a guide to action for abnormal results,
such as a standardised report for specific relevant health-care professionals and parents. As the BDA is a
short assessment that is undertaken by staff with a training background of those working in a cardiac
centre, with whom children who have CHD are in regular contact early in life and without additional
equipment successful implementation is more likely. Further research is needed to delineate the optimal
approach to assess children over time, including when to incorporate the BDA and how to establish the
most effective management strategy for babies that attend cardiac centres for interventions when they are
younger than 4 months old, as the BDA is not appropriate for them.
We note that around 19,000 children are admitted to paediatric intensive care in the UK annually, the
majority suffering an emergency critical illness or undergoing non-cardiac surgery. Currently, there is no
national audit of morbidity, as measures are not available in a useable form. The cerebral performance
category score of neurodevelopmental outcome is used in some settings,53,54 but there is vast potential for
the widespread, beneficial deployment of the BDA to other patient groups.
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Chapter 7 Measurement of incidence for the
defined morbidities in the study population
This chapter is reproduced from Brown et al.157 © 2019 Published by Elsevier Inc. on behalf of The AmericanAssociation for Thoracic Surgery. This is an Open Access article distributed in accordance with the terms of
the Creative Commons Attribution (CC BY-NC-ND 4.0) license. See: https://creativecommons.org/licenses/
by-nc-nd/4.0/. The text below includes minor additions and formatting changes to the original text.
Introduction
Having selected90 and defined98 the proposed important early morbidities associated with paediatric cardiac
surgery (see Chapters 4 and 5), taking into consideration a wide range of candidate morbidities and also
viewpoints of parents and lay people, the next step was to measure incidence in the population of interest.
As such, we moved ahead with the next phase of the study at the five children’s specialist centres
participating, these being Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), Evelina
London Hospital (EVE), Birmingham Children’s Hospital (BIRM), Bristol Children’s Hospital (BRHC) and The
Royal Hospital for Sick Children Glasgow (GLA). In combination, these centres care for around half of all the
children with CHD who undergo interventional treatments in the UK.24
Methods
Recruitment and data collection
All children aged < 17 years undergoing cardiac surgery in each of the five participating centres were prospectively
monitored for the presence of the morbidities selected90 in Chapter 4 (and defined98 in Chapter 5) by the
clinical teams liaising with the dedicated research nurse and the consultant surgeon or intensivist at each site.
The original study protocol set out the incidence study timeline as 18 months at all sites, but this timeline was
amended slightly for practical reasons and actual recruitment dates were as follows:
l GOSH: 1 October 2015 to 30 June 2017 (21 months)
l EVE: 1 November 2015 to 30 June 2017 (20 months)
l BIRM: 1 October 2015 to 30 June 2017 (21 months)
l BRHC: 1 October 2015 to 30 June 2017 (21 months)
l GLA: 15 October 2015 to 30 June 2017, with a break December 2015 to January 2016 (18 months).
Incidence data on each of the defined morbidities were collected in line with the protocols stated in
Chapter 7.98 Alongside the prospectively collected data on morbidities, we collected selected key fields
from nationally mandated audit data for the NCHDA24 and the Paediatric Intensive Care Audit Network
(PICANet).158 Data collected were drawn from copies of the audit data held within each study site and were
pseudoanonymised before being provided to the research team: all names, numbers, dates and places were
removed. For analysis, the diagnoses and procedures were grouped (see Case mix risk factor variables),
thus further reducing the chance of de-identification. The advantage of harnessing national audit data for
this study was that each field is clearly and consistently defined, it is mandatory to record every cardiac
procedure and NCHDA data, overall, are externally validated. Recruitment by centre is shown in Appendix 6.
Inclusion and exclusion criteria
The age inclusion range was from birth to 17 years.
Cardiac surgery in this instance, for the purposes of both the incidence and the impact studies, was
defined as any open, closed or hybrid operation involving the heart or circulation that is categorised as
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a cardiac surgery procedure and subjected to mandatory audit by the NCHDA,24 apart from the stated
exclusions, which were:
l premature babies undergoing persistent ductus arteriosus ligation, as these are cared for by neonatal teams
over a prolonged period, and experience a different profile of risks and outcomes to patients with CHD
l cardiothoracic transplant procedures and tracheal surgeries, as these procedures are undertaken at only
one of the five study centres and have a very distinct risk profile and set of morbidities, therefore these
were considered to be outside the current scope.
Isolated interventional cardiology procedures were not included, as these go beyond the scope of the
study topic.
Case mix risk factor variables
Given the known heterogeneity within the study population,159,160 we prespecified important clinical risk
factors in the protocol based on previous documented empiric links with mortality, as well as clinical expert
viewpoints, including patient age, weight, cardiac diagnosis, operation type, bypass time and comorbidities.
As a preparatory step prior to statistical analysis, we collapsed the categories for cardiac diagnosis and
cardiac procedure as follows in Cardiac diagnosis category and Specific procedure category, in order to
remove the smaller categories and to help with clinical interpretation. For the category of comorbidity we
used existing broad categories as described in Comorbidity. Note, in all of the risk factor groupings we
referenced previous empiric research related to paediatric cardiac surgery mortality, described as follows.
Cardiac diagnosis category
During the development and validation of the Partial Risk Adjustment in Surgery 1 (PRAiS1) model
(29 diagnosis groups)161 and then the Partial Risk Adjustment in Surgery 2 (PRAiS2) model (11 diagnosis
groups)162 for 30-day mortality after paediatric cardiac surgery, cardiac diagnosis categories were ranked
based on a combination of both clinical complexity and empiric risk of death by an expert panel. In the
current analyses, the most up to date refined and complexity ranked list of cardiac diagnoses was collapsed
further into five diagnosis groups (A–E) based on the PRAiS2 ranking order, with group A the most complex
and group E the least (see Appendix 7).
Specific procedure category
The NCHDA developed an algorithm for the grouping of paediatric cardiac operations into relatively
homogeneous groups for the reporting of mortality outcomes.24 This ‘specific procedure algorithm’ has been
refined iteratively over time by the Steering Committee of NCHDA. In the current analyses, the 50 specific
procedure groups (includes ‘not a specific procedure’) were collapsed into three broad groups of ‘reparative
or corrective operation’, ‘palliative or staging operation’ and ‘ungrouped operation’ (in which the approach
could not be determined, see Appendix 7).
Comorbidity
It is extremely common to find non-cardiac health problems that impact on outcomes for children undergoing
paediatric cardiac surgery.163 Recent research has provided us with a better understanding of these diseases
in terms of the broad groups which are known to be linked to operative mortality.160,164 In the current study
we applied the most recently developed peer-reviewed grouping for additional conditions or comorbidities
from the UK-based PRAiS2 model, which was designed for UK NCHDA data164 in order to consider these as
potential risk factors for morbidity. Therefore, six distinct categories of (1) acquired comorbidity (e.g. renal
failure, stroke), (2) congenital comorbidity, excluding Down’s syndrome (e.g. congenital defect of a major
organ or genetic syndrome), (3) Down’s syndrome, (4) additional cardiac risk factors (e.g. cardiomyopathy,
pulmonary hypertension), (5) prematurity (e.g. gestational age of < 37 weeks) and (6) severity of illness
indicator (e.g. pre-procedure respiratory failure or shock).
Primary outcome measures
The main outcome measure for our analysis was the occurrence of the selected and defined morbidities.90,159
These morbidities occur as single events in isolation and can also occur as combinations, which we refer to
as ‘multiple morbidity’. During the design of the study we noted the occurrence of multiple morbidities as
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being a particularly adverse outcome for patients and, hence, a priori we hypothesised that outcomes in
these this group would be especially poor. Furthermore, we noted that the special case of ECMO or ECLS,
which, based on experience of the study team and within the scope of the literature review (see Report
Supplementary Material 1 for complete reference list), often occurs in conjunction with other morbidities
and has a particularly poor outcome in terms of mortality and length of stay.165–169 Therefore, a rule was
created such that the occurrence of ECMO or ECLS was counted as a single standalone morbidity whether
it occurred as a single morbidity or in combination with other morbidities.
Secondary outcome measures
During the course of the study the independent Steering Committee recommended that the mortality of
patients in the incidence study should be assessed at the time point of 6 months after the operation, and
therefore this outcome was included in the analysis. The patients’ outcome at 6 months was provided at
the end of the study and was rechecked at the study sites in March 2018, using a combination of hospital
records and NCHDA data.
During the course of the study the selection panel recommended that an assessment of length of hospital
stay should be included in the analysis; therefore, this outcome was described within the incidence analysis
and is reviewed in further detail in the impact analysis. The length of stay was defined as the number of
days between the operation that led to the child entering the study and the date of discharge from the
specialist cardiac centre. Two data sources (study database and NCHDA) were cross-checked to ascertain
the accuracy of these data.
Data checking and validation
Morbidity cases were prospectively diagnosed based on the assessment of the dedicated study nurse and
the local principal investigator who was either a consultant paediatric cardiac surgeon or a consultant
paediatric intensivist, working with the clinical team caring for the child. Every child meeting inclusion and
not meeting exclusion criteria was reviewed regularly over the course of their hospital stay at the treating
centre, to ascertain whether or not the criteria for one of the morbidities were met. A case record form
was completed for every patient whether or not morbidity was diagnosed and eventually signed off by the
dedicated study nurse and the local principal investigator. Additional data checks to ensure accuracy of
study data and complete case ascertainment for incident morbidities were undertaken as follows:
l A monthly telephone conference call involving at least one person from all sites was held, in which any
grey cases were discussed and final case ascertainment was agreed.
l A check of a 3-month sample of data from each study site, relating to data collected on 443 patients
between 1 January 2016 and 31 March 2016, was undertaken. Every case from this 3-month time
period was cross-checked against the local case record collected for the NCHDA to compare the level of
completeness for ECLS, URO, renal support or dialysis (Renal), PPE and part of MAE, which by that time
point were common to both data sets. The mandatory data collection for the NCHDA is carried out
within each centre independent of data collection for our study. Note that all of the data used for the
study from the NCHDA were collected at the end of prospective morbidity data collection. There was
excellent agreement between the two sources, with nine morbidities present in the study data set but
not in the NCHDA, and zero morbidity found the NCHDA but not in the study data set.
l A final reconciliation of morbidities was undertaken at the end of the study, in which any cases where
there was partial data completion for the morbidities were re-reviewed locally by the dedicated research
nurse and a senior local clinician.
Note on sample size and morbidity groups
In the original study protocol we anticipated that between 3000 and 3300 surgical patients would participate
in the analysis across the five sites. We expected that this would have been a sufficient sample to estimate
accurately the incidence of each of the morbidities. For example, an observed incidence of 3% would have CI
2.4% to 3.6%. In fact, as we demonstrate later in Results, for five of the single morbidities in isolation the
incidence was < 1.5%.
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Therefore, we used three approaches to group morbidity outcome:
1. Two categories – any morbidity compared with no morbidity.
2. Four categories – single morbidity (excludes ECLS or ECMO), ECLS or ECMO, multiple morbidity and no
morbidity. This outcome enables the discrimination of risk factors for the particularly adverse outcomes
of ECLS and multiple morbidities.
3. Eleven categories – each of the nine individual single morbidity groups as defined, multiple morbidity
and no morbidity. The individual morbidities were ECLS, ANE, URO, feeding morbidity (Feed), MAE,
PPE, post-surgical infection (SSI), Renal and NEC.
Data analysis
Risk factors are presented with frequency (%) for categorical risk factors and mean (SD) or median (IQR),
as appropriate, based on the distribution of the data for continuous risk factors.
The incidence of each of the selected morbidities was estimated with 95% CIs, both for a single event
of one of the defined morbidities and in combination with other morbidity. Multilevel logistic regression
analysis was used to explore the role of preoperative, patient-level case-mix factors on morbidity outcome
1 (any morbidity vs. no defined morbidity), accounting for multiple procedures within patients.
The case mix risk factors considered were sex; age band (neonate, infant child); calculated weight-for-age
z-score;170 cardiac diagnosis category; functionally univentricular heart; specific procedure type category,
operation type (bypass, non-bypass or hybrid); bypass time; acquired comorbidity; congenital comorbidity,
excluding Down syndrome; Down syndrome; additional cardiac risk factors; prematurity; and severity
of illness indicator.162
For the four-category morbidity outcome 2, multinomial regression was used with robust standard errors
to adjust for clustering within patients. For both outcomes we investigated whether or not the inclusion of
site as a random factor was important and found that results were almost identical to those without site;
therefore, we present results from the model without site.
Univariate models were fitted and the estimated effects are presented along with 95% CIs. All factors
significant on univariate analysis (p < 0.1) were considered in the multivariable models. Data completeness
was excellent for most of the risk factors, although there were some missing data for weight: we state the
number of missing values when relevant in results. We used multiple imputation by chained equations to
account for missing data and the imputation model included all of the risk factors considered in the
univariate analysis, which we assumed to include all predictors of missingness. The final models were
derived by fitting a regression model for all significant predictors and estimates were combined using
Rubin’s rules.171 Model performance for the final multivariable models was assessed using the c-statistic
(area under the receiver operator curve) and Hosmer–Lemeshow statistic. All analyses were performed in
Stata® 14 (StataCorp LP, College Station, TX, USA).
We did not consider it appropriate to undertake multinomial regression for the 11-factor outcome, given
the low rates of < 1.5% for five individual morbidities, and present descriptive data for these individually.
Results
Descriptive data
The flow chart depicting inclusion and exclusion is shown in Figure 3. Of note, reoperation within
30 days was an outcome of the study and hence these are not reported in the headline total number
of procedures.
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Morbidities
After the exclusions, as shown, there were 3090 procedures in total from 2861 patients. A total of 213 patients
had two surgical procedures and 16 patients had three surgical procedures. Of the 3090 procedures:
l 2415 (78.2%) resulted in none of the nine defined morbidities
l 675 (21.8%) resulted in at least one morbidity
l 478 (15.5%) resulted in a single morbidity, including those with ECLS
l 197 (6.4%) resulted in a multiple morbidity, excluding ECLS.
Mortality
There were 16 patients discharged alive for whom we were unable to recheck the life status at 6 months.
Given instances of multiple procedure-based admissions in the same patient, we report mortality rate at
6 months based on the outcome after the latest procedure. In all cases of mortality this was a second procedure
(there were no mortalities after more than two procedures). Among 2861 unique patients there were 92
patients (who between them underwent 105 procedures) who died within 6 months, giving a mortality of 3.2%.
Looking at the latest procedure for each of the 2861 unique patients:
l 21 out of 2294 (0.9%) patients without one of the defined morbidities died
l 71 out of 567 (12.5%) patients with one or more of the defined morbidities died.
For those patients with at least one defined morbidity:
l 17 out of 355 (4.8%) patients with a single morbidity died (the 17 deaths with a single morbidity
comprised one ANE, four URO, one Feed, two Renal, five MAE, three NEC and one PPE)
l 27 out of 54 (50%) patients with ECLS died
l 27 out of 158 (17.1%) patients with multiple morbidity died.
After cross-checking the length of stay data from the two stated sources we found that values agreed,
except for three admissions which were set to missing. Overall, the length of stay was missing for nine patients.
Length of stay in hospital is shown in Table 12 and Figure 4 by morbidity type and by morbidity group.
Incidence data
(n = 3423 surgical procedures)
NCHDA data
(n = 3249 surgical procedures)
Matcheda procedures
(n = 3248)
Excluded
Matched incidence and
NCHDA procedures
(n = 3090)
• Reoperations, n = 85
• Procedures within
   30 days of index
   procedure, n = 63
• Misclassified
   procedures, n = 10
FIGURE 3 Morbidity incidence flow chart. a, Records matched on unique procedure identification.
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Incidence of morbidities
The most common morbidity was PPE (6.5% as any occurrence), then Feed (6.0% as any occurrence)
and then URO (5.2% as any occurrence). Considering single morbidities, only four morbidities occurred
in isolation at a rate of > 1.5% (this was a lower threshold prespecified in our protocol, below which a
morbidity might be considered rare or uncommon); these were PPE, Feed, URO and ECLS. However,
if considering morbidity rates based on any occurrence, meaning as a single morbidity or in combination
with other morbidities, all of the nine selected had a rate of > 1.5%, the least common being ANE, with a
rate of 2.1% (any occurrence).
The incidence of morbidity is shown in Table 13 and Figure 5, both when in combination with other
morbidities or as a single event.
0 200 400 600
Length of hospital stay (days)
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FIGURE 4 Length of stay by morbidity groups and individual morbidities. Box plot shows the median and IQR:
25th (Q1) to 75th centiles (Q3). The upper and lower bounds are Q3 + 1.5 × IQR and Q1 – 1.5 × IQR as defined by
Tukey.172 Multi, multimorbidities.
TABLE 12 Length of stay by morbidity groups and individual morbidities
Morbidity or morbidity group Number Median in days IQR
No morbidity 2411 8 5–13
Any morbidity 670 24 15–42
Single morbidity 412 20 13–31
ECLS 61 43 20–84
Multiple morbidity 197 35 22–56
ANE 14 19 12–39
URO 59 22 14–33
Feed 98 20.5 12–36
Renal 39 17 14–26
MAE 34 16.5 8–25
ECLS 61 43 20–84
NEC 32 24.5 18.5–49.5
SSI 26 20.5 11–28
PPE 110 20 14–28
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TABLE 13 Incidence of morbidities by procedure, with 95% CIs
Morbidity
Morbidity group
Multi PPE Feed ECLS URO Renal MAE NEC SSI ANE
Single morbidity
Number (%) 197 (6.4) 111 (3.6) 99 (3.2) 62 (2.0) 59 (1.9) 40 (1.3) 34 (1.1) 32 (1.0) 27 (0.9) 14 (0.5)
95% CI 5.5 to 7.3 3.0 to 4.3 2.6 to 3.9 1.5 to 2.6 1.5 to 2.5 0.9 to 1.8 0.8 to 1.5 0.7 to 1.5 0.6 to 1.3 0.2 to 0.8
Any morbidity
Number (%) 202 (6.5) 184 (6.0) 161 (5.2) 143 (4.6) 134 (4.3) 75 (2.4) 85 (2.8) 66 (2.1)
95% CI 5.7 to 7.5 5.1 to 6.8 4.5 to 6.1 3.9 to 5.4 3.6 to 5.1 1.9 to 3.0 2.2 to 3.4 1.7 to 2.7
Multi, multimorbidities.
Reproduced from Brown et al.157 © 2019 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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Multiple morbidities
There were 197 (6.4%) procedures that resulted in a multiple morbidity, excluding ECLS. Of these
197 procedures, 76 (39%) involved a feeding problem, 73 (37%) had URO, 72 (37%) had PPE, 67 (34%)
involved a MAE, 66 (34%) involved renal support, 49 (25%) involved SSI, 34 (17%) involved ANE and
33 (17%) involved NEC.
For the 197 multiple morbidity cases, 140 involved two morbidities, 39 involved three morbidities,
17 involved four morbidities and one involved five morbidities.
Extracorporeal life support morbidities
Among the 62 (2%) procedures in which there was postoperative ECLS, only two involved, ECLS only and
no other morbidities. Among these 62 ECLS morbidities there were 37 (60%) with Renal, 33 (53%) with
MAE, 29 (47%) with URO, 19 (31%) with PPE, 16 (29%) with ANE, 10 (16%) with NEC, 9 (15%) with SSI
and 9 (15%) with Feed.
Risk factors for any morbidity
Table 14 includes the frequency (%) for categorical risk factors and mean (SD) or median (IQR), as appropriate,
based on the distribution of the data for continuous risk factors. The weight was missing for 87 patients
and the weight for age was missing or not valid, based on being an extreme outlying value of > 5 SD from
the normative mean, for 186 patients (multiple imputation was used).
A summary table of risk factors by morbidities is presented in Appendix 8.
The univariate analysis showed that all risk factors were statistically significant for any morbidity, except for
sex, prematurity and Down’s syndrome. Multivariable analysis showed that all of the factors that were
significant on the univariate analysis remained significantly, independently associated with outcome, apart
from low weight.
Age was an important risk factor for the occurrence of any morbidity after adjustment for other factors:
compared with children aged ≥ 1 year, neonates had an increased chance of any morbidity, with an odds
ratio (OR) of 5.26 (95% CI 3.90 to 7.09) and, similarly, infants had an increased risk OR of 1.61 (95% CI
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FIGURE 5 Incidence of morbidities by procedure, with 95% CIs. Multi, multimorbidities. Reproduced from Brown et al.157
© 2019 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. This is an Open Access
article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license.
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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TABLE 14 Summary of risk factors by any morbidity outcome, with univariate and multivariable logistic regression results
Risk factor
Morbidity
Univariate OR (95% CI) p-value Multivariable OR (95% CI) p-valueNo (N= 2415) Any (N= 675)
Male, n (%) 1299 (53.8) 372 (55.1) 1.05 (0.89 to 1.25) 0.54
Age (days), median (IQR) 286 (105–1582) 102 (10 –331)
Child, n (%) 1111 (46.0) 160 (23.7)
Infant, n (%) 1023 (42.4) 268 (39.7) 1.82 (1.47 to 2.25) < 0.001 1.61 (1.26 to 2.05) < 0.001
Neonate, n (%) 281 (11.6) 247 (36.6) 6.10 (4.81 to 7.75) < 0.001 5.26 (3.90 to 7.09) < 0.001
Weight (kg), median (IQR) 7.7 (4.7–16.2) 4.6 (3.2–8.0)
Weight for age, mean (SD) –1.24 (1.60) –1.54 (1.49)
Low weight < 2 SDs below mean for age,
n (%)
714 (31.5) 234 (36.8) 1.27 (1.05 to 1.52) 0.01 1.21 (0.97 to 1.51) 0.09
Diagnosis, n (%)
E (reference) 1002 (41.5) 123 (18.2)
D 796 (33.0) 227 (33.6) 5.13 (3.79 to 6.93) < 0.001 2.02 (1.58 to 2.60) < 0.001
C 215 (8.9) 109 (16.2) 3.83 (2.85 to 5.13) < 0.001 1.44 (1.00 to 2.07) 0.05
B 232 (9.6) 109 (16.2) 4.13 (3.07 to 5.55) < 0.001 2.62 (1.85 to 3.71) < 0.001
A 170 (7.0) 107 (15.8) 2.32 (1.83 to 2.94) < 0.001 2.14 (1.41 to 3.24) < 0.001
Univentricular heart, n (%) 255 (10.6) 159 (23.6) 2.61 (2.11 to 3.23) < 0.001 1.55 (1.07 to 2.24) 0.02
Acquired comorbidity, n (%) 337 (14.0) 119 (17.6) 1.32 (1.05 to 1.66) 0.02 1.33 (1.03 to 1.71) 0.03
Congenital comorbidity, n (%) 537 (22.2) 178 (26.4) 1.25 (1.03 to 1.52) 0.03 1.28 (1.02 to 1.59) 0.03
Severity of illness risk, n (%) 222 (9.2) 152 (22.5) 2.87 (2.30 to 3.58) < 0.001 1.52 (1.16 to 2.00) < 0.01
Premature, n (%) 231 (9.6) 73 (10.8) 1.15 (0.87 to 1.51) 0.33
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TABLE 14 Summary of risk factors by any morbidity outcome, with univariate and multivariable logistic regression results (continued )
Risk factor
Morbidity
Univariate OR (95% CI) p-value Multivariable OR (95% CI) p-valueNo (N= 2415) Any (N= 675)
Down’s syndrome, n (%) 214 (8.9) 63 (9.3) 1.06 (0.79 to 1.43) 0.71
Additional cardiac risk, n (%) 165 (6.8) 65 (9.6) 1.45 (1.09 to 1.94) 0.01 1.39 (0.99 to 1.94) 0.05
Procedure, n (%)
Reparative/corrective (reference) 1391 (57.6) 332 (49.2)
Palliative/staged 331 (13.7) 179 (26.5) 2.27 (1.82 to 2.82) < 0.001 1.65 (1.14 to 2.38) < 0.01
Ungrouped 693 (28.7) 164 (24.3) 0.99 (0.81 to 1.22) 0.94 1.04 (0.82 to 1.31) 0.75
Bypass
Bypass time (minutes), median (IQR) 72 (42–110) 110 (62–156)
No bypass, n (%) 390 (16.2) 103 (15.3)
< 90 minutes, n (%) 1148 (47.5) 150 (22.2) 0.48 (0.35 to 0.65) < 0.001 0.78 (0.57 to 1.09) 0.14
> 90 minutes, n (%) 877 (36.3) 422 (62.5) 1.76 (1.32 to 2.34) < 0.001 2.28 (1.67 to 3.12) < 0.001
Reproduced from Brown et al.157 © 2019 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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1.26 to 2.05). Cardiac diagnosis group was the next most influential factor in the multivariable analysis,
with more complex conditions carrying a higher risk for any morbidity (adjusted OR > 2 for diagnoses A,
B and D; see Table 14 for full data), followed by a prolonged bypass time in excess of 90 minutes (adjusted
OR 2.8, 95% CI 1.67 to 3.12). A palliative or staged procedure increased the chance of a morbidity arising
(OR 1.6), as did the presence of a functionally univentricular heart (adjusted OR 1.6, 95% CI 1.07 to 2.24)
(these two factors clearly have some overlap) or a severity of illness factor (adjusted OR 1.5, 95% CI 1.16
to 2.00) (which includes pre-procedure mechanical ventilation or shock). A child being underweight or
having acquired comorbidity, congenital comorbidity and additional cardiac risk factors was not so
influential for occurrence of any morbidity.
The area under the receiver operator curve for the final multiple logistic regression model for any morbidity
was 0.77 (95% CI 0.75 to 0.79; Hosmer–Lemeshow goodness of fit p = 0.13).
Risk factors for the four-level morbidity outcome
The univariate multinomial risk factor results are shown in Table 15. The multiple multinomial model for
the four-level morbidity outcome (Table 16) indicated that in terms of single morbidities, the pattern of
important risk factors was much the same as for the two-category ‘any morbidity’ outcome. This is not
surprising given that the majority of morbidities are within this category.
The multiple multinomial model for the four-category outcome indicated that after adjustment for other
factors, neonatal status was even more strongly linked to ECLS (OR 7.9, 95% CI 2.87 to 18.52) and
multiple morbidity (OR 10.6, 95% CI 6.25 to 17.82) than it was to any morbidity (morbidity in general).
A similar picture was seen for the more complex cardiac diagnoses, for example diagnosis group A
(hypoplastic left heart syndrome, pulmonary atresia, truncus arteriosus) had an OR for ECLS of 4.3 (95% CI
1.13 to 16.36) and an OR for multiple morbidity of 3.49 (95% CI 1.71 to 7.13), adjusted for all other risk
factors. The next most important risk factor for both the outcomes of ECLS and multiple morbidity, after
adjustment for other factors, was prolonged bypass time of > 90 minutes, in particular for ECLS, with an
adjusted OR of 6.6 (95% CI 2.42 to 18.05). Increased severity of illness (which includes pre-procedure
mechanical ventilation or shock) was important for ECLS outcome (adjusted OR 3.7, 95% CI 1.91 to 7.01)
and multiple morbidities (adjusted OR 1.7, 95% CI 1.15 to 2.56). The additional factors of additional
cardiac risk factors, prematurity and congenital comorbidities were influential for the outcome of multiple
morbidities. One caution with this risk model is that the number of patients in the ECLS category was
relatively low and hence CIs are wide.
Limitations
The results are limited by the sources of the data and the morbidities that were selected and defined.
We acknowledge that there are rare morbidities and morbidities that can be difficult to define clinically,
which were not included. As we describe, it was necessary to collapse risk factors such as cardiac diagnosis
into broad groups, thus limiting interpretation of our results when considering specific individual conditions.
Although we undertook a range of actions, as reported in Data checking and validation, to check and
validate our study data, no such processes are perfect. We found low rates for certain morbidities as
standalone events, and, therefore, the small numbers limited the risk factor analysis that we were able
to undertake.
Summary and conclusions
This large prospective multicentre study of the incidence of important early morbidities after paediatric
cardiac surgery highlights some important points. First, backed up by our data checking procedures,
we believe that the study data are of high quality and form a strong basis for learning on this topic.
Then, in terms of headline numbers we note the following.
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TABLE 15 Summary of risk factors for the four-level morbidity outcome, with univariate multinomial regression results
Risk factor
No morbidity
(N= 2415)
Single (excluding
ECLS) morbidity
(N= 416) ECLS (N= 62)
Multiple
morbidity
(N= 197)
Single vs. none risk
ratio (95% CI), p-value
ECLS vs. none risk
ratio (95% CI), p-value
Multiple vs. none risk
ratio (95% CI), p-value
Male, n (%) 1299 (53.8) 242 (58.2) 26 (41.9) 104 (52.8) 1.19 (0.97 to 1.48),
0.10
0.62 (0.37 to 1.03),
0.07
0.96 (0.72 to 1.29),
0.79
Age (days), median (IQR) 286 (105–1582) 135 (15–490) 75 (7–266) 45 (8–239)
Child (reference), n (%) 1111 (46.0) 114 (27.4) 11 (17.7) 35 (17.8)
Infant 1023 (42.4) 174 (41.8) 23 (37.1) 71 (36.0) 1.66 (1.29 to 2.13),
< 0.001
2.27 (1.10 to 4.68),
0.03
2.20 (1.46 to 3.33),
< 0.001
Neonate 281 (11.6) 128 (30.8) 28 (45.2) 91 (46.2) 4.44 (3.34 to 5.90),
< 0.001
10.06 (4.95 to 20.46),
< 0.001
10.28 (6.81 to 15.51),
< 0.001
Weight (kg), median (IQR) 7.7 (4.7–16.2) 5.1 (3.3–8.7) 4.1 (3.2–7.4) 3.8 (3.0–6.7)
Weight for age, mean (SD) –1.2 (1.6) –1.6 (1.5) –1.4 (1.6) –1.6 (1.5) 0.88 (0.82 to 0.94),
0.001
0.94 (0.80 to 1.10),
0.43
0.88 (0.80 to 0.97),
< 0.01
Low weight < –2 SD, n (%) 714 (31.5) 143 (36.6) 20 (33.3) 71 (38.4) 1.25 (1.00 to 1.57),
0.05
1.09 (0.63 to 1.87),
0.76
1.36 (0.99 to 1.85),
0.05
Diagnosis, n (%)
E (reference) 1002 (41.5) 93 (22.4) 6 (9.7) 24 (12.2)
D 796 (33.0) 139 (33.4) 20 (32.3) 68 (34.5) 1.88 (1.42 to 2.49),
< 0.001
4.20 (1.68 to 10.50),
< 0.01
3.57 (2.22 to 5.73),
< 0.001
C 215 (8.9) 59 (14.2) 16 (25.8) 34 (17.3) 2.96 (2.07 to 4.23),
< 0.001
12.43 (4.81 to 32.13),
< 0.001
6.60 (3.84 to 11.36),
< 0.001
B 232 (9.6) 63 (15.1) 12 (19.4) 34 (17.3) 2.93 (2.06 to 4.15),
< 0.001
8.64 (3.21 to 23.25),
< 0.001
6.12 (3.56 to 10.52),
< 0.001
A 170 (7.0) 62 (14.9) 8 (12.9) 37 (18.8) 3.93 (2.74 to 5.63),
< 0.001
7.86 (2.69 to 22.93),
< 0.001
9.09 (5.30 to 15.57),
< 0.001
UVH, n (%) 255 (10.6) 98 (23.6) 9 (14.5) 52 (26.4) 2.61 (2.02 to 3.37),
< 0.001
1.44 (0.70 to 2.94),
0.32
3.04 (2.15 to 4.29),
< 0.001
Acquired comorbidity, n (%) 337 (14.0) 71 (17.1) 11 (17.7) 37 (18.8) 1.27 (0.95 to 1.69),
0.10
1.33 (0.69 to 2.57),
0.40
1.43 (0.98 to 2.07),
0.06
M
EA
SU
REM
EN
T
O
F
IN
CID
EN
CE
FO
R
TH
E
D
EFIN
ED
M
O
RBID
ITIES
IN
TH
E
STU
D
Y
PO
PU
LA
TIO
N
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
66
Risk factor
No morbidity
(N= 2415)
Single (excluding
ECLS) morbidity
(N= 416) ECLS (N= 62)
Multiple
morbidity
(N= 197)
Single vs. none risk
ratio (95% CI), p-value
ECLS vs. none risk
ratio (95% CI), p-value
Multiple vs. none risk
ratio (95% CI), p-value
Congenital comorbidity,
n (%)
537 (22.2) 104 (25) 18 (29.0) 56 (28.4) 1.17 (0.91 to 1.49),
0.22
1.43 (0.82 to 2.49),
0.21
1.39 (1.01 to 1.91),
0.05
Severity of illness, n (%) 222 (9.2) 75 (18.0) 25 (40.3) 52 (26.4) 2.17 (1.64 to 2.88),
< 0.001
6.67 (3.96 to 11.25),
< 0.001
3.54 (2.52 to 4.98),
< 0.001
Premature, n (%) 231 (9.6) 37 (8.9) 7 (11.3) 29 (14.7) 0.92 (0.64 to 1.33),
0.67
1.20 (0.54 to 2.67),
0.65
1.63 (1.08 to 2.45),
0.02
Down’s syndrome, n (%) 214 (8.9) 41 (9.9) 5 (8.1) 17 (8.6) 1.12 (0.79 to 1.60),
0.52
0.90 (0.36 to 2.28),
0.83
0.97 (0.58 to 1.62),
0.91
Additional cardiac risk, n (%) 165 (6.8) 36 (8.7) 8 (12.9) 21 (10.7) 1.29 (0.90 to 1.86),
0.17
2.02 (0.95 to 4.29),
0.07
1.63 (1.02 to 2.60),
0.04
Procedure, n (%)
Reparative/corrective
(reference)
1391 (57.6) 202 (48.6) 39 (62.9) 91 (46.2)
Palliative/staged 331 (13.7) 120 (28.9) 8 (12.9) 51 (25.9) 2.50 (1.93 to 3.22),
< 0.001
0.86 (0.40 to 1.86),
0.71
2.36 (1.64 to 3.39),
< 0.001
Ungrouped 693 (28.7) 94 (22.6) 15 (24.2) 55 (27.9) 0.93 (0.72 to 1.21),
0.61
0.77 (0.42 to 1.41),
0.40
1.21 (0.86 to 1.72),
0.28
Bypass
Bypass time (minutes),
median (IQR)
72 (42–110) 102 (55–144) 191 (119–293) 116 (63–160)
No bypass (reference),
n (%)
390 (16.2) 75 (18.0) 4 (6.5) 24 (12.2)
≤ 90 minutes, n (%) 1148 (47.5) 106 (25.5) 3 (4.8) 41 (20.8) 0.48 (0.35 to 0.66),
< 0.001
0.25 (0.06 to 1.14),
0.07
0.58 (0.35 to 0.97),
0.04
> 90 minutes, n (%) 877 (36.3) 235 (56.5) 55 (88.7) 132 (67.0) 1.39 (1.04 to 1.85),
0.02
6.11 (2.20 to 16.99),
< 0.01
2.45 (1.56 to 3.84),
< 0.001
Note
Sex and Down’s syndrome were not considered as important risk factors and were not included in multivariable analysis.
Reproduced from Brown et al.157 © 2019 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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Among 3090 procedures, 21.8% experienced an important morbidity. Of these, 6.4% were multiple
morbidities and 2% were ECLS, which are very serious events.
The patients who had none of the measured morbidities experienced a very low mortality rate of 0.9%
at 6 months, whereas those who had a morbidity experienced a mortality rate of 12.5% at 6 months,
this rising to 50% for ECLS and 17.1% for multiple morbidity.
The length of postoperative hospital stay in patients with no morbidity was a median of 8 days, whereas
the postoperative stay rose to a median of 24 days with any morbidity, 43 days with ECLS and 35 days
with multiple morbidities.
The most prevalent three important morbidities were PPE (6.5% as any occurrence), Feed (6.0% as any
occurrence) and URO (5.2% as any occurrence). When considering the incidence of a given morbidity,
it is important to distinguish between the rate of the morbidity as any occurrence, as well as the rate as
a single morbidity.
TABLE 16 Multivariable multinomial regression results for the four-level morbidity outcome
Risk factor
Single vs. none risk ratio
(95% CI), p-value
ECLS vs. none risk ratio
(95% CI), p-value
Multiple vs. none risk ratio
(95% CI), p-value
Child (reference)
Infant 1.58 (1.21 to 2.07), 0.001 1.94 (0.90 to 4.19), 0.09 1.98 (1.28 to 3.06), < 0.01
Neonate 3.83 (2.75 to 5.35), < 0.001 7.29 (2.87 to 18.52), < 0.001 10.56 (6.25 to 17.82), < 0.001
Diagnosis
E (reference)
D 1.62 (1.21 to 2.16), 0.001 3.09 (1.22 to 7.79), 0.02 3.44 (2.11 to 5.62), < 0.001
C 1.24 (0.82 to 1.87), 0.30 2.06 (0.65 to 6.52), 0.22 1.77 (0.91 to 4.42), 0.09
B 1.85 (1.21 to 2.82), < 0.01 8.19 (2.89 to 23.16), < 0.001 4.38 (2.35 to 8.15), < 0.001
A 1.67 (1.03 to 2.71), 0.04 4.29 (1.13 to 16.36), 0.03 3.49 (1.71 to 7.13), 0.001
Univentricular 1.52 (1.01 to 2.29), 0.04 1.11 (0.35 to 3.55), 0.86 1.77 (0.95 to 3.27), 0.07
Acquired comorbidity 1.32 (0.97 to 1.79), 0.08 1.13 (0.54 to 2.37), 0.75 1.44 (0.95 to 2.20), 0.09
Congenital comorbidity 1.21 (0.93 to 1.58), 0.15 1.34 (0.71 to 2.53), 0.37 1.49 (1.05 to 2.11), 0.03
Severity of illness 1.32 (0.97 to 1.82), < 0.001 3.66 (1.91 to 7.01), < 0.001 1.71 (1.15 to 2.56), < 0.01
Premature 0.84 (0.57 to 1.25), 0.40 1.09 (0.47 to 2.52), 0.84 1.64 (1.05 to 2.56), 0.03
Additional cardiac risk 1.29 (0.90 to 1.86), 0.17 2.02 (0.95 to 4.29), 0.07 1.63 (1.02 to 2.60), 0.04
Procedure
Reparative/corrective
(reference)
Palliative/staged 1.89 (1.26 to 2.82), < 0.01 0.72 (0.20 to 2.56), 0.61 1.43 (0.77 to 2.66), 0.26
Ungrouped 0.96 (0.73 to 1.27), 0.79 1.02 (0.52 to 2.01), 0.95 1.34 (0.90 to 1.99), 0.15
No bypass (reference)
≤ 90 minutes 0.68 (0.47 to 0.99), 0.04 0.42 (0.09 to 1.86), 0.25 1.13 (0.63 to 2.02), 0.69
> 90 minutes 1.75 (1.23 to 2.47), < 0.01 6.61 (2.42 to 18.05), < 0.001 3.30 (1.93 to 5.67), < 0.001
Reproduced from Brown et al.157 © 2019 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery.
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0)
license. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
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The most important risk factors for morbidity included non-modifiable risk factors of young age, with
neonates being very high risk, and more complex cardiac diseases, in particular diagnoses of hypoplastic
left heart syndrome, pulmonary atresia, truncus arteriosus and functionally univentricular heart. Children
who deteriorated prior to surgery who required intensive care supports (with severity of illness factors)
were more likely to experience most types of morbidity. An important independent risk factor for morbidity
that may, in selected circumstances, be modifiable, and which was especially linked to the key outcomes
of ECLS and multiple morbidities, was prolonged cardiopulmonary bypass time. This indicates that events
in the intraoperative period may have an important knock-on effect after surgery.
These data on the incidence and clinical features of important early morbidities after paediatric cardiac
surgery may be useful to clinical teams undertaking quality assurance work (see Chapter 11) and may be
used to inform discussions about ‘what to expect’ that take place routinely with parents of children
undergoing paediatric cardiac surgery.
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Chapter 8 The impact study: association between
morbidities following paediatric cardiac surgery with
quality of life and patient days at home by 6 months
Introduction
Much of the existing research on the sequelae of paediatric cardiac surgical morbidities has focused on
establishing their links with longer stays and the risk of death during the early perioperative period.6,13
There are a small number of studies in children with the specific heart conditions of transposition and
hypoplastic left heart syndrome that suggest that those who experienced prolonged stays in hospital
following their initial surgery developed higher levels of neurological disability,8,9 which is a determinant
of longer-term quality of life. In this study, we aimed to take this topic forward considerably by measuring
the impact of morbidities on patients, families and the health service, using a prospective case-matched
cohort study design. Our study design included children with all types of heart disease and incorporates
events over the first 6 months after the initial surgical procedure.
Methods
Recruitment
Overview
Recruitment to the impact study was undertaken at:
l GOSH – 1 October 2015 to 30 June 2017 (21 months)
l EVE – 1 November 2015 to 30 June 2017 (20 months)
l BIRM – 1 October 2015 to 30 June 2017 (21 months)
l BRHC – 1 October 2015 to 30 June 2017 (21 months)
l GLA – 15 October 2015 to 30 April 2016, with a break December 2015 to January 2016 (6 months).
Cases (patients with at least one of the shortlisted morbidities) and potential controls (those with none of
the shortlisted morbidities) were identified throughout the 21-month incidence study. Patient information
about the study was widely available at study sites and families were made aware of the potential for
participation by a range of routes, including verbal contact from the clinical team at each site, posters and
leaflets. The research nurse at each site approached families who expressed an interest in the study and
undertook recruitment and obtained written informed consent to participate. Families were approached
either pre- or postoperatively, as was judged best for the individual participant based on the premise of
allowing them as much time as possible in an unpressurised situation to consider the matter.
We aimed to recruit 36 matched pairs for each of the selected morbidities (see Original protocol statement
on sample size) and hence we considered all of the children who had been identified in the incidence
study across the five sites with any of the selected morbidities as eligible for the impact study. Children
who had postoperative ECLS were treated as a standalone morbidity group from the outset, even when
the child had other associated morbidities. Children with multiple morbidities excluding ECLS were
considered as a separate group, with a goal to recruit as many as possible. Contemporaneously we aimed
to recruit individually case-matched children (referred to as controls) with no morbidity.
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Exclusions
The only exclusions to participation in the impact study were families that were not resident in the UK and,
hence, were unavailable for follow-ups and families in which no family member spoke sufficient English to
enable follow-up to be undertaken. Unfortunately, validated instruments used in the follow-up assessment
for the study are not available in every language. In the case of families for whom English was not the first
language, the study teams assessed the feasibility of participation on a case-by-case basis, with a view to
include families wherever feasible, considering whether or not, with interpreter support and input from
family members who spoke English to a reasonable level, follow-up could be completed.
Neonates in impact
Given the relatively high rate of post-procedural complications in neonatal patients undergoing surgery,
we aimed to recruit all neonates to the impact study. This was because there were inevitable logistic
difficulties involved in prospectively identifying suitable case-matched children with no morbidity for
morbidity cases. In neonates, given the balance of proportions between morbidities and morbidity-free
patients, it was judged by the Project Management Team and the Steering Committee that this was the
most efficient approach.
Inclusion of deceased patients
As would be expected, during the study time frame a proportion of patients died postoperatively. Clearly
this is an emotive subject, yet it was considered [by the Project Management Team, oversight committees
and patient and public involvement (PPI) advisors] very important that the outcomes of deceased children
were incorporated within the impact study, given that this is obviously the worst outcome for all concerned.
When a child died after the family had consented to participate in the impact study, no further data were
collected; however, the data as collected up to the time of death were retained in the study data set for analyses.
Within the first 6 months of recruitment it was noted that a subset of very sick children who experienced
morbidities and died early in the ICU were not being approached for consent because the patient families
were never in a position to discuss research participation, given their exceptionally difficult circumstances.
This issue was discussed between the Project Management Team, oversight committees and PPI advisors
who recommended a protocol amendment in order that these outcomes could be ethically incorporated
in the impact study. The substantial amendment was as follows: the research nurses and co-investigators
(either a consultant surgeon or an intensivist) at each site were asked to identify patients in the incidence
study who died in the ICU before an opportunity arose for the family to be asked for consent. Of these
‘early death’ patients, a randomly selected 60% (reflecting the actual rate of consent among families who
had a child with morbidity and had been approached to participate) were included in the impact study.
Given that these were not consented participants, with Research Ethics Committee approval, we included
only the limited pseudoanonymised fields of the incidence study. For the included sample of ‘early death’
patients, all of whom had morbidity, the study sites were asked to recruit a case-matched pair with no
morbidity (a control). These ‘early death’ patients contribute to two of the three primary outcomes used
to measure the impact of morbidity (see below).
Morbidity cases and matching of pairs
Cases of morbidity have been defined in Chapter 5 and include postoperative occurrence (either single or
in combination) of ANE, URO, feeding morbidity (Feed), renal support (Renal), MAE, treatment with ECLS,
NEC, SSI and PPE.
We aimed to pair each recruited morbidity case to the next available morbidity-free patient from within the
same centre who had the following three criteria:
1. Age (matched within 3 months for children < 1 year, within 1 year in children < 5 years and within
2 years in children > 5 years).
2. Single or double ventricle status.173
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3. Surgical procedure type matched by the broad Risk Adjusted classification for Congenital Heart
Surgery (RACHS-1) category2 or where there is a choice by the finer Central Cardiac Audit Database
procedure classification.174
In the first 6 months of the study, patients were matched based on all three of these criteria; however,
from month 7 onwards the third matching criterion was removed on the advice of the Steering
Committee, because of difficulties finding the necessary three-factor matches.
Our approach to children with comorbid conditions was to recruit them as either cases or controls,
dependent on the presence of morbidity.
Controls were recruited postoperatively and close to patient discharge in most instances, so as to be sure
that they were morbidity free. In a handful of cases in which patients were recruited earlier than this and a
morbidity was diagnosed between recruitment and discharge, the patient status was reassigned as a case.
Data collected
Study patient data collection included demographics and clinical information regarding the procedure that
was undertaken and its linked hospital admission that were entered in the bespoke study database. In
addition, we obtained extracts of nationally mandated audit data from for the NCHDA24 on all procedures
undertaken over 6 months of follow-up and the PICANet158 on all admissions over 6 months of follow-up.
Based on the case mix factors collected, we utilised the following variables in the impact data set in our
analyses: sex, age, age band (neonate, infant child), weight at primary operation, calculated weight-for-age
z-score, cardiac diagnosis category (A most complex to E least complex), functionally univentricular heart,
specific procedure type category (palliative/staged, corrective/reparative or ambiguous), operation type
(bypass, non-bypass or hybrid), bypass time, acquired comorbidity, congenital comorbidity excluding Down
syndrome, Down syndrome, additional cardiac risk factors, prematurity and severity of illness indicator.
(For details and rationale for clinical variable categorisations see Brown et al.164 and Cole et al.,170 and
Chapter 7.)
We also utilised information on family income (five categories), ethnic group (categorised as white/non-white)
and study site (five categories).
Measurement of impact
We assessed the impact of the defined perioperative morbidity events over a 6-month follow-up period,
using three primary outcome measures over 6 months from the date of enrolment in the study, which was
the date of the first index paediatric cardiac surgical procedure:
1. quality of life and psychological burden on children and parents using age-specific measures
2. days at home by 6 months, as an additional measure of disruption to family life
3. NHS costs, including further interventions and hospitalisations, and costs borne by families.
The first two impact outcomes listed are discussed in the current chapter and the third is discussed in
Chapter 9.
Follow-up processes
The research nurses at each site followed up each patient to collect data four times over a 6-month period:
(1) at (first) discharge from hospital, (2) at 6 weeks, (3) at 3 months and (4) at 6 months after the primary
cardiac procedure. If a patient remained in hospital for a prolonged stay after the procedure, the follow-up
data were collected whenever possible, although if the child was very sick and required ICU care or the
parents were distressed, this was infeasible. In all cases we aimed to undertake follow-up contacts within
2 weeks of the specified time point; if this was not achieved, the data were treated as missing.
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Follow-up data were collected from patient families, with the exception of communication data (see Chapter 10),
face to face, by telephone or electronically, based on family preference or convenience. Our protocol stated
that postal completion should not be used because of the poor response rates. The measures completed by
families are listed in Table 17.
Primary outcome: quality of life
Health-related quality of life for cases and controls was assessed using the Pediatric Quality of Life Inventory
(PedsQL) 4.0 core scales, which are generic measures for children aged 0–18 years.175–177 For patients aged
< 5 years there are parent-proxy versions only; for those aged > 5 years there are self-completed versions
and parent-proxy versions. Normative data exist for all forms of the PedsQL and the measures have been
widely used with healthy and ill children, including those with heart disease.175–177 Although we prefer to
collect self-reported data when possible, the majority of patients undergoing surgery were aged < 5 years
and in most cases the parent elected to undertake the questionnaire on their child’s behalf, therefore all of
our PedsQL data were by parent proxy.
Proxy reporting of a child’s quality of life can be influenced by parental mental health and therefore we
measured this using the Patient Health Questionnaire-4 items (PHQ-4),180 to explore this with parents.
A child’s illness and subsequent treatment can also have a broader impact on the family and this was
assessed with the PedsQL family impact module.181 The PedsQL family impact data from our study,
although collected, have yet to be analysed and these data are not covered in our report.
These questionnaires typically ask respondents to consider the past 1 month. As we did not want to reflect
the early postoperative hospital experience (although we recognise that unfortunately a small number
of children do remain in hospital for longer periods), we administered questionnaires at 6 weeks and
6 months post procedure (> 1 month after discharge for most).
Primary outcome: days at home by 6 months
Another objective measure of the impact of morbidity is the number of hospital-free days a child experiences
within 6 months of the primary procedure. We collected length of stay data over the 6 months of follow-up
from NCHDA,24 which contains hospital (ward) discharge dates, and the PICANet, which contains ICU
admission dates.158 The research nurses further collated all relevant data about hospital stays in secondary as
well as specialist centres, accident and emergency department visits and outpatient appointments, and
recorded these in the study database. The survival status of all patients was rechecked with sites after the
end of the study. Patients who died during the hospitalisation of their surgery scored zero on this scale, to
reflect that this is the worst outcome.
TABLE 17 Follow-up measures for the quality-of-life primary outcome
Questionnaire
Time point
Time taken
(minutes)Discharge 6 weeks 3 months 6 months
PedsQL 4.0 generic core battery: assesses child’s
quality of life in physical, emotional and school
(where appropriate) domains175–177
✗ ✓ ✗ ✓ 5
HUI2: a preference-based, multiattribute,
health-related quality-of-life tool that delivers
a single utility score, completed by parents178,179
✗ ✓ ✓ ✓ 5
PHQ-4: a four-item scale measuring parental
anxiety and depression180
✓ ✓ ✓ ✓ 2
PedsQL family impact module: a 36-item
questionnaire completed by parents to assess
impact of child’s health on parental functioning,
family relationships and activities of daily living181
✗ ✓ ✗ ✓ 10
HUI2, Health Utilities Index Mark 2; PedsQL, Pediatric Quality of Life Inventory; PHQ-4, Patient Health Questionnaire-4 items.
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Original protocol statement on sample size
We note previous research that stated that a clinically relevant difference in quality of life between pairs
corresponds to a mean difference of at least 0.5 SDs. 182 To detect such a difference for PedsQL responses at
5% significance with 80% power requires a minimum of 32 matched pairs. Allowing for a 10% loss to
follow-up rate, we aimed to recruit 36 matched pairs for each patient with morbidity. We anticipated that in
the incidence study there would be 3000–3300 patients and, therefore, we considered that we would have
80% power to detect a significant effect for any morbidity with a prevalence of at least 1.5%. We noted
that based on an analysis of 1 year of cardiac surgery cases from GOSH,6 several major morbidities are
anticipated to have lone incidence rates of 1–3% and a multiple morbidity rate of 4–7%. Based on this we
estimated that there would be sufficient cases from which to recruit 6–10 sets of 36 matched pairs and
around 120 matched pairs for multiple morbidities (a total of 672–960 children, depending on the number
of morbidities included).
Statistical analysis
Descriptive and scoring
Demographic variables are presented as categorical values, means (SD) or medians (IQR), as appropriate
based on the skewness of the data.
The PedsQL scores (range 0–100) for social function, physical function and total scores are presented as
mean (SD) for morbidity groups and for individual morbidities at 6 weeks and 6 months. We additionally
used normal PedsQL values (mean and SD) for individual age bands to identify amber (PedsQL scores of
> 1 SD below the normative mean) and red (PedsQL scores of > 2 SDs below the normative mean)
thresholds.175–177 These threshold values based on normative data are presented in Appendix 9 for relevant
age bands, based on the relevant papers by Varni et al.175–177
The PHQ-4 scores (range 0–12) were grouped as normal (0–2), mild (3–5), moderate (6–8) or severe (9–12),
as a combined measure of parental anxiety and depression. Additionally, two binary variables were defined,
anxiety (yes/no) and depression (yes/no), as described by Kroenke et al.180
Note on matching
Although the original protocol set out the aim to case match each recruited patient with morbidity to a
patient who did not have morbidity and then to undertake analysis of matched pairs for our outcomes,
we found that for logistic reasons it was not possible to achieve a fully 100% matched sample. This was
because of the inevitable real-world situation of recruitment in the challenging situation of children
undergoing heart surgery. Although we were able to match the majority of recruited patients within a
centre on the two essential criteria, this being 279 patient pairs representing a total of 558 patients, there
were 108 patients unmatched, of whom 61 had morbidity. Among the patients with morbidity, including
those who were unmatched, there were more complex features, such as complex cardiac diagnoses, single
ventricle disease and neonatal age (see Table 19). This issue was discussed over the course of the study
among the Project Management Team, oversight committees and PPI advisors, and came as no surprise
at the analysis stage. In order to make maximal use of the valuable data pertaining to all the recruited
participants, we elected to include all of the impact patients in the analysis related to morbidity post procedure
and outcome over 6 months, adjusting for covariates related to case complexity. Although this represents a
deviation from our original matched pair design at the analysis stage, we think that this design was very useful
during recruitment since it ensured that we ended up with as balanced a sample as possible.
Analysis of impact of morbidity in terms of the outcome measures
For each of three PedsQL outcomes, physical function, psychosocial function and total score, a mixed-effects
regression model was used to compare the impact of morbidity (any morbidity vs. no morbidity) on the
outcome at 6 weeks and 6 months separately. We fitted a further set of models to compare the impact of
the four-category single morbidity, ECLS morbidity and multiple morbidities compared with no morbidity.
All models were adjusted for clustering within matched pairs; we explored the inclusion of an additional level,
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site, and found that the results changed very little so did not present these. We adjusted all models for
significant covariates linked to morbidity, based on findings in the incidence analysis, these being age, weight,
cardiac diagnosis category, functionally univentricular heart, specific procedure type category, bypass time,
acquired comorbidity, congenital comorbidity excluding Down’s syndrome, additional cardiac risk factors and
severity of illness indicator.
The PedsQL was not recorded for all patients; therefore, we used multiple imputation by chained equations
to account for missing data at the two follow-up time points. We imputed data only for those patients with
missing data, known to be alive at 6 weeks and 6 months, respectively, and the imputation models included
all of the risk factors considered in the incidence analysis, which we assume includes all predictors of
missingness. The final models were derived by fitting regression models, as described above, and estimates
were combined using Rubin’s rules.171
For the four-category PHQ-4 outcome, multinomial regression was used with robust standard errors to
adjust for clustering within matched pairs. We considered and estimated the effect of the impact of any
morbidity and the four-level morbidity categorisation on outcome at both follow-up times separately, and
adjusted all models for the same covariates as for the PedsQL models. We did not impute missing data for
the PHQ-4 outcome and present results for complete-case analysis. In general, PHQ-4 data were recorded
at the same time and for the same patients as the PedsQL data. In Results we show that there is little
difference between PedsQL responders and non-responders; therefore, we are confident that the sample
of PHQ-4 data is representative of the whole impact population.
The days at home by 6 months outcome was negatively skewed, as expected, and after exploration
of various transformation we decided to use quantile regression to estimate the effects of morbidity in
terms of differences in medians. We considered the effects of any morbidity, the ‘four-level morbidity
categorisation’ and also looked at the impact of the individual morbidity relative to the no morbidity
patients. All models were adjusted for clustering within matched pairs and robust standard errors were
used. Given that there were very few missing data for this outcome, multiple imputation was not used.
All of the estimates are presented with 95% CIs and a p-value of < 0.05 was considered significant.
All data were analysed using Stata.
Results
The number of patients and morbidities in the impact cohort
As we have outlined in Chapter 7, we included 3090 procedure episodes (675 with morbidities) in the
incidence study. These occurred in 2861 individual patients who had cardiac surgery across the five
participating sites. Nested within the incidence study we recruited patients to the impact study, although
of note, in Glasgow, we recruited to the impact study for only one-third of the study time because of local
logistic problems at that site.
The recorded recruitment rate from eligible participants across all centres was 60% (based on locally held
screening logs), and the total number recruited into the impact study was 666 patients, 340 (51%) of
whom had at least one morbidity.
Although we recruited 118 patients (18%) with multiple morbidities, which was within the anticipated range,
the numbers in many of the single morbidity categories (shown in Table 18) were lower than expected, such that
only the most prevalent morbidities, PPE (50 patients) and Feed (45 patients), exceeded the value of 32 cases
set out in the sample size calculation as required to detect a 0.5 SD difference in the quality-of-life outcome.
The number of patients with ECLS (27 patients), URO (26 patients), Renal (24 patients) and MAE (22 patients)
were all close to the target number; however, the number of patients with NEC (11 patients), SSI (11 patients)
and ANE (six patients) was much lower owing to the rarity of these morbidities in the base population.
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We note that although the total number of patients recruited to both the incidence study and the impact
study fell within the projected range stated in the original protocol, there was a lower than expected
occurrence of single complications in the study population, leading to the smaller numbers in the
categories that related to the rarest morbidities. Given the small number of patients with individual single
morbidities, we present the outcome analyses of the impact of morbidity on the quality-of-life outcome by
the same broader morbidity groups that we outlined in Chapter 7:
l Two categories: any morbidity compared with no morbidity.
l Four categories: single morbidity (excludes ECLS or ECMO), ECLS or ECMO, multiple morbidity and no
morbidity. This outcome enables the discrimination of risk factors for the particularly adverse outcomes
of ECLS and multiple morbidities.
For the days at home at 6 months and health economic analyses, which include the deceased patients,
we present the analyses of morbidity impact by the 11-category outcome, which incorporates each
individual morbidity, multiple morbidity and no morbidity.
Case mix in the impact cohort
The case mix in the impact study cohort is presented in Table 19 by presence or absence of morbidity.
Deceased patients
Twenty patients who died before they could be approached for consent were included based on a truncated
pseudoanonymised data set. Of these 20 patients, 19 patients had a morbidity, consisting of three MAEs,
eight ECLSs and eight multiple morbidities.
Over the 6-month follow-up period, there were 39 deaths among patients in the impact study cohort.
Of these, four had no morbidities and the other 35 had morbidities (one Renal, three MAE, 12 ECLS,
two NEC and 17 multiple morbidities).
The PedsQL outcome data
Participation in this outcome measure: 6 weeks
At 6 weeks, 19 patients had died and 647 patients were alive, of whom 70 were still in hospital. Of patients in
hospital at 6 weeks, 49 patients were well enough to complete the PedsQL and 22 were sick in a paediatric
TABLE 18 Morbidity types within the impact study cohort
Morbidity group Total, n (%)
No morbidity 326 (49)
ANE 6 (1)
URO 26 (4)
Feed 45 (7)
Renal 24 (4)
MAE 22 (3)
ECLS 27 (4)
NEC 11 (2)
SSI 11 (2)
PPE 50 (8)
Multiple morbidity 118 (18)
Total in cohort 666
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TABLE 19 Summaries of baseline characteristics by any morbidity
Baseline characteristic
Morbidity, n (%) or where stated median (IQR)
p-valueNo (N= 326) Any (N= 340)
Male 189 (58.0) 185 (54.4) 0.35
Age (days), median (IQR) 95 (11–398) 66 (8–283) 0.09
Child 82 (25.1) 74 (21.8)
Infant 130 (39.9) 120 (35.3) 0.11
Neonate 114 (35.0) 146 (42.9)
Weight (kg), median (IQR)a 4.9 (3.4–8.9) 4.2 (3.2–7.6) 0.01
Weight for age, mean (SD)a –1.30 (1.45) –1.42 (1.47) 0.27
Low weight > 2 SD below normal for agea 90 (29.8) 103 (32.0) 0.56
Cardiac diagnosis
E (least complex) 101 (31.0) 67 (19.7)
D 89 (27.3) 107 (31.5) < 0.01
C 62 (19.0) 62 (18.2)
B 34 (10.4) 56 (16.5)
A (most complex) 40 (12.3) 48 (14.1)
Functionally univentricular heart 53 (16.3) 81 (23.8) 0.02
Acquired comorbidity 47 (14.4) 50 (14.7) 0.92
Congenital comorbidity 45 (13.8) 76 (22.4) < 0.01
Severity of illness factor 49 (15.0) 75 (22.1) 0.02
Premature birth before 37 weeks’ gestation 26 (8.0) 34 (10.0) 0.36
Down’s syndrome 27 (8.3) 29 (8.5) 0.91
Additional cardiac risk factor 25 (7.7) 31 (9.1) 0.50
Cardiac procedure
Reparative/corrective 190 (58.3) 169 (49.7) 0.06
Palliative/staged 65 (19.9) 90 (26.5)
Ungrouped 71 (21.8) 81 (23.8)
Bypass
Bypass time (minutes), median (IQR) 83 (52–122) 114 (69–157) < 0.001
No bypass 45 (14.2) 45 (13.6)
< 90 minutes 127 (40.2) 67 (20.3) < 0.001
> 90 minutes 144 (45.6) 218 (66.1)
Ethnicity: whitea 253 (79.6) 248 (78.0) 0.63
Family income (£ per year)
< 10,000 31 (10.7) 24 (8.5) 0.14
10,000–25,000 67 (23.2) 87 (31.0)
25,000–50,000 118 (40.8) 113 (40.2)
> 50,000a 73 (25.3) 57 (20.3)
a Weight was missing for 28 patients, weight for age was missing or not valid for 42 patients, ethnic group was missing
for 30 patients and family income was missing or unknown for 96 patients.
THE IMPACT STUDY: MORBIDITIES AND QUALITY OF LIFE AND PATIENT DAYS AT HOME
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
ICU and could not complete it. It is important to note that children considered to be the most unwell, and
those who died or were in ICU and too unwell to complete the PedsQL, did not contribute to this analysis.
Overall, of surviving patients, PedsQL scores were available for 478 patients and missing for 147 patients
who had been discharged (total missing PedsQL in surviving patients was 26%). Excluding the deceased
patients and then comparing baseline factors between patients with and without 6-week data for PedsQL,
the only difference was for severity of illness factors and additional cardiac risk factors. In the missing
group, 24% of patients had a severity of illness risk factor, whereas only 16% of those completing the
measure had this covariate (p = 0.01). For acquired cardiac risk factors, in the missing group this was
12% and in those who completed the measure it was 6% (p = 0.01). Otherwise, all other baseline factors
were similar between missing and non-missing patients and, importantly, there was no difference in the
proportion of patients with or without morbidity.
Participation in this outcome measure: 6 months
At the 6-month time point 39 patients had died, 627 patients were alive and five patients were still in
hospital, of whom two completed PedsQL data. Of surviving patients, PedsQL data were available for
403 patients and missing for 224 patients (36%). There was no difference in any baseline factor or morbidity
occurrence between patients with and patients without PedsQL data at 6 months.
The PedsQL outcome by any morbidity
Pediatric Quality of Life Inventory scores for children in the impact study are presented based on the presence
of any morbidity or no morbidity in Table 20, at the follow-up time points of 6 weeks and 6 months. We
note a previous comment from Norman et al.,182 stating that a clinically significant difference in quality of life
is 0.5 SD. For PedsQL data the SD varies by age, being lower in younger children: the median age in the
impact cohort was around 3 months at enrolment and 9 months at completion of the study. Hence, we
estimate that a clinically important difference in PedsQL scores in the majority of the impact cohort is
between 5 and 7.175–177
For patients with any morbidity (after adjustment for all covariates), the total PedsQL score at 6 weeks is
lower, on average, by 5.2 units (95% CI –8.3 to –2.2 units). Looking more closely at the subdomains we
see the physical functioning plays a bigger part and is impaired more than the psychosocial functioning.
At 6 months the case mix adjusted difference in PedsQL scores has narrowed between the two groups,
with some residual difference in physical scores, which may reach an important difference for some
children.
The PedsQL outcome by four-level morbidity groups and individual morbidities
Table 21 shows the case mix-adjusted PedsQL scores categorised by the four morbidity groups and here it
is possible to see the more significant effects of ECLS and multiple morbidity on the quality-of-life outcomes;
both groups are associated with large differences in quality of life for physical scores, with moderate
differences in psychosocial scores at 6 weeks. Although these scores have improved by 6 months, a clinically
important reduction on physical quality of life persists at 6 months in the ECLS and multiple morbidities.
Although, as stated, we did not undertake statistical analyses of quality-of-life outcomes by individual
morbidity, the values for these measures are shown in Figure 6, in which we can see that ECLS, PPE and
multiple morbidity have the lowest scores at 6 weeks, particularly involving physical domains. By 6 months,
quality-of-life scores are much improved for all, although physical scores in the ECLS group remain
impaired.
The PedsQL amber and red numbers
Table 22 shows the number of children with either amber or red PedsQL scores and demonstrates that the
children in the impact study cohort across both no morbidity and morbidity groups are more likely than healthy
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TABLE 20 PedsQL score outcomes by presence of any morbidity vs. no morbidity at 6 weeks and 6 months
Score type
PedsQL score, mean (SD)
6 weeks 6 months
No morbidity
(N= 242)
Any morbidity
(N= 236)
Adjusteda difference
in means (95% CI) p-value
No morbidity
(N= 208)
Any morbidity
(N= 195)
Adjusteda difference
in means (95% CI) p-value
Physical score 79.0 (16.2) 69.1 (21.8) –8.3 (–11.8 to –4.9) < 0.001 82.3 (16.6) 76.6 (18.6) –4.2 (–7.6 to –0.8) 0.02
Psychosocial score 79.4 (14.7) 75.2 (19.0) –2.7 (–5.9 to 0.5) 0.04 78.0 (14.7) 76.4 (15.4) –0.9 (–3.5 to 1.8) 0.5
Total score 79.3 (13.8) 72.1 (19.1) –5.2 (–8.3 to –2.2) < 0.01 79.8 (13.9) 76.6 (15.0) –2.3 (–4.9 to 0.3) 0.08
a Model adjusted for all significant risk factors in incidence data (all models have been adjusted for the covariates age at index procedure, weight at index procedure, cardiac diagnosis
complexity category, bypass time category, presence of functionally univentricular heart, preoperative acquired comorbidity, preoperative congenital comorbidity, preoperative severity of
illness score, preoperative additional cardiac risk factors) and includes multiple imputation for missing values.
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TABLE 21 PedsQL outcome by the four-level morbidity groupings at 6 weeks and 6 months
Time point,
PedsQL score
No
morbidity
Single
morbidity
ECLS
morbidity
Multiple
morbidities
Difference:a
single vs.
none (95% CI),
p-value
Difference:a
ECLS vs. none
(95% CI),
p-value
Difference:a
multi vs. none
(95% CI),
p-value
6 weeks
Number 242 145 13 78
Physical score,
mean (SD)
79.0 (16.2) 72.4 (21.1) 50.4 (23.2) 66.1 (20.9) –5.8
(–9.6 to –2.0),
< 0.01
–20.9
(–31.9 to –9.9),
< 0.001
–11.9
(–16.6 to –7.2),
< 0.001
Psychosocial
score, mean
(SD)
79.4 (14.7) 76.8 (17.3) 65.6 (24.1) 73.5 (20.9) –1.4
(–5.1 to 2.2),
0.43
–4.9
(–15.0 to 5.2),
0.34
–4.9
(–9.3 to –0.4),
0.03
Total score,
mean (SD)
79.3 (13.8) 74.5 (18.3) 59.4 (22.0) 69.6 (19.3) –3.4
(–6.8 to 0.02),
0.05
–11.9
(–21.2 to –2.7),
0.01
–8.0
(–12.1 to –4.0),
< 0.001
6 months
Number 208 125 10 61
Physical score,
mean (SD)
82.3 (16.6) 79.2 (16.8) 68.4 (28.0) 72.6 (19.6) –2.3
(–6.0 to 1.5),
0.24
–12.0
(–25.3 to –1.3),
0.08
–7.3
(–12.1 to –2.5),
< 0.01
Psychosocial
score, mean
(SD)
78.0 (14.7) 76.9 (14.1) 78.9 (18.8) 74.9 (17.4) –0.3
(–3.1 to 2.6),
0.86
1.7
(–10.4 to 10.0),
0.97
–2.2
(–6.4 to 1.9),
0.29
Total score,
mean (SD)
79.8 (13.9) 78.1 (14.0) 74.6 (21.4) 74.0 (15.8) –1.1
(–3.9 to 1.7),
0.44
–5.2
(–15.7 to 5.4),
0.34
–4.4
(–8.2 to –0.5),
0.03
Multi, multimorbidities.
a Model adjusted for all significant risk factors in incidence data (all models have been adjusted for these covariates) and
includes multiple imputation for missing values.
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FIGURE 6 PedsQL total scores for each morbidity at 6 weeks and 6 months. Multi, multimorbidities.
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TABLE 22 PedsQL score outcomes by presence of any morbidity (or no morbidity) at 6 weeks and 6 months
Time point, PedsQL score
Amber Red
No morbidity Any morbidity Adjusteda OR (95% CI) p-value No morbidity Any morbidity Adjusteda OR (95% CI) p-value
6 weeks
Number 242 236 242 236
Physical score, mean (SD) 74 (30.6) 112 (47.1) 1.75 (1.18 to 2.59) < 0.01 45 (18.6) 92 (38.7) 2.20 (1.43 to 3.37) < 0.001
Psychosocial score, mean (SD) 62 (26.1) 79 (34.1) 1.21 (0.79 to 1.85) 0.38 19 (8.0) 38 (16.4) 1.59 (0.88 to 2.88) 0.12
Total score, mean (SD) 72 (29.8) 95 (40.3) 1.33 (0.89 to 2.01) 0.17 27 (11.2) 69 (29.2) 2.47 (1.49 to 4.09) < 0.01
6 months
Number 208 196 242 236
Physical score, mean (SD) 49 (23.4) 70 (35.5) 1.57 (1.02 to 2.43) 0.04 30 (14.4) 43 (21.8) 1.41 (0.83 to 2.41) 0.20
Psychosocial score, mean (SD) 58 (27.9) 56 (28.6) 1.08 (0.71 to 1.66) 0.71 17 (8.2) 24 (12.2) 1.34 (0.73 to 2.45) 0.35
Total score, mean (SD) 55 (26.4) 65 (33.2) 1.33 (0.87 to 2.00) 0.17 22 (10.6) 32 (16.3) 1.46 (0.86 to 2.45) 0.16
a Model adjusted for all significant risk factors in incidence data (all models have been adjusted for these covariates) and includes multiple imputation for missing values.
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children to have low or very low PedsQL scores at 6 weeks or 6 months after surgery. Within a normal
population, we would expect 16% of children to score amber and 2.5% of children to score red, and, as
we can see across both groups, the proportions of children for all morbidity groups at both time points are
much higher than this.175–177 The patterns for those children with a morbidity compared with those with no
morbidity appear similar to the patterns shown in the continuous data comparisons shown in Tables 20
and 21. In Table 22, for example, we see that a child with ‘any morbidity’ has an increased chance of having
a very low total PedsQL score at 6 weeks compared with a child without a morbidity (adjusted OR 2.47,
95% CI 1.49 to 4.09). Looking more closely, we see the physical functioning is more affected (adjusted OR
2.20, 95% 1.43 to 3.37), whereas psychosocial is affected less (adjusted OR 1.59, 95% CI 0.88 to 2.88).
At 6 months, although the children with morbidities are more likely to have lower scores, it is not
statistically significant.
We include a table of PedsQL scores by each morbidity at the two time points in Appendix 10 (see Table 38),
PHQ-4 scores for the four-morbidities category at the two time points in Appendix 11 (see Table 39), PedsQL
normal scores in Appendix 9 (see Table 37) and PedsQL domain scores at the two time points in Appendices 9
and 12 (see Table 37 and Figure 23).
The PHQ-4 outcome
The PHQ-4 results in Tables 23 and 24 are presented based on the collapsed score based on two levels of
either anxiety or depression. Table 23 shows that presence of any morbidity increased the level of anxiety
and depression at 6 weeks, and there is still an effect at 6 months, but it is smaller and not statistically
significant.
The analysis of PHQ-4 results based on the four-level morbidity grouping (Table 24) enables us to see that
the impact in terms of anxiety and depression is more profound for parents of children with ECLS and
multiple morbidities, as compared with other single morbidities. Although this has improved by 6 months,
there is still some suggestion that scores remain higher, especially for depression.
TABLE 23 PHQ-4 items anxiety and depression outcomes by any morbidity at 6 weeks and 6 months
Group
No anxiety,
n (%)
Anxiety,
n (%)
ORa (95% CI),
p-value
No depression,
n (%)
Depression,
n (%)
ORa (95% CI),
p-value
6 weeks
Number 335 147 400 81
No morbidity 177 (76.3) 55 (23.7) 206 (88.8) 26 (11.2)
Any morbidity 158 (63.2) 92 (36.8) 1.82 (1.17 to 2.81),
< 0.01
194 (77.9) 55 (22.1) 2.07 (1.22 to 3.52),
< 0.01
6 months
Number 338 57 356 38
No morbidity 23 (11.5) 23 (11.5) 185 (92.5) 15 (7.5)
Any morbidity 34 (17.4) 34 (17.4) 1.55 (0.83 to 2.88),
0.17
171 (88.1) 23 (11.9) 1.57 (0.75 to 3.29),
0.23
a Model adjusted for all significant risk factors in incidence data (all models have been adjusted for these covariates) and
does not include multiple imputation for missing values.
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Days at home by 6 months
One of the advantages of this outcome measure was that we were able to include 662 patients in the
analysis and only four were dropped because of missing data that were related to hospital stays. This measure
(defined inMethods) included the 39 deceased patients, the majority of whom died within their primary
hospitalisation and scored zero for the measure.
Based on the analysis using quantile regression to predict the median days at home over 6 months, adjusting
for all of the stated covariates and accounting for clustering within matched pairs we found that presence of
any morbidity reduced the median days at home by 13 days (95% CI 10.2 to 15.8 days; p < 0.001). Considering
the four-category outcome, a single morbidity compared with no morbidity reduced days at home by 7.2 days
(95% CI 5.1 to 9.3 days; p < 0.001), ECLS had a very significant impact in comparison to no morbidity, with a
median reduction in days at home of 114.7 days (95% CI 76.4 to 153.1 days; p < 0.001), and there was
a moderate reduction for multiple morbidity compared with single morbidity of 21.9 days (95% CI 15.6 to
28.1 days; p < 0.001).
The relationship between the presence of each of the individual morbidities and the outcome of days at home
by 6 months is shown in Table 25, in which we see that most morbidities, apart from renal support, had a
statistically significant impact. The distribution of the days at home by each morbidity is shown in Figure 7.
TABLE 24 PHQ-4 items anxiety and depression outcomes by four-level morbidity outcome at 6 weeks and 6 months
Group
No anxiety,
n (%)
Anxiety,
n (%)
Adjusteda OR
(95% CI), p-value
No depression,
n (%)
Depression,
n (%)
Adjusteda OR
(95% CI), p-value
6 weeks
Number 35 147 400 81
No morbidity 177 (76.3) 55 (23.7) 206 (88.8) 26 (11.2)
Single
morbidity
100 (66.2) 51 (33.8) 1.57
(0.96 to 2.57),
0.08
123 (82.0) 27 (18.0) 1.67
(0.92 to 3.01),
0.09
ECLS
morbidity
7 (43.8) 9 (56.3) 3.82
(0.98 to 14.97),
0.05
10 (62.5) 6 (37.5) 3.85
(1.00 to 14.86),
0.05
Multimorbidity 51 (61.5) 32 (38.6) 2.22
(1.24 to 3.96),
< 0.01
61 (73.5) 22 (26.5) 2.72
(1.34 to 5.49),
< 0.01
6 months
Number 338 57 356 38
No morbidity 177 (88.5) 19 (15.5) 185 (92.5) 15 (7.5)
Single
morbidity
104 (84.6) 3 (27.3) 1.40
(0.70 to 2.81),
0.35
113 (92.6) 9 (7.4) 1.03
(0.44 to 2.37),
0.95
ECLS
morbidity
8 (72.7) 12 (19.7) 3.96
(0.69 to 22.60),
0.12
9 (81.8) 2 (18.2) 6.60
(0.84 to 51.59),
0.07
Multimorbidity 49 (80.3) 19 (15.5) 1.69
(0.73 to 3.91),
0.22
2 (18.2) 12 (19.7) 2.45
(0.94 to 6.41),
0.07
a Model adjusted for all significant risk factors in incidence data (all models have been adjusted for these covariates) and
does not include multiple imputation for missing values.
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TABLE 25 Days at home by 6 months analysis for individual morbidities
Parameter
Morbidity group
None
(n= 323)
ANE
(n= 6)
URO
(n= 26)
Feed
(n= 45)
Renal
(n= 24)
MAE
(n= 22)
ECLS
(n= 27)
NEC
(n= 10)
SSI
(n= 11)
PPE
(n= 50)
Multi
(n= 118)
Days at home,
median (range)
174
(0–180)
166
(132–175)
156
(0–174)
165
(57–177)
170
(51–175)
169
(0–176)
43
(0–169)
159
(46–169)
162
(138–175)
162
(101–176)
147
(0–177)
Adjusteda median
reduction in days
relative to no
morbidity group
(95% CI), p-value
Reference 9.7
(1.0–18.4),
0.03
13.4
(2.4–24.5),
0.02
6.4
(2.8–9.9),
< 0.01
2.5
(–1.0–6.0),
0.16
7.2
(2.1–12.3),
< 0.01
114.7
(76.4–153.1),
< 0.001
10.7
(0.1–21.3),
0.05
13.8
(6.3–21.3),
< 0.01
7.0
(2.8–11.1),
< 0.01
21.8
(15.6–28.1),
< 0.001
Multi, multimorbidities.
a Model adjusted for all significant risk factors in incidence data (all models have been adjusted for these covariates) and does not include multiple imputation for missing values.
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Limitations
We were not able to recruit from one of the sites for the whole duration of the impact study because
of local logistic problems at that site; however, we did include at least 6 months of data. We regrettably
were not able to include families for whom there was nobody in the home able to speak English to at
least a reasonable standard because of the availability of validated study measures in different languages.
We report missing data for PedsQL and PHQ-4; however, the rates of missing data were not high and
there was no evidence that the missing patients differed to the patients who responded. As for the
incidence study, our analysis and conclusions in respect of the rare single morbidities that affected a very
small number of patients at each site is limited.
Summary
These data provide unique insights into the outcomes of children undergoing heart surgery that take us
beyond the current gold-standard measure of 30-day mortality. The strengths of these data are that they
were collected prospectively from a representative multicentre population and contain a large contemporary
sample of children undergoing heart surgery. Although some of the numbers of children in individual
morbidity groups were small, this represents real-world data and it takes us forward in the understanding of
which morbidities are most important in terms of both prevalence and impact over 6 months. The case mix
variables indicate that the data set captures a range of conditions and certainly represents patients at the
more complex end of the spectrum, for example neonatal surgery, single ventricle disease and comorbidities.
Although, unsurprisingly, there are some missing data, the material is in general of a relatively high standard
of capture and completeness, with only four (0.6%) patients not included in the outcome of ‘days at home
at 6 months’ and among surviving patients for the quality-of-life outcome we had 26% missing at 6 weeks
and 36% missing at 6 months. Given that the missing patients had similar clinical features to those followed
up, we were able to use multiple imputation in the analysis.
Our results emphasise the importance of the selected morbidities as potential future quality metrics, especially
the more severe morbidities of ECLS and multiple morbidity. Furthermore, the days at home by 6 months
outcome suggested that all of the morbidities apart from Renal had an important impact, thus suggesting
that their future value as quality metrics should be taken forwards.
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FIGURE 7 Days at home by 6 months, by individual morbidities. Multi, multimorbidities.
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We suggest that both the morbidities and the outcome measures we have used for the impact study,
in particular days at home at 6 months, may be of future use as part of an ‘outcome set’ for future
researchers planning interventional studies for paediatric cardiac patients.
For stakeholders considering the best way to help prepare and support the parents of children undergoing
cardiac surgery, our findings have future potential uses in preparation of information to use during consent
and also in designing therapeutic interventions to promote psychological well-being and recovery.
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Chapter 9 The impact study: association between
morbidities following paediatric cardiac surgery with
costs and health-related quality of life
Parts of this chapter are reproduced with permission from Hudson et al.183 This is an Open Access articledistributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: https://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Introduction and aims
Although some studies have investigated the costs associated with paediatric cardiac surgery, they tend
to focus on between-centre variations rather than impacts of specific morbidities and are predominantly
based in the USA.184–186 The impact of specific morbidities following paediatric cardiac surgery on costs
and health-related quality of life are unclear and have not been reported in the literature. However, these
impacts are likely to be substantial for some morbidities and patients. For example, mechanical circulatory
support, which is sometimes required for children with complex needs after cardiac surgery, can incur costs
of > £10,000 per day.11,12 The aim of the economic analysis presented in this chapter was to determine
the impact of specific perioperative surgical morbidities on health-care utilisation, costs and health-related
quality of life over the 6-month period following cardiac surgery in the UK paediatric population.
Methods
Patients
The sample for this analysis comprised the 666 patients recruited into the impact study described in Chapter 8.
Resource use and costs
Cost components
Our analysis was designed to take the NHS and societal perspectives to measuring costs over 6 months
following surgery. The 6-month time horizon started on the day of the index surgery procedure. The NHS
costs included the following components: ICU stay during the index hospitalisation for the surgical procedure;
additional ICU stays during the 6 months’ follow-up; ward stays during the index hospitalisation for the
surgical procedure; additional ward stays during the 6 months’ follow-up; surgical procedures during the index
hospitalisation; additional surgical procedures during the 6 months’ follow-up; outpatient visits during the
6 months’ follow-up; prescriptions during the 6 months’ follow-up; and primary care contacts during the
6 months’ follow-up (GP visits at the general practice, practice nurse at the general practice, GP home visits,
practice nurse home visits, telephone calls with GP, telephone calls with the practice nurse).
In addition to the above NHS costs, societal costs included the following costs borne by families: mode and
cost of travel to the hospital, car parking at the hospital, food at the hospital, overnight stays, child care
for siblings, respite care, domestic help, adaptations to the home, medical equipment, private medical fees,
counselling, physiotherapy, and days off work.
The NHS costs refer to all NHS contacts incurred by the child as a result of their surgery and subsequent
morbidities. Family costs refer to all additional personal expenses and opportunity costs incurred by the
family as a result of the child’s surgery and subsequent morbidities.
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Measuring resource use
Data on all ICU stays were extracted from PICANet data prepared by each study site.158 For each day the
patient was in the ICU during the study period, data were recorded on the level of care the patient received
(intensive care ECMO/ECLS, intensive care advanced enhanced, intensive care advanced, intensive care basic
enhanced, intensive care basic, high dependency advanced, high dependency, enhanced care). Data on the
number and length in days of ward stays at study sites and the type and duration (in minutes) of surgical
procedures were recorded for every patient by hospital audit staff. Hospital stays at study sites were validated
against NCHDA data held within each study site.24 All other cost components were collected from patients
and families at 6 weeks, 3 months and 6 months after the date of the index procedure, by research nurses
at study sites via face-to-face or telephone interviews. Hospital stays that exceeded the date of the end of
the 6-month follow-up period were censored at that date.
Unit costs
Unit costs were obtained from published sources and study sites and inflated to 2016/17 UK pounds sterling,
when necessary187–189 (see Appendix 13 for unit cost values used in the analysis). The unit costs of ICU stays
were daily costs for each level of care applied to the number of days spent receiving that level of care. Unit
costs per day for ward stays varied according to the age of the patient (< 2 years, ≥ 2 years). Unit costs for
surgical procedures were costs per minute supplied by study sites; these varied by site and so we used the
value for the site that recruited the largest number of patients to this study; this was similar to the mean
value across all sites. The costs per minute were applied to duration data for every procedure. Unit costs for
outpatient visits were based on national average costs per attendance for paediatrics outpatient visits. Unit
cost for prescriptions were based on prescription costs per consultation. Unit costs for GP visits at the general
practice were based on a surgery consultation lasting 9.22 minutes, with qualification costs including direct
care staff costs. Unit costs for a practice nurse visit at the general practice were based on the average cost per
minute of nurse time at a general practice, including qualifications, assuming a consultation lasting 20 minutes.
Unit costs for GP home visits and practice nurse home visits were assumed to cost three times the amount of
the visit at the practice, to account for travel costs. Unit costs for telephone calls with the GP and nurse were
based on the mean intervention costs per (including training) for GP-led and nurse-led telephone triage.
Given the time horizon, discounting was not applied.
Health-related quality of life and quality-adjusted life-years
Utility scores
Generic health-related quality of life was described using the Health Utilities Index Mark 2 (HUI2)178,186
descriptive system, measured at 6 weeks, 3 months and 6 months after the date of the index procedure
by research nurses. The HUI2 is a preference-based multiattribute health-related quality-of-life instrument
that was specifically developed for use with children. It consists of seven dimensions (sensation, mobility,
emotion, cognition, self-care, pain and fertility), each of which has between three and five levels, ranging
from ‘normal functioning for age’ to ‘extreme disability’. The use of the fertility dimension is discretionary and
was not used in the present study. The questionnaire was completed by parent proxy for children in the study.
The HUI2 health states were converted into utility values using a formula that attaches weights to each level
in each dimension, based on valuations by a UK general population sample.179 Utility values of 1 represent
full health, values of zero are equivalent to death and negative values represent states worse than death.
Patients who died were assigned a score of zero for all HUI2 scores at all subsequent follow-up points.
At baseline, all patients recruited to the study were critically ill and so completion of the HUI2 questionnaire
was not possible. Therefore, baseline utility was assumed to be zero for all patients; this approach has been
used in other studies in which baseline utility measurement is not possible.190,191
Calculating quality-adjusted life-years
A utility profile was constructed for every patient assuming a straight line relation between their utility
values at each measurement point. Quality-adjusted life-years (QALYs) for every patient from baseline to
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6 months were calculated as the area under the utility profile. The implications of our assumptions were
as follows. For patients who were alive at 6 months, QALYs were calculated using the utility scores at
6 weeks, 3 months and 6 months, assuming a utility score of zero at baseline and a linear interpolation
between the utility score at each point. For patients who died between baseline and 6 weeks, we assumed
that they accrued zero QALYs. For patients who died between 6 weeks and 3 months, we used a linear
interpolation between utility scores at baseline (zero value) and 6 weeks, and between 6 weeks and 3 months
(zero value). For patients who died between 3 months and 6 months, linear interpolations were applied
between baseline (zero value) and 6 weeks, 6 weeks and 3 months, and 3 months and 6 months (zero value).
The maximum QALYs achievable in the study were 0.442. We assigned all of the HUI2 data that were
collected to the 6 weeks, 3 months or 6 months measurement points, irrespective of the precise time
when they were actually measured.
Covariates and morbidities
The patient demographics and case mix (covariates), and the morbidities within the impact study cohort,
are described in full in Chapter 5.
The morbidity variable consisted of 11 categories: (1) no morbidities (the control group); (2) multiple
morbidities, or single occurrence of one of nine predefined morbidity categories (see Chapter 5);
(3) ANE; (4) URO; (5) Feed; (6) Renal; (7) MAE; (8) treatment with ECLS; (9) NEC; (10) SSI; and (11) PPE.
Each of the economic outcome measures was regressed against a limited set of the covariates (not including
the morbidity variable). This limited set was selected using a single outcome measure (total cost of hospital
stays; outcome measure 23 in Table 26) using forward and backward stepwise selection techniques, in which
only statistically significant variables (p < 0.05) were retained after each iteration.
TABLE 26 Health economic outcome measures
Number Outcome measure Description
1 Days in ICU during index hospitalisation
2 Additional days in ICU during 6 months’ follow-up
3 Total ICU days during 6 months’ follow-up Derived: measure 1+measure 2
4 Days on ward during index hospitalisation
5 Additional days on ward ICU during 6 months’ follow-up
6 Total ward days during 6 months’ follow-up Derived: measure 4+measure 6
7 Hospital days during index hospitalisation Derived: measure 1+measure 4
8 Hospital days during 6 months’ follow-up Derived: measure 2+measure 5
9 Total hospital days Derived: measure 7+measure 8
10 Cost of days in ICU during index hospitalisation Derived: cost associated with measure 1
11 Cost of additional days in ICU during 6 months’ follow-up Derived: cost associated with measure 2
12 Cost of total ICU days during 6 months’ follow-up Derived: cost associated with measure 3
13 Cost of days on ward during index hospitalisation Derived: cost associated with measure 4
14 Cost of additional days on ward during 6 months’ follow-up Derived: cost associated with measure 5
15 Cost of total ward days during 6 months’ follow-up Derived: cost associated with measure 6
16 Cost of hospital days during index hospitalisation Derived: cost associated with measure 7
17 Cost of hospital days during 6 months’ follow-up Derived: cost associated with measure 8
continued
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The final limited set of covariates was age; weight-by-age z score; congenital morbidity; severity of illness
indicator or Down’s syndrome; underlying cardiac diagnosis category; cardiac procedure category; whether
or not the patient died within 6 months; and study site. For some outcome measures, a smaller group of
covariates was used in order for the regression model to run.
Statistical analysis
Outcome measures
The primary outcome measures for the economic analysis were:
l days in ICU during index hospitalisation (outcome measure 1)
l cost of days in ICU during index hospitalisation (outcome measure 10)
l total hospital days (outcome measure 9)
l total cost of hospitalisation during 6 months’ follow-up (outcome measure 22)
l QALYs at 6 months (all patients) (outcome measure 37)
l QALYs at 6 months (survivors only) (outcome measure 41).
TABLE 26 Health economic outcome measures (continued )
Number Outcome measure Description
18 Cost of total hospital days Derived: cost associated with measure 9
19 Cost of surgical procedures during index hospitalisation
20 Cost of surgical procedures during 6 months’ follow-up
21 Total cost of index hospitalisation Derived: measure 16 +measure 19
22 Total cost of additional hospitalisation during 6 months’ follow-up Derived: measure 17 +measure 20
23 Total costs of hospital stays Derived: measure 21+measure 22
24 Number of outpatient visits during 6 months’ follow-up
25 Cost of outpatient visits during 6 months’ follow-up Derived: cost associated with measure 24
26 Total hospital costs Derived: measure 23 +measure 25
27 Number of prescriptions during 6 months’ follow-up
28 Cost of prescriptions during 6 months’ follow-up Derived: cost associated with measure 27
29 Cost of primary care contacts during 6 months’ follow-up
30 Total NHS cost Derived: measure 26 +measure 28+
measure 29
31 Family costs incurred during 6 months’ follow-up
32 Total societal cost Derived: measure 30 +measure 31
33 Days off work during 6 months’ follow-up
34 Utility score at 6 weeks (all patients)
35 Utility score at 3 months (all patients)
36 Utility score at 6 months (all patients)
37 QALYs at 6 months (all patients) Derived: from measures 34–36
38 Utility score at 6 weeks (survivors only)
39 Utility score at 3 months (survivors only)
40 Utility score at 6 months (survivors only)
41 QALYs at 6 months (survivors only) Derived: from measures 38–40
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These cost measures were selected because they are likely to account for a high proportion of the total costs,
and are based on hospital and audit data rather than patient and family reports. The QALY measures were
selected because they are a summary measure of utilities at each follow-up point. In order to derive the
primary outcome measures we analysed 41 individual component outcome measures, described in Table 26.
Regression models
We regressed each of our outcome measures against the morbidity variable and the covariates. Our outcome
measures were not normally distributed (see Figures 8 and 9), and to account for this, where possible, we
used a generalised linear model (GLM) with gamma family and log link, which has been recommended for
analysing skewed cost data.192 We also considered using log normal, Gaussian, inverse Gaussian and
negative binomial distributions, but the gamma model gave the best fit in terms of residual plots and the
Akaike information criterion. For some outcome measures it was not possible to use this type of regression
model, in which case we used ordinary least squares (OLS). We considered coefficients with p-values of
< 0.05 to be statistically significantly different from zero. All data were analysed using Stata.
Dealing with missing data
The extent of missing data for some of the outcome measures included in the analysis was large (see Table 27).
Multiple imputation was used to impute missing data for each of the non-derived outcome measures in
Table 26. Given the large number of variables, we ran the imputation separately for the resource use and
cost measures and then for the utility measures. The full set of covariates described above were included
in the imputations as additional explanatory variables (these were variables in our dataset with no missing
values). We used an iterative Markov chain Monte Carlo procedure based on multivariate normal regression,
generating 20 imputed data sets. We ran the regression models described above on each of the imputed
data sets and computed aggregate coefficients and standard errors using combination rules.171
Computing marginal effects
In every regression model ‘no morbidities’ was the omitted category and we present the results in terms of
marginal effects, that is the mean difference in the outcome measure (e.g. mean difference in hospital days,
costs and QALYs) between each morbidity category and the ‘no morbidities’ omitted category conditional
on the covariates.
In the GLM the exponentiated coefficients on the morbidity categories are interpreted as the multiplier on
the expected value of the outcome measure when that morbidity is present is compared with when it is
not.193 Therefore, to compute the marginal effects for each morbidity category we (1) exponentiated the
coefficient on that morbidity category; (2) multiplied this value by the mean value of the outcome measure
for the ‘no morbidities’ omitted category; and (3) subtracted the mean value of the outcome measure in
the ‘no morbidities’ omitted category from this product.
When we were required to run OLS models the coefficients had a more straightforward interpretation,
directly as marginal effects.
Results
Descriptive statistics
The demographics and case mix characteristics of the impact study cohort, as well as the morbidities
among the impact study cohort, are described in full in Chapter 8.
Summary statistics for the outcome measures are in Table 27. Descriptive data on the outcome measures
used in economic modelling are shown in full in Appendix 14. In terms of our primary outcome measures,
data on days in ICU during index hospitalisation (outcome measure 1 in Table 26) and cost of days in ICU
during index hospitalisation (outcome measure 10) were available for 645 patients (97% of the sample),
and the mean (SD) and median (IQR) values were 9.7 (SD 15.7) days and 5 (IQR 3–9) days and £20,058
DOI: 10.3310/hsdr08300 HEALTH SERVICES AND DELIVERY RESEARCH 2020 VOL. 8 NO. 30
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
93
TABLE 27 Descriptive statistics on health economic outcome measures
Outcome measure Mean SD Median
25th
percentile
75th
percentile Observations Missing (%)
Days in ICU during index
hospitalisationa
9.7 15.7 5 3 9 645 3
Additional days in ICU
during 6 months’ follow-up
1.2 7.1 0 0 0 666 0
Total ICU days during
6 months’ follow-up
10.7 17.7 5 3 10 645 3
Days on ward during index
hospitalisation
12.0 18.3 7 4 13 647 3
Additional days on ward ICU
during 6 months’ follow-up
1.1 5.4 0 0 0 666 0
Total ward days during
6 months’ follow-up
13.1 19.3 7 4 14 647 3
Hospital days during index
hospitalisation
21.7 26.8 13 8 22 645 3
Hospital days during
6 months’ follow-up
2.2 9.7 0 0 0 666 0
Total hospital daysa 23.8 29.5 13 8 25 645 3
Cost (£) of surgical
procedures for index
hospitalisation
4892 3368 4245 3187 5744 633 5
Cost (£) of surgical
procedures for 6 months’
follow-up
464 1705 0 0 0 666 0
Cost (£) of surgical
procedures for total
hospitalisation
5374 3858 4459 3281 6360 633 5
Cost (£) of days in ICU
during index hospitalisationa
20,058 33,767 9800 5475 18,656 645 3
Cost (£) of additional days in
ICU during 6 months’
follow-up
2064 13,257 0 0 0 666 0
Cost (£) of total ICU days
during 6 months’ follow-up
21,983 36,824 10,052 5475 20,025 645 3
Cost (£) of days on ward
during index hospitalisation
10,375 16,269 5424 3616 10,848 647 3
Cost (£) of additional days
on ward during 6 months’
follow-up
930 4743 0 0 0 666 0
Cost (£) of total ward days
during 6 months’ follow-up
11,333 17,184 5424 3616 11,752 647 3
Total cost (£) of hospital
staysa
33,277 44,080 17,250 10,613 33,313 645 3
Number of outpatient visits
during 6 months’ follow-up
4.6 11.6 1 0 5 581 13
Cost (£) of outpatient visits
during 6 months’ follow-up
916 2318 199 0 995 581 13
Total hospital costs (£) 39,916 47,437 23,028 15,117 40,439 538 19
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(SD £33,257) and £9800 (IQR £5475–18,656), respectively. Total hospital days (outcome measure 9)
were available for 645 patients (97%), with mean (SD) and median (IQR) values of 23.8 (SD 29.5) days
and 13 (IQR 8–22) days. Total cost of hospital stays during 6 months’ follow-up (outcome measure 23)
was available for 593 patients (89%), with mean (SD) and median (IQR) values of £39,916 (SD £47,437)
and £23,028 (IQR £15,117–40,439). The distribution of both these cost variables was positively
skewed (Figure 8).
Comparing mean and median values between the outcome measures in Table 27, the variables that
contributed most to the total societal cost are hospital costs, more specifically the cost of days in the ICU
and days on the ward during the index hospitalisation.
Costs are in 2016/17 UK pounds sterling. The ‘Missing’ column (see Table 27) shows the amount of
missing data for each variable included in the analysis across the 666 patients in the sample (627 in the
data for survivors only). Values may not sum across variables due to different numbers of observations.
TABLE 27 Descriptive statistics on health economic outcome measures (continued )
Outcome measure Mean SD Median
25th
percentile
75th
percentile Observations Missing (%)
Number of prescriptions
during 6 months’ follow-up
9.2 5.3 8 5 11 69 90
Cost (£) of prescriptions
during 6 months’ follow-up
257 148 224 140 308 69 90
Cost (£) of primary care
contacts during 6 months’
follow-up
448 734 248 101 623 283 58
Total NHS cost (£) 35,896 28,493 25,293 18,048 43,875 57 91
Family costs (£) incurred
during 6 months’ follow-up
826 2875 255 60 665 153 77
Total societal cost (£) 37,287 31,930 25,323 19,068 44,695 57 91
Days off work during
6 months’ follow-up
31.66 41.61 20 2 42 157 76
Utility score at 6 weeks
(all patients)
0.809 0.274 0.894 0.745 1 398 40
Utility score at 3 months
(all patients)
0.816 0.293 0.948 0.778 1 359 46
Utility score at 6 months
(all patients)
0.761 0.346 0.906 0.720 1 249 63
QALYs at 6 months
(all patients)a
0.327 0.152 0.399 0.310 0.430 194 71
Utility score at 6 weeks
(survivors only)
0.874 0.160 0.906 0.784 1 359 43
Utility score at 3 months
(survivors only)
0.901 0.139 0.949 0.846 1 320 49
Utility score at 6 months
(survivors only)
0.898 0.133 0.949 0.831 1 210 67
QALYs at 6 months
(survivors only)a
0.397 0.051 0.410 0.370 0.436 155 75
a Primary outcome measure for this analysis.
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Note that several of the non-derived resource use/cost measures (number of prescriptions during 6 months’
follow-up, cost of primary care contacts during 6 months’ follow-up, family costs incurred during 6 months’
follow-up, days off work during 6 months’ follow-up) had in excess of 50% missing data, sometimes in
excess of 90%. In addition, based on the [mean (median)] values of the cost per patient of prescriptions
during 6 months’ follow-up [£257 (£224)], primary care contacts during 6 months’ follow-up [£448 (£248)]
and family costs incurred during 6 months’ follow-up [£826 (£255)], each of these cost components is likely
to make a small contribution to the overall societal costs of morbidities {e.g. balanced against a total cost
of hospital stays [£39,916 (£23,028)]}. Given the high degree of missingness for these variables, plus the
small contribution that they make to total societal costs, we elected not to analyse them further in
regression analyses.
Mean and median QALYs at 6 months (all patients) were 0.327 (SD 0.152) and 0.399 (IQR 0.310–0.430),
respectively, in the 194 patients for whom these data were available (29%). The distribution was bimodal,
with values clustered around 0 and the maximum achievable value (0.442; Figure 9). For survivors only,
mean and median QALYs at 6 months were 0.397 (SD 0.051) and 0.410 (IQR 0.370–0.436), respectively.
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FIGURE 8 Distribution of total cost of hospitalisation during 6 months’ follow-up.
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FIGURE 9 Distribution of QALYs at 6 months (all patients).
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The imputed variables of the outcome measures had broadly similar descriptive statistics to the original
versions with missing data (see Appendix 15).
Regression results
Regression results for our primary outcome measures are shown in Tables 28–30. Regression results for the
full list of economic outcomes are reported in Appendix 16. Each table presents the association with the
morbidity variables for each outcome measure. Controlling for the covariates, on average, URO, Feed and
ECLS each resulted in significantly more ICU days during the index stay (on average 3, 4 and 23 more
days, respectively). These findings also translated into higher ICU costs during the index admission (which
were a function of both the number of days in ICU and the level of care at each of those days) and those
with multimorbidities incurred around £24,071 higher ICU costs. Total ICU days and costs for the 6-month
follow-up period were higher for ECLS patients (25 days and £54,155) than for patients with multimorbidities
(15 days and £26,389).
TABLE 28 Associated between morbidities and days on ICU and cost of days on ICU during index hospitalisation
Morbidity measure Coefficient p-value 95% CI Marginal effect p-value< 0.05?
Days in ICU during index hospitalisation (666 observations)
ANE 0.808 0.08 0.088 to 1.705 6.2
URO 0.525 0.01 0.141 to 0.909 3.4 Yes
Feed 0.535 < 0.001 0.231 to 0.839 3.5 Yes
Renal 0.408 0.05 0.010 to 0.806 2.5 Yes
MAE 0.305 0.15 –0.111 to 0.722 1.8
ECLS 1.716 < 0.001 1.331 to 2.102 22.7 Yes
NEC 0.618 0.05 –0.002 to 1.237 4.3 Yes
SSI 0.211 0.47 –0.366 to 0.787 1.2
PPE 0.114 0.45 –0.180 to 0.408 0.6
Multi 1.283 < 0.001 1.063 to 1.504 13.0 Yes
Cost of days in ICU during index hospitalisation (666 observations)
ANE 0.642 0.19 –0.325 to 1.609 £8620
URO 0.597 < 0.001 0.223 to 0.971 £7824 Yes
Feed 0.457 < 0.001 0.162 to 0.753 £5553 Yes
Renal 0.528 0.01 0.139 to 0.916 £6653 Yes
MAE 0.407 0.05 0.006 to 0.808 £4813 Yes
ECLS 1.943 < 0.001 1.569 to 2.317 £57,256 Yes
NEC 0.428 0.18 –0.202 to 1.058 £5115
SSI 0.239 0.40 –0.318 to 0.796 £2586
PPE 0.259 0.08 –0.029 to 0.548 £2837
Multi 1.257 < 0.001 1.041 to 1.472 £24,071 Yes
Notes
In every case the regression model was GLM with gamma family and log link. The marginal effects are the change in days
and costs vs. the omitted category (no morbidities). Data include values imputed using multiple imputation. Costs are in
2016/17 UK £. Controls were also included in every model for covariates as listed in Methods.
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Patients with ECLS had the highest additional hospital days and costs (around 33 more days and £71,051
higher costs); other morbidities with significantly higher days or costs were URO, Feed, Renal, NEC and
PPE. Patients with multimorbidities also incurred significantly higher hospital days and hospitalisation costs
compared with patients with no morbidity (25 days and £41,484 higher, respectively).
Extracorporeal life support across all patients, and ECLS and multimorbidities for survivors only, were associated
with significantly lower QALYs over the 6-month period than patients with no morbidity (see Table 4). Across
all patients, the QALY decrement associated with ECLS was –0.095; among survivors only, it was –0.051.
Among survivors only, multimorbidity produced a QALY decrement of –0.028. None of the other single
morbidities was associated with a significant reduction in QALYs compared with patients with no morbidity
and conditional on the covariates. Utility scores are presented in full in Appendix 15.
TABLE 29 Association between morbidities and total hospital days and total cost of hospitalisation during
6 months’ follow-up
Morbidity group Coefficient p-value 95% CI Marginal effect p-value< 0.05?
Total hospital days (666 observations)
ANE 0.44 0.30 –0.395 to 1.267 7.6
URO 0.86 < 0.001 0.467 to 1.250 18.8 Yes
Feed 0.73 < 0.001 0.418 to 1.051 15.0 Yes
Renal 0.36 0.09 –0.057 to 0.786 6.1
MAE –0.02 0.94 –0.436 to 0.405 –0.2
ECLS 1.23 < 0.001 0.832 to 1.630 33.6 Yes
NEC 0.70 0.02 0.093 to 1.316 14.2 Yes
SSI 0.50 0.10 –0.087 to 1.083 8.9
PPE 0.48 < 0.001 0.180 to 0.785 8.6 Yes
Multi 1.03 < 0.001 0.806 to 1.244 24.8 Yes
Total cost of hospitalisation during 6 months follow-up (666 observations)
ANE 0.48 0.19 –0.239 to 1.203 £13,944
URO 0.68 < 0.001 0.355 to 1.013 £22,130 Yes
Feed 0.64 < 0.001 0.373 to 0.901 £20,067 Yes
Renal 0.40 0.026 0.049 to 0.749 £11,042 Yes
MAE 0.05 0.79 –0.308 to 0.405 £1120
ECLS 1.42 < 0.001 1.086 to 1.762 £71,051 Yes
NEC 0.54 0.041 0.021 to 1.056 £16,073 Yes
SSI 0.34 0.18 –0.157 to 0.839 £9152
PPE 0.22 0.091 –0.034 to 0.467 £5443
Multi 1.04 < 0.001 0.860 to 1.228 £41,484 Yes
Multi, multimorbidities.
Notes
In every case the regression model was GLM with gamma family and log link. The marginal effects are the change in days
and costs vs. the omitted category (no morbidities). Data include values imputed using multiple imputation. Costs are in
2016/17 UK £. Controls were also included in every model for covariates as listed in Methods.
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The trends shown with respect to our primary outcomes were borne out with the other outcomes included
in the regression analysis (see Appendix 16). We report the marginal effects for each morbidity and
whether or not the coefficient was significantly different from zero. Note that the marginal effects do not
necessarily sum across the resource use and cost measures because we used two different regression
models (GLM and OLS where necessary) and the GLM model is non-linear. For nearly every resource use
and cost outcome measure, multimorbidities were associated with significantly higher values than that for
patients with no morbidity. Individual morbidities that were commonly associated with higher resource use
and costs were URO, ECLS, PPE and Feed. Where it had a statistically significant effect, ECLS was generally
the morbidity category that had the highest resource use or cost impact, usually with a larger effect than
multimorbidities. ECLS and multimorbidities were associated with utility decrements at 6 weeks (ECLS) and
3 months (multimorbidities) compared with patients with no morbidity, reflecting their impact on QALYs
shown above.
TABLE 30 Association between morbidities and QALYs at 6 months (all patients and survivors only)
Morbidity group Coefficient p-value 95% CI Marginal effect p-value< 0.05?
QALYs up to 6 months (all patients) (666 observations)
ANE –0.117 0.57 –0.524 to 0.290 –0.045
URO –0.007 0.94 –0.206 to 0.191 –0.003
Feed –0.029 0.72 –0.188 to 0.130 –0.011
Renal –0.047 0.66 –0.257 to 0.164 –0.018
MAE –0.107 0.34 –0.324 to 0.111 –0.041
ECLS –0.271 0.02 –0.491 to –0.051 –0.095 Yes
NEC 0.480 < 0.001 0.160 to 0.799 0.248 Yes
SSI –0.100 0.51 –0.399 to 0.199 –0.038
PPE –0.004 0.96 –0.157 to 0.149 –0.002
Multi (excluding ECLS) –0.103 0.07 –0.211 to 0.006 –0.039
QALYs up to 6 months (survivors only) (627 observations)
ANE –0.037 0.60 –0.179 to 0.105 –0.015
URO –0.009 0.79 –0.072 to 0.055 –0.003
Feed –0.018 0.47 –0.069 to 0.032 –0.007
Renal –0.009 0.80 –0.077 to 0.059 –0.004
MAE 0.018 0.66 –0.061 to 0.096 0.007
ECLS –0.135 0.01 –0.238 to –0.032 –0.051 Yes
NEC –0.048 0.41 –0.164 to 0.067 –0.019
SSI –0.060 0.20 –0.151 to 0.031 –0.024
PPE –0.001 0.96 –0.048 to 0.046 –0.001
Multi –0.073 < 0.001 –0.110 to –0.036 –0.029 Yes
Multi, multimorbidities.
Notes
In every case the regression model was GLM with gamma family and log link. The marginal effects are the change in
QALYs vs. the omitted category (no morbidities). Data include values imputed using multiple imputation. Controls were also
included in every model for covariates as listed in Methods.
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Limitations
There was a high fraction of missing data for costs incurred outside the hospital (NHS and non-NHS costs),
meaning that we were unable to analyse these outcome measures fully; however, descriptive statistics
suggest that they are likely to represent a small proportion of total societal costs.
Summary
We evaluated the impact of perioperative surgical morbidities on health-care utilisation, costs and health-
related quality of life over the 6-month period following cardiac surgery in the UK paediatric population.
Single morbidity and multimorbidities were significantly associated with higher hospital resource use and
costs than that for patients with no surgical morbidities. ECLS and multimorbidities, in particular, had a
substantial impact. URO, Feed, Renal, NEC and PPE were also associated with significantly higher costs.
Only ECLS and multimorbidities were significantly associated with lower QALYs.
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Chapter 10 Exploring communication between
parents and clinical teams following children’s
heart surgery
Reproduced from Pagel et al.194 This is an Open Access article distributed in accordance with the termsof the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix,
adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions and formatting
changes to the original text.
Introduction
Parents of children who are treated in intensive care experience a great deal of stress.195–198 The quality
of communication between health-care professionals and parents is a key determinant of paediatric patient
experience.107 Many children with CHD undergo heart surgery as infants, with consequent stays on intensive
care that can be prolonged and complex.6 Consistent communication with caregivers199 and involvement in
decision-making198 have been recognised as important ways to reduce stress. In 2014, the Picker Institute,
funded by the UK Care Quality Commission, carried out the UK’s first national survey of the experiences of
children and young people’s stay in hospital, receiving > 18,000 responses.107 The Picker Survey included
several questions around communication and provides an important national baseline for understanding
better how parents of children undergoing surgery for CHD experience communication.
We report here on a prospective short communication survey of parents undertaken as part of the wider
study of impact of important early morbidities among paediatric cardiac surgery patients.200
Methods
Selection of the questions about communication
As part of the broader project, a panel of clinicians and parent representatives selected morbidities to
measure,90 which were then defined by a separate panel of professionals.98 The panels included a substudy
to measure communication between parents and the clinical team. The definition panel recommended
using a subset of questions from the Picker Survey,107 as those questions were developed using focus
groups and formally validated. The Picker Institute assisted us in identifying of a shortlist of six questions to
ask parents about communication, as described in Brown et al.,98 and issued the research team with a
licence to allow our study to use these questions for patients recruited to a 6-month follow-up substudy as
part of the larger project.
The final questions were:
l Question 1: did new members of staff treating your child introduce themselves?
l Question 2: were you encouraged to be involved in decisions about your child’s care and treatment?
l Question 3: were you told different things by different people, which left you feeling confused?
l Question 4: were the different members of staff caring for and treating your child aware of their
medical history?
l Question 5: before the operation or procedure, did a member of staff explain to you what would be
done during the operation or procedure?
l Question 6: did a member of staff tell you what to do or who to talk to if you were worried about your
child when you got home?
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Population and administering the survey
Our study prospectively monitored all children aged ≤ 16 years who had cardiac surgery within the five
participating hospitals between 1 October 2015 and 30 June 2017 for the presence of nine selected
important postoperative morbidities. Families of children with these morbidities and case-matched controls
without morbidity were then approached for consent to participate in a 6-month follow-up programme.
All families who consented to participate were given the communication questionnaire either at discharge
or shortly after discharge, along with a stamped addressed envelope. Parents were asked to complete and
return it in a de-identified format within 6 weeks of their child’s operation. For staff resource reasons, only
four of the sites participated in the communication survey.
Parents were assured that neither the clinical team caring for their child nor the research team would be
able to see their responses. All responses were entered by a separate data entry clerk who only had access
to the child’s anonymised study identification. Access to the communication survey data entry screen was
password protected to prevent clinician or research team access.
Statistical analysis
For each question we transformed responses into binary responses, for which yes was defined as the
‘always positive’ response (Figure 10).
The proportion of positive responses for each question was compared with the corresponding overall
proportion reported in the Picker Survey.107 We performed two-sided binomial tests for difference at the
5% level for all control patients (no morbidity) and separately for case patients (with at least one morbidity)
to the national Picker Survey proportion. To adjust for multiple hypothesis testing, we applied a Bonferroni
correction201 and required p < 0.05/12 = 0.004 for significance at the 5% level.
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FIGURE 10 Proportion of positive responses to each of the six questions for the national Picker Survey107 (black dots),
control patients (green dots) and case patients (blue dots) from our study. Exact 95% CIs are shown for the
proportions measured in our study. Q, question.
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We explored whether or not different factors affected the proportion of positive responses using multiple
logistic regression. The candidate explanatory variables were hospital site, case versus control, black or
minority ethnicity, log age at procedure, and log length of stay. We used the natural logarithm of length
of stay because the distributions were highly skewed (skew > 2, kurtosis > 12). Additionally, the impact of
age on outcome is highly non-linear.162
Data were analysed using Stata software.
Results
There were 585 children recruited to the follow-up study across the four hospitals. We received a total
of 385 responses (response rate 66%) from parents of these 585 children, of whom 51% had at least
one morbidity (cases) and 22% were non-white. The children of respondents were relatively evenly split
across sites (numbers for each site ranged from 82 to 115). The median age at procedure was 2.6 months
(IQR 10 days–11 months) and the median length of stay was 16 days (IQR 9–26 days).
Comparison with the national inpatient survey
The proportion of positive responses to each of the six questions from parents of patients in the study is
shown in Figure 10, along with the corresponding proportion from the national Picker Survey. There were
no significant differences in the proportion of positive responses compared with the Picker Survey for
questions 1, 5 and 6. Compared with the Picker Survey, parents of children with at least one morbidity
were less likely to say that involvement in decision-making was always encouraged (question 2, p < 0.001),
whereas parents of children with none of the measured morbidities were more likely to say that professionals
were aware of their child’s medical history (question 4, p = 0.002). All parents in our study were less likely to
say they were never told different things by different people (question 3, p < 0.001), with parents of case
patients reporting lower rates than parents of controls (31% vs. 44%, 68% nationally).
Multivariable analysis of explanatory factors on responses
None of the explanatory factors was associated with responses to questions 5 and 6. Hospital site affected
responses to questions 1–4, with site A having consistently higher proportions of positive responses than
the other sites. Parents of younger children were more likely to report positively that they were involved in
decision-making (p = 0.045) and on staff always being aware of their child’s medical history (p = 0.041).
However, parents of children who stayed longer in hospital were less likely to report that they were involved
in decision-making (p = 0.013) and less likely to say that they were ‘never told different things by different
people’ (p = 0.036). Parents of children who experienced at least one morbidity were less likely to say that
staff were aware of their child’s medical history (p = 0.019). Black or minority ethnicity status was not
significantly associated with responses to any of the questions.
We illustrate the differences in responses by each factor for questions 1–4 in Figure 11. Note that although
the regressions were run using continuous log age and log length of stay, we give results in illustrative
categories for easier interpretation. We only show proportions when there was a significant association
of that factor with responses for that question under a multivariate analysis.
None of the factors was associated with responses to questions 5 and 6. We only show proportions for
questions when there was a significant association between the factor and responses in a multivariate
analysis. Proportions are shown for categorical age and length of stay bands for ease of interpretation
but the analysis was carried out using continuous variables.
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FIGURE 11 Association of each of the explanatory factors with the first four questions. (a) Site; (b) illustrative age
bands; (c) illustrative length of stay bands; and (d) case vs. control. Q, question. Reproduced from Pagel et al.194 This is
an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the
original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. This figure includes minor additions
and formatting changes to the original. (continued )
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Summary and next steps
Our results are limited by the number of respondents, which were from only four of the five sites and
represented 66% of the participants in the impact study from those four sites. Clearly, the results are also
dependent on the questions asked.
Parents of children having heart surgery had positive responses that were consistent with national results
for three of the six questions: staff introducing themselves, explaining the operation, and letting parents
know what to do once home after discharge. However, these parents were about twice as likely to say
that they were told different things by different people and left feeling confused compared with the
national picture. This is likely because heart surgery is a particularly complex treatment involving a larger
than average clinical care team, but it represents an area for potential improvement.
Perhaps unsurprisingly, parents of neonates were more likely to report that professionals were always
aware of their child’s medical history, presumably because neonates are not old enough to have amassed
a complicated history. Although, on a univariate analysis, morbidity appears to make a large difference to
responses (see Figure 10), on multivariate analysis most of this association appears to be because children
with morbidities tend to stay longer in hospital. As children stay longer, there are more opportunities for
parents to be told different things by different people (question 3) and to feel less involved in decision-
making (question 2). Morbidity only made a difference to responses for staff being aware of a child’s
medical history; perhaps not surprisingly as the evolution of a morbidity leads to changes in the patient’s
medical history.
Although a lower proportion of positive responses might be understandable when they occur for our
highly complex population, they nonetheless emphasise the need for teams providing tertiary clinical care
to communicate consistently with parents, perhaps by having dedicated members of staff assigned to each
family for updating them on their child’s progress. That improvement is possible is seen by the consistently
higher proportion of responses recorded at site A, across questions 1–4. It would be interesting to learn
whether or not there are different policies in place at site A compared with the other sites, to encourage
cross-hospital learning.
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FIGURE 11 Association of each of the explanatory factors with the first four questions. (a) Site; (b) illustrative age
bands; (c) illustrative length of stay bands; and (d) case vs. control. Q, question. Reproduced from Pagel et al.194 This is
an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the
original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. This figure includes minor additions
and formatting changes to the original.
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Chapter 11 Development of a prototype tool for
the routine monitoring and feedback of complication
data in paediatric cardiac surgery programmes
This chapter is reproduced from Grieco et al.202 © Cambridge University Press 2019. This is an Open Accessarticle distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the
original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor
additions and formatting changes to the original text.
Introduction
Short-term survival following paediatric cardiac surgery has improved markedly over recent decades.203
Given this, the focus of quality assurance and quality improvement initiatives has broadened to incorporate
longer-term survival204 and non-fatal adverse outcomes (see Jacobs et al.13).
The congenital heart databases of the STS and the European Association for Cardio-Thoracic Surgery
collect data on what they define as major complications and length of stay in addition to survival data.
Analysis of these data to date has included work to understand the burden of morbidity associated with
different groups of procedures, combining incidence of major complications with length of stay to give a
composite morbidity score.13
Designed with the intent of supporting cross-institutional quality improvement initiatives, the PC4 registry
provides a data platform for participating sites to submit data, including morbidity, and then create
bespoke data summaries that put their data in the context of data submitted by other participating sites.205
Initial studies have focused on identifying aspects of practice and outcome that show variation across
institutions, one indicator of an area of practice that may benefit form quality improvement initiatives.206
In this chapter we report on the development of a tool to support the routine monitoring of early
postoperative morbidities following paediatric cardiac surgery. These efforts are focused on the nine
complications selected as important by a panel of family representatives, surgeons, intensivists, nurses
and paediatricians,90 and then defined by a separate panel of clinicians and data managers.98
The incidence of each complication was measured among > 3090 cases over a period of 21 months at five
UK centres. In parallel to this data collection, we sought to develop a means for centres to, routinely and
in a timely manner, monitor local complication rates in the context of benchmark data from the study.
Local routine monitoring of risk-adjusted mortality has been shown to be feasible and acceptable,207
and UK centres use software developed through a previous research study for the purpose of producing
VLAD charts.55
Given the anticipated interest that routine monitoring of complication data may prompt from payers,
regulatory bodies, families and the media, and because of parallel initiatives to explain complication
rates to families and patients, we sought to ensure that methods for monitoring complications, although
primarily designed for an expert clinical audience, were accessible to non-experts.
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Methods
Initial design of icons and data summaries
As an initial step, we designed a set of icons intended to represent the complications in data summaries.
For complications affecting specific sites in the body (brain, kidney, bowel, pleural space, surgical wound)
we adapted widely used icons of that site. For events (URO, MAE) and interventions (ECLS) we aimed to
convey the essential characteristics of the complication. For Feed, we initially used safety iconography of a
red circle with a bar across to indicate ‘nil by mouth’.
We then constructed basic data displays incorporating the icons to present hypothetical data on the counts
and proportion of cases having each complication (in isolation, in combination with at least one of the
other selected complications and in total). Displays were also constructed to display combinations of
complication at the level of individual patients.
At this point we visited several of the surgical centres involved in the study to discuss with data managers
and available clinicians if and how they envisaged routine monitoring of the measured complications being
incorporated into their quality assurance processes. During each meeting we discussed local initiatives and
practice concerning the monitoring and feedback of early morbidities or complications; recognition of the
icons developed; the team’s responses to our proposed data summaries; and ideas for other data summaries
that would be found useful.
Feedback from these discussions and from presentations to the Study Steering Group informed the
redesign of icons, where necessary, and informed the functional specification of the prototype software
tool developed.
Prototype software tool development
Based on previous experience of developing an outcome monitoring tool for UK centres performing
paediatric cardiac surgery and on the software tools currently used by sites to collate, analyse and present
data, we decided to build a prototype tool within Microsoft Office, specifically an Excel® spreadsheet
(Microsoft Corporation, Redmond, WA, USA) application that could be used to generate a PowerPoint®
presentation file (Microsoft Corporation, Redmond, WA, USA) containing graphical data summaries.
Results
Icons
The final set of icons developed for use in graphical summaries of complication data are shown in Figure 12.
Feedback from clinicians and data managers at the participating sites indicated that the icons developed were,
generally, readily associated with the complications that they were designed to represent.
Changes made to the initial designs to incorporate feedback were:
l replacing the ‘nil by mouth’ icon based on the international prohibition sign of a barred red circle
with a drawing of an infant with a nasogastric tube (feedback was that the prohibition sign could be
interpreted as the clinical team saying the child was not allowed to feed, rather than the child having
difficulty feeding)
l redrawing the bloodbag component of the icon for MAE to avoid it looking like a syringe
l recolouring the patient depicted in the icon representing ECLS to reflect feedback that the clinical
experience (and indeed intent) was of children on ECLS being notably pink.
The proposed summary displays of complications data were welcomed by data managers and clinicians,
albeit with feedback and suggestions for improvement and development. Clinicians stressed the importance
of expressing the incidence of complications as a percentage of operations performed, as well as in terms
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of absolute counts. It was requested that, once the data from the ongoing study were collated, there was some
form of benchmarking to put local complication data in the context of data from multiple sites, acknowledging
that such benchmarking would not, initially, take account of case mix differences between sites.
Concerning the incidence of different combinations of complications, there was interest in exploring the
sequence of complications in individual patients. Although we recognised the clinical motivation for this
request and created some ‘mock-ups’ of how such displays would look (Figure 13), reflection on how the
morbidities were defined led us to conclude that the sequence in which complications were recorded would
not reliably reflect the sequence of clinical events, undermining the usefulness of sequence information.
FIGURE 12 Final set of morbidity icons. Reproduced from Grieco et al.202 © Cambridge University Press 2019. This is
an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
FIGURE 13 Example of representation of all possible sequences of complications (not based on actual data).
Reproduced from Grieco et al.202 © Cambridge University Press 2019. This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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There was a degree of interest in building subgroup analyses into the prototype displays, with a particular
focus on the potential for monitoring complication rates among specific complex diagnoses (e.g. those
associated with a functionally univentricular heart) and patient groups (e.g. neonates). Although we
understood the value of routine monitoring of complication data to allow for subgroup analysis in time,
we took the view that different subgroups might be of interest at different times at different centres,
depending on local quality improvement initiatives for example, and so should not be hard-wired into the
prototype tool.
Our initial ideas for presenting changing rates of morbidity over time were viewed as being complicated,
which led us to incorporate, instead, time series displays employing the same formalisms as used in routine
monitoring of mortality in UK centres. The following sections summarise the structure and content of the
prototype tool designed incorporating this set of feedback and suggestions.
Structure of automated presentation and example slides/charts
Figure 14 depicts the structure of the presentation automatically created using our tool, as well as the flow
of navigation enabled by the action buttons.
Development of the time series approach, building on widely used and accepted
mortality variable life-adjusted display charts
Variable life-adjusted display charts are simple graphs providing an intuitive representation of the occurrence
of a given clinical outcome over time, measured against a baseline risk. They were originally proposed as a
way to indicate whether a surgeon’s outcomes were better or worse than might be expected based on the
case mix of their practice (difference between expected ad actual cumulative mortality).208
We adapted VLAD charts to measure the occurrence of a given morbidity over time being above or
below a given benchmark (or baseline risk b). In the chart, every procedure is plotted from left to right
(in temporal order) on a horizontal axis:
l If the procedure is not associated with the morbidity, the line moves up by an amount equal to the risk
of occurrence of that morbidity (i.e. b).
l If the procedure is associated with the morbidity, the line moves down by an amount equal to the
chance of that morbidity not occurring (i.e. 1 – b).
In the example of VLAD chart shown in Figure 15, ANE morbidity occurs less frequently than in the
compared benchmark (baseline incidence) and its incidence seems to globally decrease over time.
Home Single
morbidity
Multimorbidity
Morbidity
co-occurrences
Any
morbidity
Temporal
summaries
FIGURE 14 Structure of output presentation.
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Excel tool
We developed a tool for the automatic creation of a document containing a structured set of the graphical
summaries described above. The tool was developed by embedding visual basic for applications programming
code into an Excel spreadsheet storing source data about morbidities. Source data consist of a list of
procedures (one procedure per row in the spreadsheet) along with procedure date, current life status and
diagnosed morbidities (i.e. yes/no for each of the morbidities considered in this study). Benchmark risks for
each morbidity can also be specified (default values are provided) as an input to generate temporal summary
graphs. A ‘Run’ button enables the automatic creation of a PowerPoint presentation as a separate file,
incorporating action buttons to facilitate navigation.
From the home page, users can access a set of slides summarising the number of morbidities reported in the
source data. Icons are reported in a circular layout and labelled with numbers or percentages (the user can
switch between the two types of visualisation), representing morbidity occurrences. Navigation buttons also
allow to switch between summary considering procedures with (1) any number of morbidities; (2) exactly
one morbidity; or (3) with at least two comorbidities. Information on deaths and on procedures without any
complication is also reported.
A button ‘Temporal summary’ gives access to a slide reporting VLAD charts for all morbidities, for which
users can have a quick overview of the temporal trend of each morbidity across a time window covering
the source data.
Finally, from the ‘Procedures with multiple morbidities’ slide, users can click on any morbidity icon to
access a slide summarising how many times the morbidity co-occurred with each of the other morbidities
across all procedures. Examples of the slides in the output are included in Appendix 17.
Discussion
We have described the design process and outcomes of an exercise to develop a tool for use in routinely
monitoring complications data. The tool developed allows users to generate, from an Excel spreadsheet
containing routinely collated data concerning a set of nine specified and defined complications being followed
in a major UK study, a set of PowerPoint slides summarising the data for use in feeding back recent outcomes
to clinicians in the context of a multidisciplinary team meeting or a quality improvement collaborative.
The value of engaging early and openly with potential end-users was reinforced several times, with feedback
and suggestions form clinicians and data managers playing a key role in the specification for the current
prototype. In addition, this engagement provided us with valuable insight into the limitations of the tool at
present and additional function that clinicians would wish to see in the future.
FIGURE 15 Example of VLAD-style chart.
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The prototype tool has been presented to a group of clinicians and data managers associated with the
study. There was some discussion of how the use of VLADs in which an ascending line indicates a lower
than benchmarked incidence of complications [chosen to be consistent with current presentation of
(predicted – actual) mortality] could be reconciled with standard presentations of, say, infection data.
That aside, the prototype tool was received positively and several centres expressed an interest in using the
tool once final decisions had been made at a national level about the set of complications recommended
for routine monitoring and any modifications to the definitions used in the course of the study.
This pilot has been limited in scope so far to the centres participating in the wider study, and data
collection has benefited from the presence of the research nurses in those sites. If routine monitoring of a
subset of the nine proposed complications is adopted by UK centres with the support of the NCHDA, the
next steps for this work would involve any necessary adaption (to the set of complications displayed) and
implementation of the prototype tool at surgical centres. Future development of additional function to put
complication rates in the context of local case mix and to support robust subgroup analysis would then be
possible, subject to sharing of accrued data for this purpose.
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Chapter 12 Co-developing parent
information materials
Introduction
One of the aims of objective 6 of the original protocol was to develop graphical summaries to distil the
findings of the incidence study for use in informing patients and families about the levels of different
surgical morbidities experienced by patients following paediatric cardiac surgery. We planned, when
possible, to use separate data summaries for different subgroups of patients, with the data presented
in a consistent format across groups.
Our experience during a separate National Institute for Health Research project on developing a website
to explain how the audit monitor reports on survival after children’s heart surgery163 highlighted the
importance of involving parents in the design and content of information throughout.
Preparation
We held two workshops with parents of children who had been recruited as morbidity cases in the impact
substudy and representatives from the CHF. Before the first workshop, CP and MU prepared some
example representations of incidence data based on frequency diagrams to discuss during the workshop,
but purposefully did not prepare any written explanations, so that we could be open to listening to
participants about what level of detail was appropriate.
Parents in the impact study were approached by research nurses from each site by e-mail or letter,
asking them if they wished to attend a workshop in London.
The first workshop
The first workshop was held on Saturday 10 February 2018 in central London. Present at the meeting were
project team members AKC (a PPI co-applicant), KB, JW, MU and CP and two parents of a child who had
previously had a wound infection and had participated in the wider impact study. With each participant’s
consent, the workshop was audio-recorded and professionally transcribed.
KB gave a brief introduction, explaining the purpose of the study and going through each of the nine
measured morbidities to explain what they are and how they can arise.
CP then showed a series of pre-prepared slides, providing different options for presenting incidence
information. Discussion was encouraged for each slide, exploring depiction, first impressions, level of detail
and understanding.
First, participants were shown a summary of the nine morbidities along with nine graphical depictions
(using the same graphics as developed for the routine monitoring tool) and we checked whether or not
participants could intuitively match the symbols to the descriptions (Figure 16). There were no problems in
identifying the appropriate morbidity for each symbol.
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Next we introduced a baseline depiction of 100 patient symbols to represent 100 children undergoing
heart surgery and then presented three options for displaying the same overall incidence data on that
baseline graphic.
The three options are shown in Figure 17. In options 1 and 2, morbidities are shown to be randomly
scattered throughout the 100 baseline figures, whereas in option 3, they are arranged in one corner to
enable easy counting. Option 2 differentiates between the different morbidities, whereas option 1 does
not. All of the options have the same text, giving the number of children who do not experience any of
the morbidities out of 100.
FIGURE 16 Asking participants to match the symbol to the description of each morbidity.
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Responses and feedback on materials
Participants preferred option 1 to the others, commenting that option 3 might encourage people to look
for explanations. One parent commented that ‘It looks like you’re employing a bad surgeon on those
particular children’.
The participants suggested starting with option 1, but then providing the information on the separate
morbidities as additional information.
There was an important discussion led by participants and the PPI co-applicant around normalising morbidities.
Participants preferred wording that said ‘18 out of 100 children experience at least one problem’, as they
found it reassuring to know that it was not unique to their child. One parent commented:
. . . it’s nice to know that, you know, this isn’t just a one-off, and, ‘Oh my gosh, my baby’s got this
infection, and no one knows what it is, and no one knows what to do with it’. If it’s already identified,
and the hospital already have experience in making it better, then that’s comforting information,
almost. It makes it less scary, in a way.
We also asked participants about the language of ‘morbidity’ versus ‘complication’ versus ‘problem’ and,
after some discussion, the word ‘complication’ was preferred.
We went on to show similar diagrams for children with different categories of risk: older children with
the least complex heart conditions (incidence ≁ 3%) and young babies with the most complex conditions
(incidence ≈ 33%). Participants thought that it was important information, but preferred the presentation
without the detail (option 4 preferred to option 5 in Figure 18), as the full information looked too
overwhelming. Again, normalisation was an important theme.
I think it would be useful to know not necessarily the gory details, but . . . it’s almost saying, ‘We’ll
cross each bridge as it comes’, but there is a chance, even if it’s effectively a 33% chance, that
something could happen, then you don’t feel so alone.
We also asked participants about how and whether or not to include information about increased risk of
death for different morbidities within the displays. Somewhat to our surprise, the feedback was strongly
against including mortality information on the grounds that it was a qualitatively different outcome to
FIGURE 17 The three incidence options shown to participants in workshop 1.
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morbidity and it was already something that was discussed separately during consent and planning for the
surgery. Some comments about mortality versus morbidity were:
It’s almost at a different, kind of, level of information. It’s a different level of anxiety.
It’s incurable. I mean, if a child dies, that’s it. To me, this is mostly, ‘We can cure this, and we have a
plan for it’.
It’s not that you’re not told. When you sign that surgery information . . .
The final piece we asked parents about was representing the potential impact of experience of a morbidity
in terms of length of stay in hospital, as our preliminary data showed that children who experienced
morbidity were significantly more likely to stay longer in hospital. Figure 19 shows one of the examples
we showed people, with the key to reading the graphic at the top. We chose to show the IQR and no
point estimate (like a mean or a median) to communicate how variable length of stay could be.
The participants thought that the information was very useful and that they would have liked to have seen
this before their child was admitted for surgery:
So, to know what was going to possibly happen in the weeks leading after the birth was important
to me, even down to, like, how much I pack, and what arrangements I make, you know, for the cat,
and things like that . . .
. . . if there are other siblings and things, so that families can look and think, ‘Hopefully I’ll be out in
16 days, but what happens if we’re not? How do we cope with . . . ,’ ‘Looking at the maths for 20+
days, what do we do, childcare or whatever?’ It enables you to be . . . , that whole thing about being
prepared for it.
FIGURE 18 Incidence options for young babies with serious heart defects.
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We discussed providing more detailed information for each of the individual morbidities, as there was a wide
variation in length of stay depending on the morbidity experienced. Participants felt that information on all
of the morbidities would be too overwhelming, especially as some of them were very rare. The consensus
was that if a morbidity was experienced, then more specific information from this study about that morbidity
could be shared, similar to the existing information already shared with parents about ECLS.
Participants thought that the range was useful, to normalise the situation both if a child stays longer than
the initially anticipated time period and if the child stays for less time.
Another important insight that emerged from the discussion was the benefit in having more information
to enable discussion and support with other parents going through similar situations on the ICU:
I think, to get a whole better understanding . . . , also, in the expressing room, it was such a little
support network to each other. So, to have a bit more of an understanding, to be able to talk to each
other, with better education, I suppose, would have been good.
Similarly, participants thought that it would be useful to have this information in writing to share with family,
employers or schools, so that they knew better what to expect and that heart surgery was not a simple
‘quick fix’.
We discussed how and whether or not to add in further information about morbidities once the impact
follow-up data had been analysed. Participants thought that it might be useful if your child experienced
one of the morbidities, but that information would have to be accompanied with advice on what to do
FIGURE 19 Examples of how morbidity can affect length of stay. Green icons indicate none of the nine morbidities
and yellow icons indicate at least one morbidity.
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next or signposting to resources that would help. In a similar vein, we were told that we needed to ensure
that there was sufficient narrative to accompany the graphics in any leaflet, to ensure that there was context
and trustworthy information about where these data had come from and what they meant.
The key points that we took away from the first workshop and used to prepare a draft information
leaflet were:
l the importance of normalising morbidities and emphasising that hospitals are used to dealing
with them
l layering information
l not combining morbidity with mortality information.
The second workshop
The second workshop was held on Saturday 6 May 2018 in central London. Present at the meeting
were project team members KB, CP and MU, three parents of two children who had had a morbidity,
both of whom had participated in the wider impact study and were treated at Great Ormond Street
Hospital, and a representative of the CHF. We did not record the second workshop.
For this second workshop, we had prepared draft information leaflets. KB again gave a brief introduction
to the project and then we gave each participant 10–15 minutes to read through the draft on their own.
The draft shared with parents included:
l preamble about heart surgery and the possibility of complications
l emphasis that complications are relatively common and that hospitals are experienced in spotting and
treating them
l a table explaining each of the complications in non-expert language
l several updated incidence graphics, in the same style as each other, for the overall population and then
by different risk factors
l updated graphics illustrating length of stay information.
Responses and feedback
Participants were largely positive about the text, the explanation of the morbidities and the graphical
displays and found the displays intuitive to interpret. However, we received valuable feedback on
improvements, which included:
l Fewer graphics for incidence – parents felt that only one or two examples additional to the overall
incidence were needed, otherwise the sheer number was overwhelming.
l Participants thought that the length of stay information would be useful for everyone, whereas some
parents might not want to see the incidence data, and so they suggested putting this information
before the incidence data.
l We were told that navigating the document was difficult and we should add a clearer overview of the
content to the beginning.
l Parents asked if we could signpost readers to other resources and charities that would be helpful.
l Parents suggested adding a sentence about plans for your child changing during the hospital stay,
to prepare families better for potential uncertainty.
Additionally, when asked about adding impact data once they were, available, participants suggested
focusing on practical information (e.g. time out of work, time in hospital) rather than clinical information.
We were also told that parents might not read the information immediately, but that having a leaflet
printout to hand might be invaluable later.
CO-DEVELOPING PARENT INFORMATION MATERIALS
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The latest version of the information
Following the second workshop, we updated the draft leaflet and shared it with the broader project team
for feedback. The current version, following incorporating of team feedback, is attached as Appendix 18.
We now have a ‘key messages’ section and a clear navigation section to help readers access the information.
The final page is a list of the major charities for families of children with CHD, along with web links and a
brief description.
The included graphics are presented in the Appendix 18.
Summary and limitations
We have co-developed information resources for parents that depict the incidence of important morbidities
linked to paediatric cardiac surgery. This was limited by the scope of our main project to cover the
complication events that we studied in the five centres and also by the relatively small number of parents
who were in a position to give time to assist. The overall feedback for the current draft, which has been
shared by e-mail with patient user groups, nurses and doctors linked to the study, has been overwhelmingly
positive. We are aware that detailed information about specific complications or morbidities is not included
and a longer-term goal is to utilise the final analysis of the impact data to prepare morbidity specific leaflets
for the most common morbidities. Furthermore, we believe that an evaluation of the information resources
would be an important and useful next step to follow.
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Chapter 13 Conclusions
We report a mixed-methods study that ultimately aimed to select, define and evaluate the importantearly morbidities associated with paediatric cardiac surgery. Given that the study design entailed a
diverse range of methods and had a long duration spanning 52 months, we presented a discussion of the
limitations alongside a short summary of the findings with each chapter. Therefore, in this final section we
will sum up our overall conclusions and suggestions for future practice and research.
The needs of parents and carers
Perspectives of parents and health professionals
Our research study sought to integrate the viewpoints of parents and carers via the use of focus groups,
an online discussion forum run by a user group, by engaging with parent advisors (LA and BT) during
the course of the project about the protocol and the analysis of study data, and finally by undertaking
workshops with parents to co-develop information resources.
Reflecting on these activities and noting the sensitivity of the topic, we suggest that although there is much
common ground between parents, carers and health-care professionals, all of whom want to see the best
outcome for the child, the range of focus for parents and carers differs somewhat to that of clinicians. This
leads to some divergence between the two groups about the fundamental issues of what the important
morbidities linked to paediatric cardiac surgery are: clinicians tended to prioritise clearly clinical issues related to
the heart (use of ECLS and reoperation), whereas parents placed greater emphasis on holistic outcomes for
their child (feeding, child development and communication). During the consent process and the postoperative
periods, the highly skilled practitioners involved in paediatric cardiac surgery understandably have a particularly
intense level of attention on the conduct and success of the procedure itself. Although parents and carers
obviously share this priority, given their role as primary carers they wish to know more about what their child
will be doing afterwards in the medium and longer term: clearly both areas are very important.
Information resources
We used study data collected during the course of the morbidity project to co-develop parent and carer
information resources. To date, this has been focused predominantly on showing what the morbidities are
and how their incidence and the length of stay may vary based on the complexity of the child’s condition.
For example, a newborn baby with a very complex heart defect has a one in three chance of experiencing a
complication, whereas an older child with a less complex heart defect has a 1 in 20 chance of a complication.
Parents emphasised consistently that the default position should be to offer the information during the
consent process, even though not every parent may wish to accept and read it immediately. They told us that
it helps parents to know first that, they are not alone in facing a complication; second, that clinical teams
have seen complications before and know how to deal with them; and third, that it is better as a parent to
‘be prepared’. Furthermore, they indicated that information about impact, such as nearly all children who
experience a complication and recover, will have a similar quality of life to children who did not experience a
complication by the 6-month mark, was very useful to know. We believe that the developed information
resources represent a major step forwards; however, they would be optimally backed up by an evaluation
study and a plan for their dissemination into general use.
Quality assurance and quality improvement
Morbidities tell us more about outcome than mortality
The main measure used to evaluate outcome of paediatric cardiac surgery remains 30-day survival, which
is very high (above 98% in the UK for 2016/17) and is now not discriminatory enough as an outcome
measure for teams that wish to explore new routes to improve patient care.
DOI: 10.3310/hsdr08300 HEALTH SERVICES AND DELIVERY RESEARCH 2020 VOL. 8 NO. 30
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121
We have identified nine measures of morbidity: ANE, URO, Feed, Renal, MAEs, ECLS, NEC, SSI and PPE.
Younger children and those with the most complex CHD were at greatest risk of getting morbidity, as
were children with prolonged cardiopulmonary bypass times. Patients with any morbidity present had
mortality at 6 months of 12.5% and a median perioperative length of stay of 24 days. We note that the
length of stay and mortality outcomes within the population of patients who did not experience any
morbidities were excellent: their survival at 6 months post operation was 99.1% and their median length
of stay was 8 days, and this leads us to believe that the morbidities we selected do capture most of the
complication-related adverse outcomes for this context.
Patients with any morbidity scored, on average, 5.2 points lower on their total quality-of-life score at
6 weeks, but this difference had narrowed to only 2 points less by 6 months. At the 6 months mark, most
types of morbidity had comparable quality-of-life scores to patients without morbidity, except for patients
who had been treated with ECLS. Most of the individual morbidities were linked to a greater number of
days in hospital and higher hospital costs over 6 months, but ECLS patients had the fewest days at home at
6 months (median 43 days out of 183) and highest costs (£71,051 higher costs), followed by patients
with multimorbidities (147 days and £41,484 higher costs).
How can morbidity monitoring be taken forward?
There is evidence that stakeholders are interested in taking forward the use of morbidity measures for
quality improvement, given that selected clinical teams around the country have begun to share other
quality markers, such as accidental extubation rates and hospital-acquired infection rates locally. We note
the success of the multicentre collaborative (PC4) reporting morbidity outcomes from a North American
setting, albeit focused on clinician-selected metrics. Therefore, looking forward, there is the potential for
use of our study findings at a local and at a national level. It is particularly important to consider future
research that has the potential to reduce the rate of morbidity or to ameliorate its effect on patients.
In centres
Within the scope of this project a new Excel tool has been developed and piloted that enables clinical
teams to benchmark and report the local rates of morbidities with a quality assurance goal, such as in a
mortality and morbidity conference. It is hoped that this Excel tool has the future potential to supplement
the previously developed software for monitoring of 30-day mortality rates. Although straightforward to
use, resources are required for morbidity monitoring to be implemented. Enabling clinical teams to make
morbidities more visible is a first step towards reducing these events.
Nationally
Over the course of the project, we have kept in close contact with the NCHDA and the Clinical Reference
Group for CHD services. NCHDA has already started to collect morbidities within the nationally mandated
data set, using the definitions that we developed. It will be for these two organisations to take this issue
forward after the end of the study, after they have considered our final grant report. We note that NCHDA
reported its first centre-specific morbidity data, based on our study definitions, in its 2019 report.209
Future research
The measurement and monitoring of morbidity is inherently more complex than mortality, and there are
logistic difficulties in taking forward some of the morbidity measures. It was noted that, in particular, feeding
problems are difficult to capture, although these were considered important by families and, hence, there is
strong motivation to explore these further. Additional research may help determine the best way to alleviate
the impact of feeding problems in CHD. Our measure of renal failure was the need for renal support, and
this may not be the optimal method to capture this morbidity. Further research may help us to understand
the best approach to manage postoperative renal injury in CHD.
CONCLUSIONS
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Neurological and developmental surveillance and follow-up
We note that in the selection work, neurodevelopmental morbidities came up as the most important
morbidity affecting children with CHD across all stakeholders, both clinicians and lay people. Nonetheless,
the definition that was arrived at for the morbidity of ANE, which captured major early acute neurological
complications after surgery, had a rate of 0.5% as a single event and 2.1% in combination with other
complications, in the incidence study. This low ANE rate may be reviewed in the context of the BDA
validation study in which we assessed a representative sample of children with CHD using validated
neurodevelopmental tests (against which the BDA was compared). In the sample of 400 children aged
between 15 months and 5 years (selecting an age band where developmental tests are more reliable
rather than a very young age band where they are less reliable), we found that the Mullen result was more
than 2 SDs below the normative mean in between 17% and 21% (depending on exact inclusion criteria).
The difference between the rate of ANE and the rate of very low scores in children with CHD when
assessed in a different context is stark and suggests that ANE represents the ‘tip of the iceberg’.
Since undertaking the BDA validation study, we have completed a Delphi survey in three rounds to
establish consensus as to the process for evaluation of suspected neurodevelopmental abnormalities in
children with CHD. We have also undertaken an assessment of the services that children with CHD were
under within the validation sample, asking the research question ‘how many children with low scores on
gold standard testing were under appropriate child development services?’ These secondary follow-on
projects are currently being analysed for publication. We suggest that there is a pressing need to take this
topic forward, with changes to the follow-up pathway for neurodevelopment in children who have CHD.
We suggest that further research is needed to explore at what time points in the patient pathway should
the BDA be used, what actions should be taken when the BDA is amber or red and whether or not use of
the BDA is effective.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 The PRISMA flow diagram for the
literature review
Id
en
ti
fi
ca
ti
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n
Records identified through
MEDLINE/EMBASE/CINAHL search
(n = 5023)
Records after duplicates
removed and initial screening
(n = 3854)
Records screened
(n = 1169)
Full-text articles assessed
for eligibility
(n = 261)
Original research studies on
paediatric cardiac surgical
morbidity
(n = 235)
Sc
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ib
ili
ty
In
cl
u
d
ed
Records excluded
• Not used as not on study
   population or conditions of
   interest, n = 922
• Reviews and guidelines
   retained for reference, n = 28
• Adult patients, n = 8
• Case series of < 15 patients, n = 1
• Letter to editor, n = 3
• Review article retained for
   reference, n = 3
• Guideline retained for
   reference, n = 2
• Combined surgical and catheter
   procedure, n = 2
• Description of future study, n = 1
• Other, n = 5
FIGURE 20 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the
literature review. CINAHL, Cumulative Index to Nursing and Allied Health Literature.
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Appendix 2 List of morbidities generated by the
literature review
BOX 3 The initial 66 terms under consideration in selection panel meeting 1, derived from the literature review,
focus groups and online forum discussions
1. Anxiety/fear/aggression.
2. Problems feeding.
3. Reflux/vomiting.
4. Pleural effusion.
5. Swallowing and choking.
6. Global permanent neurological impairment.
7. Mediastinitis.
8. Myocardial ischaemia.
9. Focal permanent neurological impairment.
10. Sensory neural deafness.
11. Brain injury.
12. Cardiac arrest.
13. Renal failure/insufficiency.
14. Length of ICU stay.
15. Post-traumatic stress disorder.
16. ECMO/mechanical support.
17. Communication.
18. Hospital procedural anxiety.
19. Adjustment to difference.
20. Attachment.
21. Neurological insult.
22. Chylothorax.
23. Acute kidney injury.
24. NEC.
25. Junctional ectopic tachycardia.
26. Pulmonary hypertension.
27. Superior vena cava obstruction.
28. Swelling of head and neck.
29. Chest exploration.
30. Thrombosis of venous pathways.
31. Irreversible neurological damage.
32. Renal replacement therapy.
33. URO within 30 days.
34. Prolonged ventilation.
35. Complications during surgery.
36. Developmental delay.
37. Financial difficulties.
38. Lack of support at home.
39. Laryngopharyngeal dysfunction.
40. Vocal cord dysfunction.
41. Delay in establishing feeding.
42. Brain damage.
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43. Low cardiac output.
44. Sepsis.
45. Gastrosomy.
46. Massive haemorrhage.
47. Thrombosis.
48. Impaired cognitive function more than a month after surgery.
49. Quality of life.
50. Prolonged hospital length of stay.
51. Permanent pacemaker.
52. Long-term renal support.
53. Any serious incident during patient stay.
54. Cost per quality measure.
55. Seizures.
56. Stroke.
57. Sternal wound infection.
58. Psychological/behavioural issues.
59. Growth retardation.
60. Tracheostomy.
61. Diaphragmatic palsy.
62. Delayed chest closure.
63. Respiratory infection.
64. Wrong clinical decision.
65. Wrong clinical diagnosis.
66. Death before surgery/delayed surgery.
BOX 3 The initial 66 terms under consideration in selection panel meeting 1, derived from the literature review,
focus groups and online forum discussions (continued )
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Appendix 3 Voting process for the selection panel
The voting process used as part of the nominal group technique deployed was based on the algorithmpresented in Utley et al.93 A short summary is presented here.
In a secret ballot, each panellist ranked the candidate options in order of descending importance. They
were permitted to use tied ranks and were not obliged to rank every option. For each and every possible
pair of options (candidate morbidities A and B say) we determined whether or not at least as many
participants preferred option A to option B as preferred option B to option A. We then used the analysis
summarised in Figure 21 to identify group preferences among the set of candidate morbidities.
In the first panel meeting, the rankings supplied by individual panellists were entered into an Excel spreadsheet
and a visual basic for applications macro written by Martin Utley and Christina Pagel was used to conduct the
analysis. For the online poll conducted after the second panel meeting, we used the web-based tool available
at URL: https://crankit-voting.appspot.com/.
Step 1 Step 2 Step 3
A
B
C D
E
A
B
E
C
D
Rank before
tiebreaks
Option Rank after
tiebreaks
1 A 1
2 B 2
2 C 3
2 D 4
5 E 5
Draw an arrow from option A to B
if at least as many participants ranked
A higher than B as ranked B higher
than A. Repeat process in each
direction for all pairs of options
In this example there is an arrow in both
directions between B and D, indicating that
exactly as many participants preferred B to
D as preferred D to B . . .
Identify the hierarchy
of subsets of options.
Within a subset there is
no clear group ranking
of options
. . . there is a majority
preference for A above every
other option and E is least
favoured. The cycle of
arrows  between B, C and D
indicates that there is no
unambiguous ranking of
these three . . .
Try to rank options within subsets by first counting
the arrows leaving each option within that subset
and then, if there are ties, counting just those
arrows between tied options
. . . there are two arrows leaving B and just one leaving
each of C and D, so the first tiebreak places B above C
and D. Then, considering just C and D, the second
tiebreak places C above D
FIGURE 21 Explanation of the robust group ranking process used in the nominal group approach employed by the
selection panel.
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Appendix 4 Causal mapping diagrams used in
the selection process
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Direction of influence
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after surgery
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ECMO/mechanical
support
Acute kidney injury
Mental health
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FIGURE 22 Causal mapping diagrams. One view on (a) the relationship of other candidate morbidities to mental health consequences; (b) the relationship of other candidate
morbidities to feeding problems; and (c) the whole picture (relationships of candidate morbidities to each other). (continued )
A
PPEN
D
IX
4
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
154
Direction of influence
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during surgery
Level of support at home
FIGURE 22 Causal mapping diagrams. One view on (a) the relationship of other candidate morbidities to mental health consequences; (b) the relationship of other candidate
morbidities to feeding problems; and (c) the whole picture (relationships of candidate morbidities to each other). (continued )
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Level of support at home
Poor communication
between clinical team
and family
Complications during
surgery
Surgical bleeding
(graded)
URO/reinterventionQuestionable clinical
team decision and
diagnosis
Recurrent laryngeal
nerve palsy
Phrenic nerve injury Complete heart block
Low cardiac output
Acute kidney injury
NEC
New permanent
neurological impairment
Hospital-acquired
infection
Vascular thrombosis
PPE
Prolonged hospital stay
Developmental delay
Mental health
consequences
Problems feeding
(graded)
New impaired cognitive
function more than one
month after surgery
Length of
ICU stay
ECMO/mechanical
support
Near miss
(categorised)
FIGURE 22 Causal mapping diagrams. One view on (a) the relationship of other candidate morbidities to mental health consequences; (b) the relationship of other candidate
morbidities to feeding problems; and (c) the whole picture (relationships of candidate morbidities to each other).
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Appendix 5 Summary of selection panel decisions
at final meeting including comment on limitations
TABLE 31 Comments from the selection panel about each morbidity at their final meeting
Morbidity Comment (including limitations) Decision
ANE Although this was one of the rarest morbidities, the
panel unanimously agreed that it should be monitored,
as it was considered severe and likely the tip of the
iceberg in terms of neurological consequences from
heart disease and treatment
Suggested for routine monitoring
noting its limits in scope
URO/reintervention There was some discussion about intercentre differences
in willingness to reintervene. The panel thought that as
long as monitoring was within hospitals and assessment
was against that each hospital’s recent history, then this
would not be a problem
Suggest for routine monitoring
with some cautions as to
interpretation for intercentre
Feed (excluding NEC) This generated a lot of discussion. Many panellists felt
that the definition was messy and that it was difficult
to disentangle feeding problems due to surgery rather
than underlying disease. The panel also discussed the
importance of feeding problems for parents and that
they were relatively common. There was also discussion
about whether or not measuring feeding problems
would help raise the issue among clinical teams and
potentially drive improvements in feeding support. The
surgeons felt that laryngeal nerve injuries were important
to capture
Suggest for internal within
programme monitoring
‘Association with surgery’ rather
than complication attributed to
surgery
Further research needed
Renal (excluding ECMO) The project team reported that there seemed to be
genuinely different practices between centres on when
and whether or not to use renal replacement therapy
following surgery. The panel noted that originally they
had wanted to measure acute kidney injury and the
definition panel selected renal replacement therapy as
the currently most objective and feasible method to
measure this. The panel also noted that it would be
ideal to have a new definition of ‘acute kidney injury’
applicable to this setting. In the meantime, the panel
felt that it was very important to first understand what
intercentre differences mean before recommending
any routine monitoring
Further research is needed
to understand inter centre
differences in use of renal
replacement therapy and what
this means for monitoring and
treating acute kidney injury
MAE The panel noted that this morbidity encompassed an
important set of complications that had a major impact
on mortality
Suggest for routine monitoring
ECLS/ECMO The panel all felt that this was an extremely adverse
morbidity and should be routinely monitored
Suggest for routine monitoring
NEC The panel noted the importance of a clear definition for
NEC based on consistent criteria
Suggest for routine monitoring
Hospital-acquired infection
(graded/categorised)
The panel were unanimous and agreed that this
morbidity be routinely monitored
Suggest for routine monitoring
PPE/chylothorax There was a long discussion in which it was noted that
PPE leading to delayed discharge had a significant impact
on patients. There were some reservations based on the
clinical links between case mix factors, such as single
ventricle heart disease and PPEs
Suggest for routine monitoring,
but with reservations
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Appendix 6 Recruitment numbers by centre
TABLE 33 Impact by site
Site Frequency (%), cumulative
GOSH 185 (27.78), 27.78
EVE 135 (20.27), 48.05
BIRM 156 (23.42), 71.47
BRHC 133 (19.97), 91.44
GLA 57 (8.56), 100.00
Total 666 (100.00)
TABLE 32 Incidence by site
Site Frequency (%), cumulative
GOSH 979 (31.68), 31.68
EVE 538 (17.41), 49.09
BIRM 726 (23.50), 72.59
BRHC 518 (16.76), 89.35
GLA 329 (10.65), 100.00
Total 3,090,100.00
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Appendix 7 Cardiac diagnosis and procedure
mappings to the PRAiS2 groups reported by
Rogers et al.114
TABLE 34 Specific procedures included in each specific procedure group, with their respective frequencies and
30-day mortalities
Specific procedure group banded for PRAiS2 Procedure type
30-day mortality from
Rogers et al.114 (%)
Group 1 11.1
Norwood procedure (stage 1) A 10.7
HLHS hybrid approach A 15.9
Group 2 7.2
TAPVC repair and arterial shunt A 60.0
Truncus and interruption repair B 6.7
Truncus arteriosus repair B 5.3
Interrupted aortic arch repair B 5.1
Arterial switch and aortic arch obstruction repair (with/without VSD
closure)
B 8.6
Group 3 7.8
Arterial shunt A 7.8
Group 4 3.9
Repair of total anomalous pulmonary venous connection B 5.2
Arterial switch and VSD closure B 2.6
Isolated pulmonary artery band A 4.0
Group 5 4.1
PDA ligation (surgical) C 4.1
Group 6 1.2
Arterial switch (for isolated transposition) B 1.5
Isolated coarction/hypoplastic aortic arch repair B 1.0
Aortopulmonary window repair B 0.0
Group 7 4.6
Senning or Mustard procedure A 12.5
Ross–Konno procedure B 2.9
Mitral valve replacement C 3.7
Pulmonary vein stenosis procedure A 6.3
Pulmonary atresia VSD repair B 4.5
Tetralogy with absent pulmonary valve repair B 4.2
Unifocalisation procedure (with/without shunt) A 5.5
continued
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TABLE 34 Specific procedures included in each specific procedure group, with their respective frequencies and
30-day mortalities (continued )
Specific procedure group banded for PRAiS2 Procedure type
30-day mortality from
Rogers et al.114 (%)
Group 8 2.7
Heart transplant A 3.3
Tricuspid valve replacement C 5.9
Aortic valve repair B 2.1
Pulmonary valve replacement B 1.8
Aortic root replacement (not Ross procedure) B 3.4
Cardiac conduit replacement C 1.8
Isolated right ventricular to pulmonary artery conduit construction C 3.3
Tricuspid valve repair A 4.3
Group 9 3.5
Multiple VSD Closure B 1.7
Atrioventricular septal defect and tetralogy repair B 2.0
Cor triatriatum repair B 5.6
Supravalvar aortic stenosis repair B 3.9
Rastelli: REV procedure B 3.8
Group 10 1.7
Bidirectional cavopulmonary shunt A 1.7
Group 11 1.0
Atrioventricular septal defect (complete) repair B 1.0
Group 12 1.0
Fontan procedure A 1.0
Group 13 0.4
Aortic valve replacement: Ross procedure B 0.7
Subvalvar aortic stenosis repair B 0.3
Mitral valve repair B 0.4
Sinus venosus ASD and/or PAPVC repair B 0.4
Group 14 0.6
Atrioventricular septal defect (partial) repair B 0.5
Tetralogy and Fallot-type DORV repair B 0.7
Vascular ring procedure B 0.4
Group 15 0.1
Anomalous coronary artery repair B 0.0
Aortic valve replacement: non-Ross procedure B 0.0
ASD repair B 0.0
VSD repair B 0.2
No specific procedure group 2.9
No specific procedure C 2.9
A, palliative or staged; ASD, atrial septal defect; B, reparative or corrective; C, ungrouped/could be either one;
DORV, double outlet right ventricle; HLHS, hypoplastic left heart syndrome; PAPVC, partial anomalous pulmonary venous
connection; PDA, patent ductus arteriosus; TAPVC, total anomalous pulmonary venous connection; VSD, ventricular
septal defect.
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TABLE 35 Diagnoses included in each diagnosis group, with their respective frequencies and 30-day mortality rates
PRAiS2 cardiac diagnosis group
Diagnosis complexity
group
30-day mortality from
Rogers et al.162 (%)
Group 1 6.4
HLHS A 6.5
Truncus arteriousus A 4.8
Pulmonary atresia and IVS A 8.9
Group 2 4.6
Functionally UVH B 4.5
Pulmonary atresia and VSD B 4.7
Group 3 3.3
TGA – VSD/DORV – TGA C 3.3
Interrupted aortic arch C 2.9
Group 4 4.1
PDA D 4.1
Group 5 2.4
Miscellaneous primary congenital diagnosis D 2.2
Tricuspid valve abnormality (including Ebstein’s) D 2.7
TAPVC C 3.0
Procedure N/A 1.7
Comorbidity N/A 4.3
Normal N/A 0.0
Empty/unknown N/A 0.0
Group 6 2.5
Acquired D 2.5
Group 7 1.5
AVSD D 2.0
Fallot/DORV fallot E 1.1
Group 8 1.6
Aortic valve stenosis (isolated) E 1.9
Mitral valva abnormality E 1.0
Miscellaneous congenital terms E 1.9
Group 9 2.0
TGA and IVS C 2.0
Group 10 0.7
Aortic arch obstruction and VSD/ASD E 0.8
Pulmonary stenosis E 0.5
Group 11 0.4
Subaortic stenosis (isolated) E 0.0
Aortic regurgitation E 0.0
VSD E 0.7
ASD E 0.1
Arrhythmia E 0.8
ASD, atrial septal defect; AVSD atrioventricular septal defect; DORV, double outlet right ventricle; HLHS, hypoplastic left
heart syndrome; IVS, intact ventricular septum; N/A, not applicable; PDA, patent ductus arteriosus; TAPVC, total anomalous
pulmonary venous connection; TGA, transposition of the great arteries; UVH, functionally univentricular heart;
VSD, ventricular septal defect.
A–E diagnosis groups ranked by complexity.
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Appendix 8 Summary descriptive table of risk
factors by individual morbidity outcomes
DOI: 10.3310/hsdr08300 HEALTH SERVICES AND DELIVERY RESEARCH 2020 VOL. 8 NO. 30
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
165
TABLE 36 Summary descriptive table of risk factors by individual morbidity
Risk factor
Morbidity group
Multi
(N= 197)
PPE
(N= 111)
Feed
(N= 99)
URO
(N= 59)
Renal
(N= 40)
MAE
(N= 34)
SSI
(N= 27)
NEC
(N= 32)
ANE
(N= 14) ECLS (N= 62)
Male, n (%) 104 (52.8) 66 (59.5) 47 (47.5) 36 (61.0) 28 (70.0) 21 (61.8) 15 (55.6) 19 (59.4) 10 (71.4) 26 (41.9)
Age (days), median (IQR) 45 (8–239) 519
(167–1652)
46 (7–154) 169 (37–521) 15 (7–185) 102 (10–381) 188 (56–524) 53 (10–124) 153 (7–233) 75 (7–266)
Child (reference), n (%) 35 (17.8) 62 (55.9) 9 (9.1) 18 (30.5) 5 (12.5) 9 (26.5) 8 (29.6) 0 (0) 3 (21.4) 11 (17.7)
Infant, n (%) 71 (36.0) 42 (37.8) 43 (43.4) 28 (47.5) 11 (27.5) 12 (35.3) 13 (48.2) 18 (56.3) 7 (50.0) 23 (37.1)
Neonate, n (%) 91 (46.2) 7 (6.3) 47 (47.5) 13 (22.0) 24 (60.0) 13 (38.2) 6 (22.2) 14 (43.8) 4 (28.6) 28 (45.2)
Weight (kg), median (IQR) 3.8 (3.0–6.7) 9.3 (6.2–17.2) 3.6 (3.0–5.2) 6.2 (3.9–8.5) 3.6 (2.9–5.8) 4.5 (3.2–8.9) 5.8 (3.9–7.9) 3.7 (2.8–4.4) 6.1 (3.4–7.3) 4.1 (3.2–7.4)
Weight for age, mean (SD) –1.6 (1.5) –1.2 (1.4) –1.8 (1.4) –1.8 (1.5) –1.7 (1.3) –1.2 (1.6) –1.6 (1.8) –2.2 (1.4) –1.2 (1.4) –1.4 (1.6)
Low weight < 2 SDs below
mean for age, n (%)
71 (38.4) 29 (27.9) 38 (40.9) 22 (40.0) 14 (36.8) 12 (36.4) 11 (44.0) 16 (55.2) 1 (7.1) 20 (33.3)
Diagnosis, n (%)
E (reference) 24 (12.2) 14 (12.6) 31 (31.3) 18 (30.5) 6 (15.0) 7 (20.6) 3 (11.1) 12 (37.5) 2 (14.3) 6 (9.7)
D 68 (34.5) 42 (37.8) 29 (29.3) 20 (33.9) 12 (30.0) 8 (23.5) 15 (55.6) 8 (25.0) 5 (35.7) 8 (24.5)
C 34 (17.3) 9 (8.1) 9 (9.1) 4 (6.8) 19 (47.5) 6 (17.7) 6 (22.2) 3 (9.4) 3 (21.4) 6 (17.7)
B 34 (17.3) 24 (21.6) 12 (12.1) 12 (20.3) 1 (2.5) 7 (20.6) 1 (3.7) 5 (15.6) 1 (7.1) 7 (20.6)
A 37 (18.8) 22 (19.8) 18 (18.2) 5 (8.5) 2 (5.0) 6 (17.7) 2 (7.4) 4 (12.5) 3 (21.4) 6 (17.7)
Univentricular heart, n (%) 52 (26.4) 44 (39.6) 26 (26.3) 10 (17.0) 2 (5.0) 7 (20.6) 3 (11.1) 4 (21.5) 2 (14.3) 9 (14.5)
Acquired comorbidity,
n (%)
37 (18.8) 22 (19.8) 15 (15.2) 9 (15.3) 7 (17.5) 4 (11.8) 5 (18.5) 8 (25.0) 1 (7.1) 11 (17.7)
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Risk factor
Morbidity group
Multi
(N= 197)
PPE
(N= 111)
Feed
(N= 99)
URO
(N= 59)
Renal
(N= 40)
MAE
(N= 34)
SSI
(N= 27)
NEC
(N= 32)
ANE
(N= 14) ECLS (N= 62)
Congenital comorbidity,
n (%)
56 (28.4) 28 (25.2) 19 (19.2) 12 (20.3) 11 (27.5) 6 (17.7) 12 (44.4) 12 (37.5) 4 (28.6) 18 (29.0)
Severity of illness, n (%) 52 (26.4) 13 (11.7) 27 (27.3) 11 (18.6) 9 (22.5) 4 (11.8) 2 (7.4) 9 (28.1) 0 (0) 25 (40.3)
Premature, n (%) 29 (14.7) 11 (9.9) 6 (6.1) 8 (13.6) 4 (10.0) 1 (2.9) 1 (3.7) 6 (18.8) 0 (0) 7 (11.3)
Down’s syndrome, n (%) 17 (8.6) 16 (14.4) 10 (10.1) 5 (8.5) 2 (5.0) 2 (5.9) 3 (11.1) 2 (6.3) 1 (7.1) 5 (8.1)
Additional cardiac risk,
n (%)
21 (10.7) 8 (7.2) 10 (10.1) 5 (8.5) 2 (5.0) 3 (8.8) 2 (7.4) 4 (12.5) 2 (14.3) 8 (12.9)
Procedure, n (%)
Reparative/corrective 91 (46.2) 45 (40.5) 42 (42.4) 30 (50.9) 30 (75.0) 16 (47.1) 18 (66.7) 13 (40.6) 8 (57.1) 39 (62.9)
Palliative/staged 51 (25.9) 49 (44.1) 35 (35.4) 11 (18.6) 2 (5.0) 11 (32.4) 2 (7.4) 6 (18.8) 4 (28.6) 8 (12.9)
Ungrouped 55 (27.9) 17 (15.3) 22 (22.2) 18 (30.5) 8 (20.0) 7 (20.6) 7 (25.9) 13 (40.6) 2 (14.3) 15 (24.2)
Bypass
Time (minutes),
median (IQR)
116 (63–160) 96 (58–128) 87 (0–121) 91 (52–135) 146 (102–166) 112 (68–166) 122 (80–164) 78 (0–140) 110 (80–147) 191 (119–293)
No bypass (reference),
n (%)
24 (12.2) 12 (10.8) 30 (30.3) 13 (22.0) 1 (2.5) 6 (17.7) 1 (3.7) 11 (34.4) 1 (7.1) 4 (6.5)
< 90 minutes, n (%) 41 (20.8) 40 (36.0) 23 (23.2) 15 (25.4) 6 (15.0) 5 (14.7) 8 (29.6) 6 (18.8) 3 (21.4) 3 (4.8)
≥ 90 minutes, n (%) 132 (67.0) 59 (53.2) 46 (46.5) 31 (52.5) 33 (82.5) 23 (67.7) 18 (66.7) 15 (46.9) 10 (71.4) 55 (88.7)
Multi, multimorbidities.
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Appendix 9 PedsQL normal scores
TABLE 37 PedsQL scores for healthy norms
Healthy norms Number of patients PedsQL score, mean (SD)
Infant (0–12 months) 246
Physical summary 84.98 (9.45)
Psychosocial summary 80.47 (12.64)
Total score 82.47 (9.95)
Infant (13–23 months) 141
Physical summary 88.84 (7.68)
Psychosocial summary 83.12 (11.02)
Total score 85.55 (8.74)
Toddler (2–4 years) 2900
Physical summary 89.82 (15.43)
Psychosocial summary 86.56 (12.31)
Total score 87.86 (12.19)
Parent of child: 5–7 years 2314
Physical summary 80.11 (20.85)
Psychosocial summary 79.25 (15.44)
Total score 79.56 (16.02)
Parent of child: 8–12 years 2935
Physical summary 82.91 (20.56)
Psychosocial summary 79.16 (16.21)
Total score 80.48 (16.28)
Parent of adolescent: 13–18 years 1281
Physical summary 83.87 (20.13)
Psychosocial summary 80.55 (15.82)
Total score 81.75 (15.72)
Data drawn from Varni et al.175–177
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Appendix 10 PedsQL outcomes by individual
morbidity groups at 6 weeks and 6 months
TABLE 38 PedsQL outcomes by individual morbidity groups and 6 weeks and 6 months
Time point,
PedsQL score None ANE URO Feed Renal MAE ECLS NEC SSI PPE Multi
6 weeks
Number 242 3 19 34 22 14 13 8 7 38 78
Physical score,
mean (SD)
79.0
(16.2)
70.3
(27.1)
72.4
(19.2)
74.1
(18.0)
78.3
(17.2)
85.5
(15.7)
50.4
(23.2)
74.4
(23.2)
79.7
(21.9)
61.2
(23.9)
66.1
(20.9)
Psychosocial score,
mean (SD)
79.4
(14.7)
87.9
(11.3)
76.5
(17.1)
82.0
(14.7)
74.3
(19.2)
81.8
(13.5)
65.6
(24.1)
85.1
(7.7)
75.2
(15.4)
69.5
(19.6)
73.5
(20.9)
Total score,
mean (SD)
79.3
(13.8)
80.1
(18.1)
74.2
(16.3)
78.4
(15.4)
76.2
(17.1)
83.3
(12.4)
59.4
(22.0)
80.3
(13.6)
77.1
(16.8)
64.9
(22.2)
69.6
(19.3)
6 months
Number 208 3 13 26 18 13 10 6 7 39 71
Physical score,
mean (SD)
82.3
(16.6)
73.4
(18.9)
81.1
(15.0)
77.6
(16.6)
80.7
(13.3)
86.6
(12.9)
68.4
(28.0)
83.1
(13.9)
79.6
(14.1)
76.4
(20.5)
72.6
(19.6)
Psychosocial score,
mean (SD)
78.0
(14.7)
83.1
(9.7)
76.5
(13.2)
77.0
(15.3)
78.3
(10.2)
81.4
(15.6)
78.9
(18.8)
77.6
(13.8)
74.3
(13.8)
74.8
(15.5)
74.9
(17.4)
Total score,
mean (SD)
79.8
(13.9)
79.0
(13.0)
78.5
(13.6)
77.3
(15.0)
79.6
(10.1)
83.7
(12.8)
74.6
(21.4)
80.2
(8.1)
76.6
(13.5)
75.7
(16.4)
74.0
(15.8)
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Appendix 11 PHQ-4 outcomes by four morbidity
categories at 6 weeks and 6 months
TABLE 39 PHQ-4 items results by the four morbidity outcome categories at 6 weeks and 6 months
Morbidity
group
PHQ-4, n (%) Risk ratio (95% CI), p-value
Normal Mild Moderate Severe
Mild vs.
normal
Moderate vs.
normal
Severe vs.
normal
6 weeks
No morbidity
(N = 232)
149 (64.2) 52 (22.4) 25 (10.8) 6 (2.6)
Single morbidity
(N = 150)
79 (52.7) 37 (24.7) 22 (14.7) 12 (8.0) 1.21 (0.70 to
2.08), 0.50
1.58 (0.78 to
3.21), 0.21
3.37 (1.19 to
9.54), 0.02
ECLS morbidity
(N = 16)
5 (31.3) 4 (25.0) 6 (37.5) 1 (6.3) 1.86 (0.42 to
8.29), 0.42
3.95 (0.71 to
21.94), 0.12
4.39 (0.55 to
35.36), 0.16
Multimorbidity
(N = 83)
35 (42.2) 29 (34.9) 4 (4.8) 15(18.1) 2.11 (1.11 to
3.99), 0.02
0.64 (0.19 to
2.17), 0.48
11.33 (4.05 to
31.69), < 0.001
6 months
No morbidity
(N = 200)
149 (74.5) 34 (17.0) 13 (6.5) 4 (2.0)
Single morbidity
(N = 122)
87 (71.3) 22 (18.0) 8 (6.6) 5 (4.1) 1.09 (0.57 to
2.10), 0.80
0.89 (0.35 to
2.25), 0.80
2.63 (0.41 to
17.12), 0.31
ECLS morbidity
(N = 11)
4 (36.4) 5 (45.5) 1 (9.1) 1 (9.1) 7.82 (1.63 to
37.55), 0.01
6.95 (0.37 to
130.90), 0.20
6.86 (0.71 to
66.53), 0.10
Multimorbidity
(N = 61)
35 (42.2) 29 (34.9) 4 (4.8) 15 (18.1) 2.13 (1.06 to
4.29), 0.03
1.45 (0.47 to
4.51), 0.52
2.25 (0.27 to
18.42), 0.45
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Appendix 12 PedsQL psychosocial and physical
scores for each morbidity at 6 weeks and 6 months
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FIGURE 23 PedsQL psychosocial scores for each morbidity at 6 weeks and 6 months. Multi, multimorbidities.
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FIGURE 24 PedsQL physical scores for each morbidity at 6 weeks and 6 months. Multi, multimorbidities.
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Appendix 13 List of unit costs
TABLE 40 Unit costs
Cost component Unit Unit cost (£) Source
XB01Z Intensive Care
ECMO/ECLS
Day 5440 Department for Health and Social Care187
XB02Z Intensive Care Advanced
Enhanced
Day 3748 Department for Health and Social Care187
XB03Z Intensive Care Advanced Day 2538 Department for Health and Social Care187
XB04Z Intensive Care Basic
Enhanced
Day 2151 Department for Health and Social Care187
XB05Z Intensive Care Basic Day 1899 Department for Health and Social Care187
XB06Z High Dependency
Advanced
Day 1448 Department for Health and Social Care187
XB07Z High Dependency Day 1173 Department for Health and Social Care187
XB09Z Enhanced Care Day 870 Department for Health and Social Care187
Cost of ward stay for patient
< 2 years old
Day 904 Study data
Cost of ward stay for patient
≥ 2 years old
Day 680 Study data
Cost of surgical procedure Minute 13.39 Study data
Outpatients visits Visit 199 Curtis and Burns188
GP visit at general practice Visit 36 Curtis and Burns188
Practice nurse visit at general
practice
Visit 14.33 Curtis and Burns188
GP home visits Visit 108 Curtis and Burns188
Nurse home visits Visit 43 Curtis and Burns188
GP telephone consultation Consultation 14.60 Curtis and Burns188
Nurse telephone consultation Consultation 7.90 Curtis and Burns188
Prescription cost Prescription cost per
consultation
28 Royal College of General Practitioners189
Note
Costs are in 2016/17 UK.
DOI: 10.3310/hsdr08300 HEALTH SERVICES AND DELIVERY RESEARCH 2020 VOL. 8 NO. 30
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
177

Appendix 14 Descriptive statistics on
41 outcome measures used for economic analysis
TABLE 41 Descriptive statistics on 41 outcome measures used for economic analysis
Outcome measure Mean SD Median
25th
percentile
75th
percentile
Days in ICU during index hospitalisation 9.6 13.5 5 3 11
Total ICU days during 6 months’ follow-up 10.4 15.0 5.0 3.0 11.0
Days on ward during index hospitalisation 13.7 20.2 7 4 15
Total ward days during 6 months’ follow-up 14.8 21.1 8 4 16
Hospital days during index hospitalisation 23.4 26.6 14 9 27
Total hospital days 25.2 28.6 14 9 30
Cost (£) of days in ICU during index hospitalisation 20,041 28,282 10,052 5475 22,945
Cost (£) of total ICU days during 6 months’ follow-up 21,479 31,181 10,703 5475 24,093
Cost (£) of days on ward during index hospitalisation 11,850 17,889 6328 3616 12,656
Cost (£) of total ward days during 6 months’ follow-up 12,775 18,789 6328 3616 14,464
Cost (£) of surgical procedures during index hospitalisation 5484 3534 4914 3214 6655
Cost (£) of surgical procedures during 6 months’ follow-up 5312 4467 4472 2651 6521
Total cost (£) of index hospitalisation 37,556 38,662 23,751 15,227 44,091
Total cost (£) of hospitalisation during 6 months’ follow-up 40,294 42,417 24,580 15,254 49,201
Number of outpatient visits during 6 months’ follow-up 3.0 10.4 1 0 7
Cost (£) of outpatient visits during 6 months’ follow-up 598 2072 199 0 1384
Total hospital costs (£) 40,780 42,605 24,895 15,996 49,466
Total non-hospital costs (£) 337 441 230 87 575
Utility score at 6 weeks (all patients) 0.883 0.191 0.906 0.773 1
Utility score at 3 months (all patients) 0.899 0.166 0.925 0.808 1
Utility score at 6 months (all patients) 0.9 0.157 0.912 0.809 1
QALYs at 6 months (all patients) 0.396 0.063 0.405 0.363 0.437
Utility score at 6 weeks (survivors only) 0.885 0.185 0.906 0.776 1
Utility score at 3 months (survivors only) 0.902 0.157 0.926 0.811 1
Utility score at 6 months (survivors only) 0.903 0.146 0.913 0.811 1
QALYs at 6 months (survivors only) 0.397 0.059 0.406 0.363 0.437
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Appendix 15 Utility scores
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TABLE 42 Utility scores
Morbidity group
Utility score
6 weeks (all patients) 3 months (all patients) 6 months (all patients)
6 weeks (survivors
only)
3 months (survivors
only)
6 months (survivors
only)
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
ANE –0.089 –0.096 –0.050 –0.032 –0.022 –0.054
URO –0.006 –0.022 0.002 –0.010 –0.013 0.001
Feed –0.016 –0.051 0.002 –0.020 –0.027 0.003
Renal –0.044 –0.045 0.002 –0.003 –0.014 –0.003
MAE –0.107 –0.086 0.022 0.018 0.013 0.018
ECLS –0.410 Yes 0.017 –0.062 –0.176 Yes –0.105 –0.065
NEC 0.498 Yes 0.412 0.028 –0.039 –0.033 –0.063
SSI –0.086 –0.093 –0.037 –0.056 –0.060 –0.037
PPE –0.006 –0.016 0.011 –0.009 –0.005 0.012
Multi –0.059 –0.139 Yes –0.037 –0.087 Yes –0.066 Yes –0.037
Regression model GLM GLM OLS GLM GLM GLM
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Appendix 16 Regression results for full list of
health economic outcomes
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TABLE 43 Regression results for full list of health economic outcomes
Morbidity
group
Health economic outcome
Additional days in ICU
during 6-month
follow-up
Total ICU days
during 6 months
follow-up
Days on ward during
index hospitalisation
Additional days on
ward during 6 months
follow-up
Total ward days
during 6 months
follow-up
Hospital days during
index hospitalisation
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
ANE –0.6 5.1 1.7 –0.1 2.0 8.0
URO –0.1 3.7 Yes 11.3 Yes 3.5 Yes 16.1 Yes 14.1 Yes
Feed 1.2 5.2 Yes 12.3 Yes –0.5 11.4 Yes 13.7 Yes
Renal –0.4 2.4 3.6 –0.3 3.9 6.4 Yes
MAE –1.1 1.0 –0.5 –0.7 –0.4 1.1
ECLS 0.7 24.7 Yes 11.3 Yes 0.1 14.0 Yes 31.7 Yes
NEC 4.3 7.8 Yes 6.6 3.6 Yes 9.7 9.1
SSI 0.0 1.5 4.2 3.5 Yes 6.4 4.2
PPE –0.9 0.3 6.2 Yes 0.3 5.6 Yes 8.4 Yes
Multi 1.8 Yes 15.3 Yes 9.6 Yes 1.6 Yes 10.7 Yes 21.2 Yes
Regression
model
OLS GLM GLM OLS OLS GLM
A
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Morbidity
group
Cost (£)
Additional days in ICU during 6 months’
follow-up
Total ICU days during
6 months’ follow-up
Days on ward during
index hospitalisation
Additional days on
ward during 6 months’
follow-up
Total ward days
during 6 months’
follow-up
Marginal effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
ANE –1343 9593 1848 –18 –222
URO –236 7769 Yes 11,188 Yes 3189 13,529 Yes
Feed 1796 9052 Yes 10,678 Yes –470 13,943 Yes
Renal –906 5344 3738 –317 1390
MAE –2120 2475 220 –602 –1282
ECLS 1422 54,155 Yes 11,655 Yes 90 8237 Yes
NEC 7757 9374 5276 3199 9688
SSI –175 1262 2680 2391 4357
PPE –1835 2125 3706 196 5449 Yes
Multi 3171 Yes 26,389 Yes 7763 Yes 1486 Yes 9882 Yes
Regression
model
OLS GLM GLM OLS GLM
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TABLE 43 Regression results for full list of health economic outcomes (continued )
Morbidity
group
Cost (£) of surgical
procedures during
index hospitalisation
Cost (£) of surgical
procedures during
6 months follow-up
Total cost (£) of
index hospitalisation
Total costs (£) of
hospital stays after
index hospitalisation
Number of outpatient
visits during 6 months
follow-up
Cost (£) of outpatient
visits during 6 months
follow-up
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
Marginal
effect p< 0.05
ANE 618 650 16,807 –1404 6.1 1215
URO 2924 Yes 3016 Yes 20,679 Yes 2876 1.6 322
Feed 294 559 16,906 Yes 1296 2.7 543
Renal 1251 Yes 1234 10,089 –1495 5.2 Yes 1032 Yes
MAE –58 –324 1790 –3041 –0.6 –119
ECLS 4309 Yes 4761 Yes 77,559 Yes 2626 1.6 312
NEC 791 1964 Yes 5867 11,867 Yes 1.6 320
SSI 1049 1187 7054 2102 2.1 418
PPE 904 Yes 636 7075 –1763 –0.4 –76
Multi 2537 Yes 2406 Yes 37,523 Yes 4665 Yes 3.5 Yes 696 Yes
Regression
model
GLM GLM GLM OLS OLS OLS
A
PPEN
D
IX
16
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
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Morbidity group
Total hospital cost (£)
Marginal effect p< 0.05
ANE 12,154
URO 24,752 Yes
Feed 17,902 Yes
Renal 11,332 Yes
MAE 1176
ECLS 69,954 Yes
NEC 16,449 Yes
SSI 9251
PPE 8366 Yes
Multi 37,956 Yes
Regression model GLM
D
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Appendix 17 Examples of slides included
in the output presentation for the morbidity
monitoring software
(a) (b)
(c) (d)
FIGURE 25 Examples of slides included in the output presentation for the morbidity monitoring software.
(a) Procedures with morbidities; (b) procedures with multiple morbidities; (c) temporal summaries; and (d) feeding:
accompanying morbidities, excluding ECLS. Multi, multimorbidities. Reproduced from Grieco et al.202 © Cambridge
University Press 2019. This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Appendix 18 Example graphics from draft
patient information derived from study data
FIGURE 27 Graphic showing breakdown of the different complications aimed at lay people.
FIGURE 26 Updated incidence of morbidity graphic for the whole population aimed at lay people.
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FIGURE 28 Length of stay information updated to be more intuitive and to show a broader spread of the
distribution aimed at lay people.
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